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Although  the  oral   route  of  administration   tends  to  be  the  most  common  and  feasible  way  to  orally  
deliver   drugs,   there   are   some   pediatric   and   geriatric   patients   that   experiences   discomfort   when  
ingesting  drugs,  a  problem  often  associated  with  physical  and  /  or  mental  restraints,  or  even  the  size  
of  the  drug  in  itself.  Now-­a-­days,  there  has  been  an  increase  in  the  development  of  fast  drug  delivery  
systems  that  have  an  appealing  and  convenient  design,  without  compromising  its  effectiveness  and  
pharmaceutical  dosage.  Thus,  the  goal  was  the  creation  of  two  oral  formulations:  an  orodispersible  
film  containing  an  antiemetic  (e.g.  metoclopramide)   for   the  fast  relief  of  emesis  or  vomiting,  and  a  
scaffold  containing  a  saliva-­inducing  agent  (e.g.  xylitol)  for  symptomatic  relief  of  xerostomia.  Hence,  
electrospinning  –  a  fiber  forming  technique  that  uses  an  applied  electrical  field  in  order  to  obtain  fibers  
from  electrically  conductive  polymeric  solutions  –  was  used  in  the  manufacture  of  orodispersible  films,  
and  cryogelation  coupled  with   supercritical   carbon  dioxide  extraction  or  drying  –  a   technique   that  
induces  pore  formation  through  ice  crystal  growth  at  subzero  temperatures,  with  subsequent  solvent  
extraction  by  carbon  dioxide  in  supercritical  conditions  –  was  used  to  produce  scaffolds.  FucoPol  was  
the  main  component  in  both  formulations  –  a  hydrophilic,  biocompatible  and  biodegradable  bacterial  
exopolysaccharide.  The  fiber-­rich  planar  orodispersible  films  dissolved  in  6  to  10  seconds,  releasing  
80%  of   its  metoclopramide  content.  The   films  had  an  overall   thickness  of   (10±2)  x  10  µm  and  an  
average  fiber  diameter  of  (1.6  ±  0.08)  x  10  µm  and  (2.9  ±  0.03)  x  10  µm.  Cytotoxic  studies  revealed  
that   the   films   had   cytotoxic   behavior   when   higher   amounts   of  metoclopramide   (>   1mg/mL)   were  
present.  Scaffolds,  non-­toxic  cylindrical  porous  structures,  presented  500  to  800  mm  in  height,  having  
an  average  pore  diameter  of  154  µm.  Additionally,  scaffolds  presented  a  maximum  water  uptake  of  
30%  before  mass-­loss  due  to  disintegration,  a  process  that  occurred  between  5  to  15  minutes.  Both  
structures  (i.e.  orodispersible  films  and  scaffolds)  showed  that   the  drug  delivery  was  controlled  by  
anomalous  diffusion  (Korshmeyer-­Peppas  model)  and  although  there  is  still  room  for  improvement,  
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Resumo  
  
Apesar   de   a   via   oral   ser   um   dos   métodos   mais   práticos   e   comuns   no   que   toca   à   toma   de  
medicamentos,  certas  populações  pediátricas  e  geriátricas  apresentam  maior  dificuldade  na  ingestão  
de  medicamentos  muitas  vezes  associado  a  constrangimentos  físicos  e/ou  psicológicos,  ou  à  própria  
dimensão  do  fármaco.  Nos  últimos  anos,  têm-­se  desenvolvido  medicamentos  de  acção  rápida  que  
possuam  um  design  mais   apelativo   e   conveniente,   sem   comprometer   a   sua   eficácia   e   dosagem  
farmacêutica.  Assim,  neste  trabalho,  teve-­se  por  objectivo  a  criação  de  duas  formulações  orais:  um  
filme   orodispersível   para   o   alívio   rápido   da   emése   ou   vómito,   contendo   um   antiemético   (e.g.  
metoclopramida)   e   um   scaffold   para   alívio   sintomático   provocado   pela   xerostomia,   contendo   um  
indutor  de  saliva  (e.g.  xilitol).  Para  tal,  recorreu-­se  à  electrofiação  –  técnica  electroestática  que  induz  
a  formação  de  fibras  a  partir  de  soluções  poliméricas  electricamente  condutoras  –  para  a  produção  
de   filmes   orodispersíveis,   e   à   criogelação   com   recurso   a   extração   ou   secagem   por   dióxido   de  
carbono  supercrítico  –  cristalização  de  uma  solução  aquosa  a  temperaturas  negativas  com  posterior  
extracção  em  condições  supercríticas  –  para  produção  de  scaffolds.  Ambas  as  formulações  tiveram  
como   base   o   FucoPol   –      exopolissacárido   bacteriano   que   apresenta   elevada   hidrofilicidade,  
biocompatibilidade   e   biodegradabilidade.  Os   filmes   orodispersíveis,   estruturas   planares   ricas   em  
fibras,  dissolveram-­se  entre  6  a  10  segundos,  libertando  80%  do  seu  conteúdo  em  metoclopramida  
por  difusão  anómala  (Korshmeyer-­Peppas).  Apresentam,  em  média,  (10±2)  x  10  µm  de  espessura  e  
um  diâmetro  médio  de  fibra  entre  (1.6±0.08)  x  10  µm  e  (2.9±0.03)  x  10  µm.  Demonstram  ainda  um  
comportamento  citotóxico  quando  o  fármaco  se  encontra  presente  em  concentrações  >1mg.mL-­1.  Os  
scaffolds,  estruturas  tridimensionais  cilíndricas  e  porosas,  sem  efeito  citotóxico,  apresentaram  500  a  
800  µm  de  espessura,  possuindo  um  diâmetro  médio  de  poro  de  154  µm.  Com  uma  capacidade  de  
absorção  de  água  de  30%  e  um  tempo  de  dissolução  entre  5  a  15  minutos.  Ambas  as  estruturas  (os  
filmes  orodispersíveis  e  os  scaffolds)  apresentam  libertação  do  fármaco  controlada  por  uma  difusão  
anómala  através  das  suas  matrizes  (modelo  Korshmeyer-­Peppas)  e,  embora  ainda  haja  espaço  para  
melhorar,  os  resultados  obtidos  mostram  que  ambas  as  técnicas  provaram  ser  adequadas  para  a  
produção  de  filmes  orodispersíveis  e  scaffolds  de  misturas  poliméricas  contendo  Fucopol.  
  







     
  
  
   XI  
Table  of  Contents  
1 General Introduction ........................................................................................ 1 
1.1 Motivation .............................................................................................................. 1 
1.2 Context ................................................................................................................... 2 
1.2.1 Oral drug administration ................................................................................... 2 
1.2.2 Oral excipients manufacturing .......................................................................... 3 
1.2.3 Polysaccharides ................................................................................................ 6 
1.3 Proposed solution ................................................................................................. 9 
1.4 Outline .................................................................................................................. 10 
2 Production of a FucoPol orodispersible film by electrospinning .............. 12 
2.1 Fiber formation technology ................................................................................ 12 
2.2 Electrospinning ................................................................................................... 14 
2.3 Orodispersible systems ...................................................................................... 16 
2.4 Nausea and vomiting .......................................................................................... 18 
2.4.1 Metoclopramide hydrochloride ........................................................................ 19 
2.5 Experimental section .......................................................................................... 20 
2.5.1 FucoPol downstream processing .................................................................... 20 
2.5.2 Orodispersible film production by electrospinning .......................................... 20 
2.5.3 Analysis of electrospinning working parameters ............................................. 21 
2.5.4 Orodispersible film morphological analysis ..................................................... 22 
2.5.5 Orodispersible film chemical composition ....................................................... 23 
2.5.6 Orodispersible film characterization ................................................................ 24 
2.6 Results and discussion ...................................................................................... 28 
2.6.1 Analysis of electrospinning working parameters ............................................. 28 
2.6.2 Orodispersible film morphological analysis ..................................................... 32 
2.6.3 Orodispersible film chemical composition ....................................................... 35 
2.6.4 Orodispersible film characterization ................................................................ 41 
2.7 Concluding remarks ............................................................................................ 47 
3 Production of FucoPol-based 3D constructs by cryotopic gelation ......... 49 
3.1 Scaffolds: 3D porous constructs ....................................................................... 50 




3.2.1 Cryogelation .................................................................................................... 51 
3.3 Supercritical Fluid Technology .......................................................................... 52 
3.3.1 Supercritical carbon dioxide (scCO2)-assisted drying ..................................... 53 
3.4 Xerostomia ........................................................................................................... 54 
3.4.1 Xylitol .............................................................................................................. 55 
3.5 Experimental Section .......................................................................................... 57 
3.5.1 FucoPol downstream processing .................................................................... 57 
3.5.2 Scaffold production ......................................................................................... 57 
3.5.3 Analysis of supercritical process parameters ................................................. 58 
3.5.4 Scaffold morphological analysis ..................................................................... 59 
3.5.5 Scaffold chemical composition ....................................................................... 59 
3.5.6 Scaffold characterization ................................................................................ 59 
3.6 Results and Discussion ...................................................................................... 62 
3.6.1 Scaffold production ......................................................................................... 62 
3.6.2 Analysis of supercritical process parameters ................................................. 64 
3.6.3 Scaffold morphological analysis ..................................................................... 65 
3.6.4 Scaffold chemical composition ....................................................................... 68 
3.6.5 Scaffold characterization ................................................................................ 69 
3.7 Concluding remarks ............................................................................................ 72 
4 Concluding remarks and future work ........................................................... 75 
4.1 Contributions ....................................................................................................... 75 
4.2 Future work .......................................................................................................... 76 
5 References ...................................................................................................... 80 
6 Supplementary Information ........................................................................... 91 
6.1 Annex 1 ................................................................................................................ 91 
6.2 Annex 2 ................................................................................................................ 93 
6.3 Annex 3 ................................................................................................................ 94 
6.4 Annex 4 ................................................................................................................ 95 




   XIII  




List  of  Figures  
  
Figure 1.1 - Oral cavity and its main components; adapted from 
http://www.hibbettpatientcare.com, assessed 24th October 2015 and Dodds et al., 2015. ........ 3 
Figure 1.2 - Outline of oral dosage forms (Ph. Eur. 5th, 2000); orodispersible films where recently 
added in (Ph. Eur. 8th Edition, 2015) .......................................................................................... 4 
Figure 1.1 – Outline of polysaccharides and their bio-based sources. (Freitas et al., 2011; 
Venugopal, 2011) ........................................................................................................................ 6 
Figure 1.4 – Schematic representation of the work performed in this dissertation in order to 
produce and ODF and a SCA. ................................................................................................ 10 
Figure 2.1 – Electrospray versus electrospinning: droplet and fiber production, respectively; 
(adapted from www.bioinicia.com, acessed 28th February 2016). ...................................... 13 
Figure 2.2 – Flow behavior: Newtonian and Non-Newtonian fluids; emphasis on shear-thinning 
behavior. ................................................................................................................................... 15 
Figure 2.3 –Metoclopramide hydrochloride molecule (adapted from Sigma). ......................... 19 
Figure 2.4 – Schematic representation of the computer controlled electrospinning process (A), 
with special attention to fiber collection. A set of spatial coordinates (defined by the user) are 
introduced into a graphical interface, establishing a connection between the user and the Arduino 
microcontroller, used to control the mechanical structure were the collector is placed (Lopes, 
2012). The spatial Cartesian coordinates (x,y,z) used were (111,182,31); (114,182,61); 
(114,165,61) and (114,165,31). ................................................................................................ 21 
Figure 2.5 – Schematic representation of the hemocytometer used to count the number of 
viable VERO cells. ................................................................................................................... 27 
Figure 2.6 – Cytotoxic assays; schematic representation of the two 96-well plates used to test of 
initial subtracts cytotoxicity used to produce samples S1, S2 and s3: Plate (1) – 1 % (w/v) FP (1 
to 5); 1 % (w/v) PEO (6 to 10);positive control (C+): DMEM media with 10 μl of Dimethylsulfoxide 
(DMSO) (11); negative control (C-): cells grown in DMEM media (12); Plate (2) – 1.5 % (w/v) 
MET (1 to 5); 2.6 % (w/v) sample S3 (6-10); positive control (C+): DMEM media with 10 μl of 
DMSO (Merck) (11); negative control (C-): cells grown in DMEM media (12). Successive dilutions 
of each component were performed in each plate: ½, ¼, 1/8, 1/8, 1/16, 1/32 (w/v) from A to F, 
with respective media control H (1 to 4). Adapted from http://www.cellsignet.com, assessed in 1st 
March 2016 ............................................................................................................................... 27 
Figure 2.7 – Viscosity (η) of different compounds used to produce the electrospun ODF. All the 
control samples were prepared according to the individual concentrations found in each ODF 
sample (Table 2.3). Flow curves were obtained at 25ºC. .......................................................... 29 
  
  
   XV  
Figure 2.8 – Thermal analysis (DSC) of S3 at a temperature range of -90 ºC to 180 ºC at 5 ºC.min-
1. Sample S3 was inserted into an aluminum hermetic pans in order to allow water 
evaporation. DSC analysis for over 4 hours, using two heating cycles for water 
evaporation (blue) and sample melting (green) and two cooling cycle for sample 
recrystallization (red). ............................................................................................................. 31 
Figure 2.9 – SEM imaging of sample S2 under 5K (left)  and 20K (right) amplifications. 
Electrospinning conditions were set to 0,5mL.h-1, 13.5 kV, 23cm, 20-30% and 25-30ºC. Average 
fiber diameter and standard deviation – 0.294±0.034 µm –  were measured from n=25 different 
fibers, using ImageJ software. .................................................................................................. 32 
Figure 2.10 - SEM imaging of sample S3 under 5K (left)  and 20K (right) amplifications. 
Electrospinning conditions were set to 0,5mL.h-1, 13.5 kV, 23cm, 20-30% and 25-30ºC. Average 
fiber diameter and standard deviation – 0.163±0.082 µm –  were measured from n=25 different 
fibers, using ImageJ software. .................................................................................................. 33 
Figure 2.11 – 2D and 3D AFM imaging of sample S2. AFM analysis was performed at 
environmental temperatures and pressures. ............................................................................. 35 
Figure 2.12 - Survey spectra for samples S1, S2 and S3. ........................................................... 36 
Figure 2.13 - XPS C 1s and O 1s regions of pure PEO (green), sample S1 (red) and S3 (orange). 
In yellow, simulated spectra with the relative contributions of 0.5 of PEO and 0.5 of FP is 
included for comparison effects. ........................................................................................... 37 
Figure 2.14 – FTIR spectra of sample S2 (dark blue). FP (dark blue) and PEO (green) FTIR spectra 
were used as controls. .............................................................................................................. 39 
Figure 2.15 - FT-IR spectra of sample S3. The FTIR spectra of sample S2 blend and MET were 
used as controls. ....................................................................................................................... 40 
Figure 2.16 – Schematic representation of the difference between ductile and brittle behavior 
(left); Experimental data retrieved from stress/strain mechanical tests by sample S3 
uniaxial elongation (right). Three ODF samples (n=3) were placed between two clamps at a 
distance of 1 cm and elongated at 2 mm.min-1 with a maximum load of 20N and a maximum 
displacement of 90 mm. Tests were performed at ambient temperature and pressure. ........... 41 
Figure 2.17 – Surface pH of samples S1, S2 and S3. Surface pH is an average result from four 
consecutive measurements. ..................................................................................................... 43 
Figure 2.18 – Wetting an disintegration of sample S3 and solvent casting ODFs. The samples 
were in direct contact with a sponge that was previously hydrated using 250 mL of simulated 
saliva at pH 6.8. The time required for sample S3 and solvent casting ODFs to dissolve was 




Figure 2.19 – Drug release kinetic profile of MET (1). Drug release from sample S3 (ES) and 
solvent casting ODFs (SC) is detail (2). MET was quantified by UV/Visible spectrophotometry 
using a calibration curve available in Annex 4. ......................................................................... 44 
Figure 2.20 – Metoclopramide release studies modeled according to Korsmeyer and Peppas. 
Drug release modeling of electrospun (ES) and solvent casting (SC) ODFs – plot 1 and 2. .... 46 
Figure 2.21 – VERO cell viability after exposure to sample S3 and its individual components. 
Cell viability was assessed 24 hours later to cell exposure by UV/Visible analysis of the 
metabolized resazurin at 570 and 600 nm. Negative control (C-) contains 10 µL of DMSO; 
positive control (C+) is composed by the growth of VERO cells in DMEM medium. ................ 46 
Figure 3.1 – Schematic representation of cryogelation process. A homogeneous casting solution 
(1) is frozen at subzero temperatures where pore formation begins due to ice crystal growth (2); 
solvent extraction process (3) is required in order to obtain a dried cryogel with interconnected 
pores (4). Adapted from LANG et al .......................................................................................... 52 
Figure 3.2 – CO2 phase diagram. ................................................................................................... 53 
Figure 3.3 – Xylitol molecular structure. ...................................................................................... 55 
Figure 3.4 – Schematic representation of the supercritical apparatus used to produce 
scaffolds; (1) CO2 tank (Air Liquid), Gilson HPLC pump (2), Frigomix S cryostat, Braun (3), 
thermostatic water bath (Hart Scientific, Model 2200) (4), stainless-steel high pressure cell 
(Temtem et al., 2008)  (5), Jasco BP-2080 Plus Automatic Back Pressure Regulator (6). Manual 
valves (V1 to V5); CO2 entry valve (V4); CO2 exit valve (V5). .................................................. 58 
Figure 3.5 - Schematic representation of the two 96-well plates used to test the substracts’ 
cytotoxicity used to produce sample SCA2: Plate (1) - FucoPol (1 to 5); Xylitol (6 to 
10);positive control (C+): Dulbecco's Modified Eagle Medium (DMEM) with 10 μl of 
dimethylsulfoxide (DMSO) (11); negative control (C-): cells grown in DMEM (12); Plate (2) 
– SCA 2 (1 to 5); positive control (C+): DMEM with 10 μl of DMSO (Merk) (11); negative 
control (C-): cells grown in DMEM media (12). Successive dilutions of each component 
were performed in each plate: ½, ¼, 1/8, 1/8, 1/16, 1/32 (w/v) from A to F, with respective 
media control H (1 to 4). Adapted from http://www.cellsignet.com, assessed in 1st March 
2016. ......................................................................................................................................... 61 
Figure 3.6 – Scaffolds prepared by cryogelation at -20 ºC (24h) using water-acetone 
replacement (- 20 ºC, 48h hours)  prior to scCO2-assisted drying at 150 bar, 45º C, 10 
mL.min-1 (3 hours). .................................................................................................................. 63 
Figure 3.7 – Thermal analysis (DSC) of scaffolds produced by 66.66% of FucoPol and 33% of 
xylitol, at a temperature range of -90 ºC to 180 ºC at 5 ºC.min-1. SCA2 sample was inserted 
into an aluminum hermetic pan in order to allow water evaporation. DSC analysis lasted over 4 
hours, using three heating cycles to induce sample melting (blue, green, brown) and two cooling 
  
  
   XVII  
cycles for sample recrystallization (red, pink). Water evaporation was registered in the first 
heating cycle (blue). The last heating cycle (brown line) was performed at 30 ºC.min-1. .......... 65 
Figure 3.8 – Visual representation of the scaffolds obtained by cryogelation at -20 ºC (24h) 
using 2-propanol-water replacement (- 20 ºC, 48h hours) prior to scCO2-assisted drying 
(150 bar, 40º C, 10 mL.min-1, 8 hours). .................................................................................. 66 
Figure 3.9 – SEM imaging of superficial and cross-section SCA2 scaffolds containing 075 wt.% 
of FP and 25 wt.% of xylitol, under 30k (upper row) and 100k (lower row) amplifications. 
Cryogelation occurred for 24h at -20 ºC with subsequent 2-propanol-water replacement for 48 
hours at -20 ºC and supercritical carbon dioxide (scCO2)-assisted drying for solvent extraction 
for 8 hours at 40ºC, 150 bar, 10 mL/minute of CO2 and depressurization rates around 10-20 
minutes. ..................................................................................................................................... 67 
Figure 3.10 – FT-IR spectra of SCA2. The individual FTIR spectra of FP and xylitol were used as 
controls. ..................................................................................................................................... 68 
Figure 3.11 – Surface pH of SCA2 samples. Surface pH is an average result from six consecutive 
measurements applied to FP, and SCA2 samples. .................................................................. 69 
Figure 3.12 – Water uptake ability (left) and in vitro disintegration time (right) of SCA2 samples 
(n=3) using 10 mL of simulated saliva at pH 6.8, 37 ºC . Disintegration studies were also 
performed at 100 rpm. ............................................................................................................... 70 
Figure 3.13 – Xylitol qualitative release studies from SCA2 samples. The presence of xylitol in 
SCA2 samples was assessed by HPLC using an electrochemical detector, a flow rate of 1 
mL/minute of NaOH 18 mM mobile phase, a column temperature of 30 ºC and an injection 
volume of 25 µL. ........................................................................................................................ 71 
Figure 3.14 - VERO cell viability after exposure to SCA2 samples and its individual 
components, FP and xylitol. Cell viability was assessed 24 hours after to cell exposure to the 
provided material. Cell viability was determined by UV/Visible analysis in order to quantify the 
metabolized resazurin at 570 and 600 nm. Negative control (C-) contained 10 µL of DMSO; 
positive control (C+) consisted in DMEM media. ...................................................................... 72 
Figure 6.1 – DSC data from pure poly (ethylene oxide) showing Tg and Tc temperatures. .... 94 
Figure 6.2 – DSC data from pure metoclopramide showing Tg temperature. .......................... 94 
Figure 6.3 - Metoclopramide UV profile from 200 to 700 nm (UV/Vis Perkin Lambda). ............. 95 
Figure 6.4 – Calibration curve used to quantify the amount of metoclopramide released upon 
in vitro pharmacokinetic studies. .......................................................................................... 95 




List  of  Tables  
  
Table 1.1 – Short recap of most common production methods for oral dosage forms. (Kailash 
et al., 2014; Ph. Eur. 5th, 2000) .................................................................................................. 5 
Table 1.1 – Water-soluble microbial EPS produced by eukaryotic and prokaryotic 
microorganisms. ....................................................................................................................... 7 
Table 2.1 – Over-the-counter orodispersible thin films by market sector (Slavkova and 
Breitkreutz, 2015) . .................................................................................................................... 17 
Table 2.2 – Antiemetic ODF available on the market. (Slavkova and Breitkreutz, 2015) ............ 19 
Table 2.3 – Sample formulations used in the production and characterization of electrospun 
and solvent casting orodispersible films: Sample S1 -  2 wt.% of FucoPol (FP) (bacterial 
exopolysaccharide produced and provided by Pure Cultures Group from UCIBIO-
REQUIMTE/FCT/UNL, Mw ~106); Sample S2 – 3 wt. % of a physical blend between FP and 
poly(ethylene oxide) (PEO) (Sigma-Aldrich, Mw 2x106), using the proportion 2:1 (w/w); Sample 
S3 – Sample S2 and 0.17 wt. % of metoclopramide (MET) (Sigma-Aldrich). ........................... 20 
Table 2.5 –XPS atomic percentages and ratios ........................................................................... 38 
Table 2.6 – Mechanical properties of sample S3 comprising the Young’s modulus (E), stress (σ) 
and strain (ε); S.D. is the standard deviation. *n=3 ................................................................... 41 
Table 3.1 – Typical properties of gases, supercritical fluids (SCF) and liquids. (Foster et al., 
2010) ......................................................................................................................................... 52 
Table 3.2 – Over the counter products for xerostomia releave. ................................................ 55 
Table 3.3 – Sample formulations used in the production of scaffolds by cryogelation coupled 
with supercritical carbon dioxide (scCO2)-assisted drying: Sample FPX1 -  10 wt.% of 
FucoPol (FP) (bacterial exopolysaccharide produced and provided by Pure Cultures Group from 
UCIBIO-REQUIMTE/FCT/UNL, Mw ~106) and 5wt.% of Xylitol (Sigma-Aldrich) in 14 mL of 
deionized water; Sample FPX2 – 11.67 wt. % of FucoPol and 3.89wt.% of xylitol in 18 mL of 
deionized water. *Apparent viscosity was measured at 25 ºC and 45 ºC (Annex 5). ................ 57 
Table 3.4 – Water miscible solvents tested as anti-solvents to FucoPol and xylitol. The solvents 
were classified as partially soluble (PS), non soluble (NS) or soluble (S) according to their ability 
to dissolve each component. Xylitol solubility was assessed first and later, FucoPol solubility was 
tested in the solvents that did not solubilize xylitol. ................................................................... 62 
Table 3.5 – Solubility and boiling temperature parameters of the solvents involved in water-
replacement (Hansen, 2007) ................................................................................................... 63 
Table 3.6 – Solvent screening for FucoPol  electrospun solutions (A1 to A8). *Acetic acid 
(Sigma Aldrich). **Formic acid (Sigma Aldrich). .................................................................. 91 
  
  
   XIX  
Table 3.7 – Cross-linkers tested in order to allow electrospinning production of an 
orodispersible film containing FucoPol. 1Hydroxilpropil cellulose;  2Poly(ethylene oxide); 




List  of  Abbreviations  
 
3D      Tridimensional  
A      Cross-­sectional  area  
AA      Acetic  acid  
AFM      Atomic-­force  Microscopy  
ANS      Autonomic  Nervous  System  
API      Active  Pharmaceutical  Ingredient  
ATR      Attenuated  Ressonance  
BE      Binding  energy  
CINV      Chemotherapy  induced  nausea  and  vomiting  
CO2      Carbon  dioxide  
DMEM      Dulbecco’s  Modified  Eagle  Medium  
DMSO      Dimethyl  sulfoxide  
DSC      Differencial  Scanning  Calorimetry  
EPS      Exopolysaccharide  
ES      Electrospinning  
ESEM      Environmental  Scanning  Electron  Microscope  
FA      Formic  acid  
FAT      Fourrier  Attenuated  Transmission  mode  
FCT      Faculdade  de  Ciências  e  Tecnologia  
FDA      Food  and  Drug  Administration  
FID      Flame  Ionization  Detector  
FP        FucoPol  
FP/PEO   Physical  blend  blend  between  FucoPol  (2wt.%)  and  poly  (ethylene  oxide)  (1  wt.%)    
FTIR      Fourier  Transform  Infrared  Spectroscopy  
HPC      Hydroxylpropil  cellulose  
  
  
   XXI  
HPLC      High  pressure  liquid  chromatography  
HPMC      Hydroxylpropil  methylcellulose  
IST      Instituto  superior  técnico  
IgG      Immunoglobulin  G  
MET      Metoclopramide  hydrochloride  
Mt  Mass of drug release at a time 
M∞  Mass of drug release as time approaches infinit 
MWCO     Molecular  weight  cut-­off  
N&V      Nausea  and  Vomiting  
NS      Non-­soluble  
ODF      Orodispersible  film  
ODT      Orodispersible  tablet  
PEO      Poly  (ethylene  oxide)  
PGSS      Particle  generation  with  supercritical  carbon  dioxide  
OS      Partially  soluble  
PVP      Polyvinilpirrolidone  
PVA      Poly  (vynil  alcohol)  
REQUIMTE   Rede  de  química  e  tecnologia  
RESS      Rapid  expansion  of  supercritical  solutions  
S      Soluble  
SC      Solvent  casting  
scCO2      Supercritical  carbon  dioxide  
SCA      Scaffold  
SCF      Supercritical  fluid  
SEM      Scanning  Electron  Microscopy  
SFE      Supercrirital  fluid  extration  




Tboiling      Boiling  temperature  
Tc   Cristalization  temperature    
Tg                                            Glass-­transition  temperature  
TEM                                    Transmission  Electron  Microscope  
Tm      Melting  temperature  
UCIBIO     Research  Unit  on  Applied  Molecular  Biosciences  
UNL      Universidade  NOVA  Lisboa  
UV      Ultraviolet  
WHO      World  Health  Organization  




     
  
  
   XXIII  
  




List  of  symbols  
  
1s      K  atomic  orbital  (low  energy)  
  
𝒂 Cylinder  radius 
C Carbon 
𝑫 Constant  drug  diffusion  coeficient 
𝑬 Young’s  modulus 
𝐹 Applied  force 
H Hidrogen  
𝒉        Planck  constant  
𝒌        Constant  
𝑳𝟎   Distance  between  clamps     
Mg        Magnesium  
𝒏        Diffusional  exponent  
O        Oxigen  
N        Nitrogen  
NaOH        Sodium  hydroxide  
𝒕        Time  
  
𝜸        Shear  rate  
∆𝒍        Displacement  
𝜺        Strain     
𝜼𝟎         Viscosity  at  Newtonian-­plateau  
𝜼          Viscosity  
𝝊        Frequency  
𝝅           Pi  
𝝈        Stress  
























     






1  General  Introduction  
  
In  this  chapter  we  start  by  motivating  our  work,  giving  an  overview  of  the  context  in  which  our  work  is  
based  on  and  a  brief  description  of  other  techniques  that  aim  to  tackle  some  of  the  challenges  that  
we  have  identified.  Later,  we  provide  a  description  of  our  proposed  solution  to  these  challenges  and  
concluding  with  the  outline  of  this  document.    
1.1   Motivation  
Exploring  new  biomaterials  and  techniques  will  enable  process  optimization  and  the  design  of  newer  
products   with   enhanced   properties,   capable   of   improving   the   efficiency   of   a   given   therapy   and  
promoting  overall  well  being.  Bio-­based  materials  (e.g.  polysaccharides)  have  been  gaining  interest  
as   a   viable   alternative   for   pharma   excipients   in   drug   delivery   systems.   Their   unique   chemical  
characteristics  as  stabilizing,  thickening  or  film  formation  agents  makes  them  versatile  as  emerging  
new  polymers  in  tissue  engineering  and  in  pharma  applications.    
Plus,  current  fuel  fossil  depletion  has  led  the  industry  to  the  investment  in  sustainable  greener  bulk  
materials  and  technologies  that  can  provide  equal,  or  higher  performance  as  the  ones  available  on  
the  market,  at  lower  production  costs  (e.g.  bacterial  polysaccharides).    
With   that   in   mind,   the   work   presented   in   this   dissertation   proposes   to   combine   medical   therapy  
efficiency   with   the   needs   of   the   industry,   using   a   bacterial   synthetized   fucose-­containing  
exopolysaccharide  in  order  to  develop  two  new  drug  delivery  systems  –  an  orodispersible  film  (ODF)  
and   a   cryogel   –   using   electrospinning   for   orodispersible   film   (ODF)   production   and   cryogelation  
1  
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followed  by  supercritical  carbon  dioxide  drying  (supercritical  CO2-­assisted  drying)  for  scaffold  (SCA)  
production.  
1.2   Context  
1.2.1   Oral  drug  administration  
Drug   intake  can  be  mainly  performed  through  the  skin  (i.e.   transdermal),  blood  (i.e.  parenteral)  or  
gastrointestinal   tract   (i.e.   enteral).   In   enteral   administration   the   drug   is   swallowed   by   the  mouth,  
digested  in  the  stomach  and  absorbed  in  the  intestines.  In  general,  enteral  oral  dosage  forms  show  
considerably  higher  drug  loadings  due  to  gastric  of  liver  absorption,  promoting  a  decrease  in  the  drugs  
bioavailability  upon  reaching  the  systemic  circulation.  This  process  is  known  as  first-­pass  metabolism  
(Hearnden  et  al.,  2012;;  Rowland,  1972).      In  order   to  bypass   first-­pass  effect,  new  drug   releasing  
systems  have  been  developed  in  order  to  allow  drugs  to  diffuse  into  the  systemic  circulation  through,  
pulmonary   alveoli   (e.g.   inhalations   devices)   or   epithelial   tissue   (e.g.   sublingual   dosage   forms).  
Through  these  systems,  the  drug  can  diffuse  through  the  mucous  membrane  directly  into  the  blood  
stream  without  experiencing  first-­pass  effect.  (Allen  and  Cullis,  2004;;  Prausnitz  and  Langer,  2008)  
The  human  mouth  has  non-­keratinized  and  keratinized  tissues  that  comprise  the  masticatory,  lining  
and   specialized   mucosa   (e.g.   tongue).   Masticatory   mucosa,   responsible   for   processes   like  
mastication  and  speech,  includes  the  dorsal  side  of  the  tongue,  gingiva  and  hard  palate.  The  lining  
comprises  the  inner  cheeks,  soft  palate,  sublingual  and  ventral  tongue  areas,  being  responsible  for  
secretion  and  selective  adsorption;;  it  also  provides  mechanical  strength  and  avoids  stress-­induced  
chemical  abrasion.  (Marieb  and  Hoehn,  2007)    
The  oral  cavity  is  filled  with  saliva,  an  exocrine  solution  made  from  99%  water  and  1%  electrolytes,  
proteins,  hormones  and  vitamins.  Due  to  masticatory  function,  enzymes  like  α-­amylase  are  present  
to  initiate  starch  breakdown,  while  lipase  disintegrates  dietary  triglycerides  and  lysozyme  acts  as  an  
antibacterial  agent  by  hydrolysis  of  the  peptidoglycan  present  in  bacterias’  cell  wall.  As  seen  in    
Figure  1.1,  approximately  90%  of  saliva  is  produced  by  three  major  salivary  glands:  the  submandibular  
(65%),   the   parotid   (20%)   and   the   sublingual   (5-­7%).  Minor   glands   like   labial,   lingual,   buccal   and  
palatine  produce  the  remaining  10%.  In  normal  conditions  (i.e.  unstimulated  secretion)  salivary  flow  
is   about   0.1   to   0.3  mL/minute   in   healthy   subjects,   reaching   a  maximum   of   3   to   7  mL/min   when  
artificially  stmulated.  (Dodds  et  al.,  2005).  Saliva  production  is  controlled  by  the  autonomic  nervous  
system  (ANS)  and  its  production  can  vary  depending  on  several  conditions,  including  stress,  thirst  or  
sweet/sour  food.  (Dodds  et  al.,  2015;;  Soares  Nunes  et  al.,  2015;;  Wang  et  al.,  2015)  






Figure  1.1  -­  Oral  cavity  and  its  main  components;;  adapted  from  http://www.hibbettpatientcare.com,  assessed  
24th  October  2015  and  Dodds  et  al.,  2015.  
Oral   complications   can   arise   from  a   number   of   causes.  Usually,   there   is   a   breakdown   in   cellular  
growth  and  a  disruption  of  healthy  bacteria  in  the  mouth.  These  changes  may  lead  to  bleeding  gums,  
mouth  sores,  infections  and  tooth  decay.  Other  common  side  effects  are  the  loss  of  normal  salivary  
flow,  nausea  and  vomiting  (Epstein  et  al.,  2012).    
  
Tablets  are   the  most  common  oral  drug  delivery  devices  used   in   the   treatment  or   the  relieve  of  a  
number  of  ailments.  Among  others,  there  are  several  key  factors  that  are  taken  into  account  when  
projecting  and  designing  a  pharmaceutical  formulation,  namely  the  drug’s  bioavailability  and  loading,  
as  well  the  drug’s  absorption  process  and  its  therapeutic  window.  (Slavkova  and  Breitkreutz,  2015)      
A  description  of  different  compounds  (e.g.  excipients)  and   techniques  applied   in   the  production  of  
pills,  or  oral  dosage  forms,  is  provided  ahead.    
  
1.2.2   Oral  excipients  manufacturing  
Excipients,  synthetic  or  natural  matrix  developed  alongside  an  active  pharmaceutical  ingredient  (API);;  
the  most   common   are   shown   in   Figure   1.2.   Excipients   are   evolving   from   their   traditional   role   as  
providers  of  stable  physicochemical  support  in  weight,  volume  and  consistency,  having  a  great  input  
as  release,  solubility  and  delivery  performance  enhancers.    Plus,  they  are  able  to  incorporate  different  
types  of  molecules;;  for  instance,  dendrimers  can  enhance  the  solubility  of  poor  water-­soluble  drugs  
(e.g.  ibuprofen),  providing  a  controlled  drug  release  in  a  wide  range  of  pH.  (Restani  et  al.,  2014)  
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Figure  1.2  -­  Outline  of  oral  dosage  forms  (Ph.  Eur.  5th,  2000);;  orodispersible  films  where  recently  added  in  
(Ph.  Eur.  8th  Edition,  2015)  
In   the   last   few   years,   the   pharma   sector   has   been   researching   new   drug   delivery   systems   that  
promote  higher  drug  bioavailability.  In  order  to  obtain  these  two  oral  formulations,  different  excipients  
and  manufacturing  techniques  can  be  applied  (Kadajji  and  Betageri,  2011;;  Leuner  and  Dressman,  
2000;;  Rathbone  et  al.,  2008).  Table  1.1  provides  a  simplified  recap  of  most  common  procedures  used  
























































Table  1.1  –  Short  recap  of  most  common  production  methods  for  oral  dosage  forms.  (Kailash  et  al.,  2014;;  
Ph.  Eur.  5th,  2000)  















✓                     ✓  
Powders  /  
Granules  
                  ✓   ✓  
Liquid  
preparations  
                     ✓  
Capsules      ✓      ✓   ✓           
Oromucosal  
preparations  
✓   ✓   ✓      ✓   ✓      ✓  
Tablets   ✓   ✓   ✓      ✓   ✓      ✓  
References   (Garg  and  Goyal,  2014;;  Jiang  et  al.,  2004;;  Kailash  et  al.,  2014;;  Kolakovic  et  al.,  2013;;  Saigal  et  al.,  2008)  
  
Bio-­based   materials   can   be   used   as   solid   matrices   for   drug   delivery   in   different   forms,   such   as  
orodispersible  films,  gels,  scaffolds,  beads  and  micro  or  nanoparticles.  Oral  thin  films  and  scaffolds  
can   be   built   from   polymeric   matrices   made   from   natural   or   semi-­synthetic   polymers,   which   are  
naturally   occurring   polymers   that   suffered   chemical   treatment   in   order   to   obtain   certain   specific  
characteristics   that  did  not  occur  without  chemical  modification   (e.g.  cellulose).  Cellulose  or  chitin  
derivatives  like  hydroxypropil  (HPC)  (Qiu  and  Hu,  2013),  hydroxypropil  methylcellulose  (HPMC)  and  
chitosan   (Takeuchi  et  al.,  2013)  are  often   found   in  many  marketed  oromucosal   formulations   (e.g.  
buccal  films),  due  to  their  characteristic  adhesive  properties  and  their  natural  ability  to  swell  and  retain  
water.    Polyvinyl  alcohol  (PVA)  (Alipour  et  al.,  2015),  polyvinylpyrrolidone  (PVP)  (Illangakoon  et  al.,  
2014)  and  poly(ethylene  oxide)  (PEO)  (Kojima  et  al.,  2008)  are  some  of  the  most  common  synthetic  
polymers  used  in  oral  thin  films  since  they  exhibit  enhanced  stability  and  hydrophilicity,  ideal  for  fast  
dissolving  dosage  forms  (Borges  et  al.,  2015).    Hydrocolloids  –  dispersion  of  hydrophilic  polymers  in  
in  a  two-­phase  aqueous  system  –  can  also  be  found  in  many  oral  formulations,  being  already  well  
established   in   the   food   industry  as   thickeners  and  starch  substitutes,   in  order   to  avoid  unpleasant  
mouthfeel.  Many  hydrocolloids  are  polysaccharides  derived   from  natural   sources,   like  plants   (e.g.  
cellulose,  pectin)  or  algi  (e.g.  agar-­agar),  while  others  arise  as  a  byproduct  of  bacterial  growth.    
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1.2.3   Polysaccharides                                                                                                                                                                                
In  2008,  the  extraction  of  natural  polysaccharides  from  plants  and  algae  represented  a  market  value  
of  over  $4  million  (Freitas  et  al.,  2011).  Polysaccharides  present  high  molecular  weights  (104-­106),  
and   can   be   classified   as   intracellular,   structural   or   extracellular   according   to   their   function   and  
biosynthesis.   Intracellular   polysaccharides   provide   energy   as   an   intrinsic   carbon   source   while  
structural  polysaccharides  act  as  main  components  of  the  cell  wall;;  extracellular  polysaccharides  -­  
exopolysaccharides  (EPS)  -­  are  discharged  into  the  environment  as  capsules  or  as  slime,  a   loose  
matrix  made  from  a  combination  of  water  and  extracellular  polymer  in  order  to  protect  the  cell  from  
desiccation  and/or  predation  (Venugopal,  2011).  Slimes  or  biofilms  are  very  simple  to  extract  when  
microbial  fermentation  occurs  in  a  controlled  environment,  such  as  in  an  aseptic  closed  bioreactor.  
Exopolysaccharides  can  be  linear  or  branched,  made  by  several  types  of  monosaccharides  linked  
together   by   glycosidic   bonds.   Homopolysaccharides,   like   dextran   or   levan,   present   the   same  
monomeric  unit  repeatedly,  while  heteropolysaccharides  (e.g.  xanthan,  gellan)  are  built  from  different  
types  of  sugar  monomers.  (Stephen  et  al.,  2006)  
  
Figure  1.3  –  Outline  of  polysaccharides  and  their  bio-­based  sources.  (Freitas  et  al.,  2011;;  Venugopal,  2011)  
Although  there  are  a  number  of  polysaccharide  sources  available  (Figure  1.3),  microorganisms  can,  
unlike  plants,    be  exponentially  grown  in  days  instead  of  months  or  years.  In  this  controlled  process,  
they  are  safeguarded  against  climate  or  environmental  change,  allowing  for  less  product  variability  
and   higher   product   purity   that   sometimes   cannot   be   achieved   in   plants   or   algae   (e.g.   bacterial  
cellulose).   Plus,   microbial   strains   are   not   exposed   to   seasonal   changes,   meaning   that   under  
controlled   conditions   a   consistent   product   can   be   achieved,   with   low   production   costs   at   high  


























different  product  outcomes  while  process  optimization  (e.g.  glycerol,  CO2  or  cheese  whey).  (Antunes  
et  al.,  2015;;  Freitas  et  al.,  2009)  
  
Polysaccharides’   physicochemical   versatility   is   applied   industrially   as   thickening,   emulsifying,  
stabilizing  and  flocculating  agents.  Table  1.2  shows  dextran,  the  first  microbial  polysaccharide  to  be  
commercialized   and   approved   for   food   applications   by   FDA,   followed   by   xanthan   gum,   used   in  
pharma  as  stabilizer  or  thickening  agent  able  to  retard  drug  release  in  tablets.  (Benny  et  al.,  2014)    
Table  1.2  –  Water-­soluble  microbial  EPS  produced  by  eukaryotic  and  prokaryotic  microorganisms.    
*Generally  Recognized  As  Safe  polymers  for  human  consumption  by  FDA,  available  for  consultation  under  GRAS  170.30  
  
The  pharmaceutical  industry  continues  to  strive  for  innovation  and  efficiency  in  their  products.  EPS  
intrinsic  properties  can  be  extremely  desirable,  available  to  be  exploited  by  different  technologies  in  
order  to  expand  the  scope  of  biopolymer  application.  
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1.2.3.1   FucoPol  
A  conscious  effort  has  been  made  to  decrease  most  common  toxic  procedures  and  increase  the  use  
of   greener   technologies   that   aim   to   reduce   or   eliminate   the   use   of   hazardous   substances   in   the  
design,  manufacture   and   application   of   chemical   products.   The   use   of   renewable   feedstock   from  
industrial  waste  (e.g.  glycerol)  has  added  value  to  industrial  waste,  maximizing  the  reuse  of  otherwise  
forgotten  substrates.  Biodiesel   industry   is  predicted   to  produce  140  billion   liters  by  2016,   in  which  
17.700  tons  correspond  to  the  production  of  glycerin  each  year  (Yang  et  al.,  2012).    
  
FucoPol  (W.O.  Patent  No.  011073874  A3,  2010)  is  a  recent  EPS  of  high  molecular  weight  (106),  a  
fucose-­containing  heteropolysaccharide  produced  by  gram-­negative  bacteria  Enterobacter  A47  DSM  
23139  (Freitas  et  al.,  2010).  Bacterial  fermentation  occurred  under  nitrogen  and  oxygen  depletion,  
using  an   industrial  waste  –  glycerol      –  as   the  energy   source,   insuring   the  bacteria’s   survival   and  
growth  (Freitas  et  al.,  2010,  Reis  et  al.,  2016).  
  
Torres,   2012   produced   FucoPol   in   a   stirred   bioreactor   where   in   the   first   24   hours   there   was   an  
exponential   bacterial   growth,   under   nitrogen   exhaustion   (batch  mode);;   the   following   72   hours,   a  
sustained  carbon  source  and  nutrient  fed  was  provided  to  the  bioreactor  (fed-­batch  mode).  Freitas  et  
al.,   2010   were   the   first   to   synthesize   this   new   exopolysaccharide,   measuring   its   sugar   content,  
molecular  weight,  intrinsic  viscosity  and  rheological  properties.  Torres,  2012  and  Freitas  et  al.,  2014  
obtained   different   amounts   of   FucoPol   with   different   chemical   compositions   by   changing   the    
fermentative   parameters;;   standard   production   parameters   FucoPol   contains   a   mixture   of   neutral  
sugars   that   involve   fucose   (35  mol.%),   glucose   (29%  mol.%)   and   galactose   (21  mol.%)   as  main  
components,  along  with  glucoronic  acid  (12  mol.%),  and  mannose  (3  mol.%)  or  rhamnose  (3  mol.%),  
common  in  shorter  FucoPol  biosynthesis.  Pyruvate,  succinate  and  acetate  are  branched  acyl  groups  
responsible   for   the   polymers’   anionic   character,   with   concentration   varying   from   batch-­to-­batch  
(Cândido,  2015).  The  presence  of  high  molecular  weight  residual  proteins  can  also  be  found,  since  
proceeding  purifications  steps  are  unable  to  remove  them  upon  dialysis  without  washing  away  part  
of  the  polymer  (Freitas  et  al.,  2014).    
  
Lourenço,   2015   performed      DSC   analysis   in   order   to   determine   the   amount   of   heat   required   to  
observe  fusion  and  crystallization  phenomena  when  FucoPol  was  exposed  to  25  ºC  to  550  ºC,  with  
heating  rates  of  5  ºC.min-­1  in  air.  Lourenço  states  that  FucoPol  does  not  present  a  glass  transition  or  
melting   temperature   (Tg)   due   to   its   amorphous   character,   possessing   a   degradation   temperature  
around  220  ºC  to  250  ºC.    Although  the  polymer’s  molecular  structure  is  still  unknown,  FucoPol  has  
already  shown  great  versatility,  revealing  promising  emulsifying  and  flocculating  activities,  as  well  as  




emulsion   and   stabilizing   properties   for   food   (Antunes   et   al.,   2015)   and   packaging   applications  
(Ferreira  et  al.,  2014).    
  
FucoPol   was   also   used   to   produce   ethanol   dehydration   membranes by   pervaporation,   using  
trichloroacetic   acid   and   polyethersulfone   as   crosslinking   agents   (Meireles   et   al.,   2013).   In  
biotechnological  applications  FucoPol  was  used  as  a  nanoparticle  coating  agent  for  antibody  capture  
(Dhadge   et   al.,   2014)   and   a  main   component   in   the   production   of   novel   polymeric   structures   by  
dissolution   in  biocompatible   ionic   liquids   (Cândido,  2015).   Its   fiber   forming  abilities,   as  well   as   its  
interaction  with   supercritical   carbon   dioxide,  will   be   analyzed   in  Chapter   2   and  Chapter   3   of   this  
dissertation.    
When   using   FucoPol   as   a   platform   for   biological   applications,   product   design   must   be   carefully  
evaluated;;  its  ability  to  absorb  water  (i.e.  hygroscopy)  can  be  advantageous  as  an  oral  excipient  for  
film  or  hydrogel  production.  Orodispersible  formulations  require  fast  dissolution  rates,  even  when  in  
contact   with   low   salivary   flow.   Hydrogels,   despite   experiencing   a   slower   dissolution   due   to  
hydroscopic  behavior,  are,  generally,  long-­lasting  matrices  that  can  have  higher  drug  loadings  and  
sustained  drug  release  profiles.  The  manufacturing   techniques   to  be  used   in   the  production  of  an  
orodispersible  film  and  a  hydrogel  require  careful  evaluation,  since  each  design  differs  in  application,  
drug  loading  and  morphology.  
1.3   Proposed  solution  
Since   occasionally   tablets   reveal   themselves   as   non-­compliant   for   patients   that   somehow   exhibit  
physical   or  mental   restrains   like   Alzheimer’s   disease,   the   creation   of   two   new   oral   drug   delivery  
platforms  with  higher  patient  compliance   is  proposed,  since   they  display  biodegradable  properties  
that   can   be   developed   to   increase   the   drugs   bioavailability   while   promoting   faster   drug   release  
rates.(García-­González  et  al.,  2011)    
  
To   achieve   this   goal,   the   use   of   electrospinning   for   orodispersible   film   (ODF)   production   and  
cryogelation  coupled  with  supercritical  drying  for  scaffold  (SCA)  production  is  proposed.  Below  is  a  
schematic  representation  that  summarises  the  work  performed  in  this  dissertation  (  
Figure  1.4).  
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Figure  1.4  –  Schematic  representation  of  the  work  performed  in  this  dissertation  in  order  to  produce  and  
ODF  and  a  SCA.  
1.4   Outline  
In  Chapter  1  context  is  brought  to  the  reader  through  the  gathering  of  previous  work,  along  with  some  
fundamentals  required  for  understanding  our  experimental  development  throughout  this  dissertation.  
An  initial  example  of  the  proposed  solution  is  provided  while  concluding  with  the  main  contributions  
of  the  work  performed.  
Chapter  2  will  be  devoted  to  the  production  process  of  FucoPol-­based  orodispersible  film,  providing  
an  overview  of  fiber  forming  technologies,  focusing  on  electrospinning  and  its  fundamentals,  related  
work  and  current  marketed  products.  A  description  of   the  experimental  procedure  will  be  detailed,  
concluding  with  a  discussion  of  the  obtained  results,  while  providing  some  concluding  remarks  and  
future  work.  
In  Chapter  3  a  scaffold  will  be  produced  using  cryogelation  and  supercritical  extraction  techniques.  A  
brief   survey   of   most   common   scaffold   production   techniques   will   be   mentioned,   converging   to  
cryogelation   and   supercritical   fluid   technology,   describing   the   fundamentals   and   related   work.  
Experimental  description  of  the  performed  process  will  be  provided  in  detail,  as  well  as  a  discussion  
of  the  obtained  results,  previous  to  concluding  remarks  and  future  work.  
Finally,  in  Chapter  4  some  concluding  remarks  about  the  work  that  was  done  in  this  dissertation  will  
be  provided,  discussing  some  possibilities  of  future  work.    
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2  Production  of  a  FucoPol  
orodispersible  film  by  
electrospinning    
  
In   this   chapter,   the   production   of   the   first   of   the   two   platforms   intended   for   oral   drug   delivery   will   be  
presented.  A  FucoPol-­containing  fast-­dissolving  platform  will  be  obtained  by  electrospinning,  a  green  fiber  
forming  technique  that  will  be  described  in  detail  throughout  this  chapter.    An  overview  of  orodispersible  
systems  regarding  their  advantages,  formulations  and  currently  marketed  products  will  be  described,  with  
emphasis   on   chemotherapy   induced   nausea   and   vomiting   (CINV).   A   description   of   the   experimental  
procedure,  performed  in  order  to  obtain  a  FucoPol-­based  orodispersible  film,  will  be  detailed.  Additionally,  
a   brief   description   of   each   technique   used   to   physically,   chemically   and   morphologically   characterize  
FucoPol-­based  orodispersible  film  will  be  provided  and  further  discussed  upon  analysis  of    the  experimental  
data.    
2.1   Fiber  formation  technology  
Much  like  spider’s  silk  spun  webs,  most  fibers  are  created  by  forcing  a  viscous  solution  through  the  holes  
of   a   device   called   spinneret.  Man-­made   spinnerets   are   similar   to   shower   heads   and,   through   different  
configurations,  can  spin  several  hundreds  of  fibers  at  the  same  time.  Fibers  can  be  manufactured  by  four  
conventional  solution  spinning  processes:  wet  spinning,  dry  spinning,  dry-­wet  spinning  and  melt  spinning.  
In  wet  spinning  (Jalili  and  Shepherd,  2013)  a   fiber   forming  solution   is   forced  through  a  spinneret   that   is  
submerged   in  a   chemical   bath  with  a  precipitating/anti-­solvent  agent,  while   in  dry   spinning   (Zhang  and  
Ogale,  2013)  the  solvent  evaporates  due  to  a  stream  of  air  or  inert  gas.  Dry-­wet  spinning  (Tasselli  et  al.,  
2013)  combines  the  two  processes  mentioned  above,  being  applied  to  gels;;  the  gel-­like  solution  travels  by  
an  air  cooled  path  into  a  cooled  liquid  bath  where  fiber  precipitation  occurs.    Melt  spinning  (Tkatch  et  al.,  




others.  The  substance   is  melted  upon  extrusion  through  the  spinneret  and,  once   it  passes  through   it,   is  
directly  solidified  by  cooling.      
  
  
Electrospray  is  a  technique  in  which  high  voltage  is  applied  in  order  to   induce  aerosolization  of  a   liquid,  
through  a  glass  or  metallic   capillary.   It   is   commonly  applied   in   inkjet   printing,  mass   spectrometry   (Loo,  
1997),  FID  detectors  (Rigort  et  al.,  2012)  and  in  the  production  of  drug  carriers  and  particles  of  different  
shapes   and   formulations.  When   a   concentrated   fiber   forming   solution   is   ejected   from   an   electrospray  
device,    a  solid  fiber  is  formed  in  a  process  known  as  electrospinning,  exemplified  in  Figure  2.1.  (Li  and  
Wang,  2013)  
Figure  2.1  –  Electrospray  versus  electrospinning:  droplet  and  fiber  production,   respectively;;   (adapted  from  
www.bioinicia.com,  acessed  28th  February  2016).  
In  the  beginning  of  the  20th  century  Cooley,  1900  and  Morton,  1902  made  electrospinning  noteworthy  by  
filing  for  four  different  spinneret  patents.  Since  then,  the  process  gained  attention  (Norton,  1936)  and,  in  the  
60’s,   Sir   Geoffrey   Taylor      mathematically   modeled   the   shape   of   a   liquid   droplet   when   exposed   to   an  
electrical  field,  commonly  known  as  the  Taylor’s  cone  (Taylor,  1964).  In  the  mid-­1990’s  Doshi  and  Reneker,  
1995  became  interested  in  the  production  of  nanofibers  due  to  their  high  surface  to  volume  ratio,  a  potential  
advantage  in  scaffold  production  and  nano-­filtration  devices.  In  short,  electrospinning  can  be  considered  a  
variation  of  electrospray  and  melt-­spinning,  since   instead  of  droplets  a  fiber   is  produced,  and   instead  of  
direct  cooling  of  the  extruded  solution,  a  jet  is  stretched  due  to  applied  electrostatic  forces.  Electrospinning  
apparatus  can  be  adapted  into  melt  electrospinning  (Nagy  et  al.,  2013),  coaxial  electrospinning  (Ye  et  al.,  
2015),  emulsion  electrospinning  (Yazgan  et  al.,  2015),  wire  electrospinning  (Chiu  and  Chen,  2015),  high  
speed  electrospinning  (Nagy  et  al.,  2015)  and  others  (Hernández-­Navarro  et  al.,  2016).    
  
Over   the   last   century,   natural   polymers   produced   by   animals,   plants,   algae   or  microbial   sources   have  
gained  relevance  due  to  an  ongoing  investment  in  renewable  energy.  In  a  report  filed  by  Preis  et  al.,  2014,  
marketed  ODF  are  mostly  made  by  a  mixture  of  sweeteners  (e.g.  sucralose),  plasticizers  (e.g.  glycerol),  
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cross-­linkers  (e.g.  citric  acid)  and  natural  polysaccharides  like  maltodextrin,  carrageenan,  starch,  bacterial  
cellulose,  pullulan  and  xantham  gum.  (Hoffmann  et  al.,  2011)  Orodispersible  films  made  by  fiber  forming  
technologies   can   possess   certain   heightened   characteristics   that   other   oral   dosage   forms   do   not;;  
electrospinning  produced  matrices  are  made  by  micro  or  nanofibers  that  concede  the  membrane  a  high  
area  to  volume  ratio,  even  in  a  small  area.  Plus,  electrospinning  is  able  to  produce  solvent-­free  ready-­to-­
use  thin  films.  Thickness  of  the  film  can  be  fine-­tuned  by  extending  or  decreasing  the  solutions  deposition  
time.  (Pham  et  al.,  2006)  
2.2   Electrospinning  
Electrospinning  is  an  electrostatically  driven  process  used  for  non-­woven  fiber  production  by  solvent  loss,  
yielding  fibers  whose  diameters  can  range  from  nano  to  few  microns.  It  usually  involves  a  syringe  pump,  a  
static   or   rotating   collector   and   a   high   voltage   power   supply.   In   this   process,   an   electrically   conductive  
polymeric  solution   is   subjected   to  an  applied  electrical   field,  while  being   forced  out   from  a  syringe  at  a  
constant  rate.  The  fiber  is  formed  when  the  electrostatic  forces  overcome  the  surface  tension  threshold  of  
the  droplet  accelerating  and  stretching  the  jet.  The  deformation  of  the  droplet  increases  with  the  applied  
voltage  leading  to  solution  ejection  and  droplet  disintegration  when  the  voltage  is  excessive.  Fibers  will  dry  
due  to  gradual  solvent  evaporation  during  jet  flight  towards  the  collector.  (Pham  et  al.,  2006),  (Liang  et  al.,  
2007)    
  
Electrospinning  has  a  number  of  working  parameters  that  need  to  be  controlled  and  adjusted  according  to  
the  system  under  study.  These  can  be  divided  in  solution,  processing  and  environmental  parameters.  All  
are   essential   but   each   one   contributes   differently   in   order   to   obtain   a   desired   fiber   design.   Solution  
parameters   involve   concentration,   viscosity,   surface   tension,   molecular   weight   and   conductivity.   Fiber  
spinning   strongly   depends   upon   surface   tension,   a   parameter   that   will   determine   the   upper   and   lower  
boundaries  of  the  electrospinning  process.  Different  solvents  can  maintain  or  increase  the  surface  tension  
of   a   given   solution   (Deitzel   et   al.,   2001).  Although   surface   tension   can   influence   fiber  morphology   and  
diameter,   concentration   is   the   key   parameter   since   electrospinning   at   low   concentrations   leads   to   the  
production  of  nano  or  sub-­micron  drops   in  a  process  known  as  electrospray   (Yang  et  al.,  2004),(Costa,  
2010).  While  an  optimal  concentration  leads  to  smoother  fibers,  higher  polymer  concentrations  favor  the  
production  of  bead-­defected  fibers  that  can  hamper  the  mechanical  properties  of  the  polymeric  matrix.  G  
Eda   and   JP   Canejo   et   al.   report   that   electrospun   fibers   of   polystyrene   and   cellulose   at   very   high  
concentrations  produce  helix-­shaped  ribbons  (Canejo  et  al.,  2008),(Goki  Eda,  2007).    
  
Concentration  is  closely  related  to  the  polymer  molecular  weight  and  the  solutions’  viscosity.  In  general,  
polymers  of  higher  molecular  weight  require  less  mass  in  order  to  achieve  optimal  viscosities  and  at  lower  
concentrations  since  the  amount  of  intermolecular  interactions  is  higher,  but  the  minimal  amount  of  polymer  
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required  to  obtain  fibers  differs  from  system  to  system  (polymer/solvent)  and  each  case  must  be  evaluated.  
The  viscosity  of  a  given  solution  can  also  be  influenced  by  mechanical  stress  and  temperature.  Viscous  
solutions  can  behave  as  Newtonian  or  non-­Newtonian  fluids,  depending  on  how  the  viscosity  changes  in  
the   presence   of   stress   (Figure   2.2).   Newtonian   fluids   have   linearly   proportional   to   the   strain   rate   (e.g.  
deformation  over  time),  maintaining  a  constant  viscosity  (e.g.  water).  Non-­Newtonian  fluids  are,  however,  
a  lot  more  common,  experiencing  shear-­thickening  (not  represented)  and/or  shear-­thinning  behavior  in  the  
presence  of  increasing  shear  rates,  leading  to  a  decrease  in  apparent  viscosity  with  increased  deformation.  
The  rearrangement  of  broken  molecular  bonds  is  equally  matched  by  the  formation  of  new  ones  causing  a  
constant  apparent  viscosity  (Torres  et  al.,  2015).  This  is  rapidly  proceeded  by  a  pseudo-­plastic  behavior  
resulting  from  an  increase  in  shear-­rate  that  causes  a  decrease  in  viscosity,  meaning  that  the  formation  of  
new  molecular  bonds   is  overcome  by   loss  of  others,  disrupting   the  polymers’   internal   structure.  This   is  
common  for  some  food  grade  products,  silicone  coating  and  some  polymeric  solutions  (da  Silva  and  Rao,  
2007).  
  
Figure  2.2  –  Flow  behavior:  Newtonian  and  Non-­Newtonian  fluids;;  emphasis  on  shear-­thinning  behavior.  
  
Because  electrospinning  involves  an  external  electrical  field,  the  intrinsic  conductivity  of  the  polymer  or  the  
solvent  has  to  be  carefully  evaluated.  The  ability  to  conduct  electricity  increases  with  the  polyelectrolytic  
nature  of  the  polymer.  Higher  conductivity  induces  the  formation  of  thinner  fibers  since  the  voltage  applied  
to  the  charge  carrying  polymeric  jet  further  stretches  the  polymeric  chains.  Subjecting  the  jet  to  very  high  
voltage  can  induce  overcharging  resulting  in  jet  breaking,  solution  ejection  and  overall  poor  fiber  formation.  
  
The  charge  carrying  capacity  of  the  polymer  is  related  to  the  amount  of  voltage  that  is  needed  to  promote  
the  ejection  of   fiber   forming  polymer   jet   from   the  Taylor’s  cone,  meaning   that  a   lower  voltage  would  be  
required  to  induce  fiber  formation  in  polymers  having  a  great  amount  of  polyelectrolytes.  Everything  beyond  
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that  would  induce  further  fiber  stretching  promoting  thinner  fibers.  On  the  other  hand,  Reneker  and  Chun  
reported  that  electrical  field  and  fiber  diameter  are  not  related  while  Zhang  et  al.  and  T.  Reis  et  al.  (Reis  et  
al.,  2013)  reported  that  higher  voltages  induce  higher  fiber  diameter.    
  
In  terms  of  flow  rate  and  distance  between  the  collector  and  the  tip  of  the  syringe,  if  the  rate  is  too  high,  a  
large  portion  of  the  solution  will  be  ejected  leading  to  fibers  with  larger  diameter.  If  the  distance  between  
needle   and   collector   is   too   short,   the   solvent   will   dry   slowly,   potentially   leading   to   fiber   fusion.   Larger  
distances   and   lower   rates   are   recommended   in   order   to   obtain   a   suitable   fiber.   Collector   should   be  
conductive,  but  depending  on  the  polymer  and  the  application,  the  collector  can  be  adjusted.  On  top  of  an  
aluminum  foil  sheet  parchment  paper,  glass,  paper,  Teflon,  grids,  rotating  rods  or  wheels  can  be  placed  
(Ganesh  et  al.,  2012;;  Neves  et  al.,  2007;;  Panda  and  Ramakrishna,  2007;;  Thieme  et  al.,  2009).  
  
Last  but  not  least,  environmental  conditions  are  the  primary  factor  that  can  destabilize  the  electrospinning  
process  because  it  is  very  hard  to  completely  monitor  and  control  them.  Mit-­uppatham  et  al.(Mit-­uppatham  
et  al.,  2004)  report  that  an  increase  in  temperature  leads  to  thinner  fibers  with  smaller  diameters,  while  an  
increase  in  humidity  leads  to  thicker  fibers  due  to  the  neutralization  of  the  superficial  negative  charges  of  
the   jet   and   consequent   decrease   in   stretching   forces.   Furthermore,   Casper   et   al.(Casper   et   al.,   2004)  
proved  that  fiber  surface  porosity  increases  with  humidity.  For  some  polymers,  a  low  humidity  is  required  
since  at   these  conditions   the  solvent  evaporation   increases   leading   to  a  dried   fiber  mat.   (Li  and  Wang,  
2013)  
  
One  of  many  advantages  of  electrospinning  films  is  the  high  surface  area  to  volume  ratio.  They  also  present  
tunable  porosity  and  one  can  manipulate  nanofiber  composition  in  order  to  get  desired  properties,  function  
and  malleability,  over  a  wide  variety  of  sizes  and  shapes.  (Liang  et  al.,  2007)  
2.3   Orodispersible  systems  
Orodispersible  films  are  a  good  alternative  to  administer  low  dosage  forms  since  the  drug  can  have  a  faster  
systemic  onset,  not   requiring  chewing  or  swallowing.  With  dissolution   times  usually   less   than  1  minute,  
sublingual   dosage   forms   are   patient   compliant   and   an   easy,   painless   and   efficient   alternative   in   drug  
release.  Due  to  their  fast  dissolving  purpose,  ODFs  must  be  designed  with  hydrophilic  compounds  that  can  
quickly  disintegrate  when   in  contact  with   the  mouth’s  salivary   flow.   (Hoffmann  et  al.,  2011;;  Shen  et  al.,  





Table  2.1  –  Over-­the-­counter  orodispersible  thin  films  by  market  sector  (Slavkova  and  Breitkreutz,  2015)  .    
Area   Active  ingredient   Commercial  name   Manufacturer  
Migraine   Zolmitriptan   Zolmitriptan  Renantos   Renantos  
Anemia   Ferric  oxide   Hemoramin   C.L.  Pharm  
Erectile  disfuntion   Sildenafil  citrate   Sildenafil  Sandoz   Sandoz  
Anti  flatulence   Silicone  oil   Gas-­X  Tongue  twisters   Gas-­X  
Mouth  refreshner   Mint  oil   Listerine  pocket  packs   Pfizer  
Nicotine  withdrawal   Nicotine   NiQuitine  Strips   GSK  
Alzheimer’s  disease   Donezepil  hydrochloride   Donezepil-­HCL   Hexal/Sandoz  
Schizophrenia   Risperidone   Risperidone  HEXAL   Hexal/Sandoz  
    
Pharmaceutical  companies  try  to  achieve  optimal  drug  delivery  systems  that  will  add  value  to  the  product  
(e.g.  enhanced  disintegration  time)  and  be  convenient  for  patients.  Catalent  produce  orodispersible  tablets  
(ODT)   like   Zydis®,   Lyoc®   and   Quicksolv®   by   freeze-­drying/lyophilization,   Orasolv®/Durasolv®   and  
Flashtab®  by  compression  and  WOWtab®  by  molding  (McLaughlin  et  al.,  2009).  These  technologies  may  
successfully   produce   orodispersible   sublingual   films   for   protein   or   peptide   delivery   (Zydis®   Bio).  
Orodispersible  films  can  incorporate  binders  (e.g.  PEO,  xylitol),  disintegrants  (e.g.  PVP,  starch),  coatings  
(e.g.  gelatin,  HPMC)  and  preservatives   (e.g.  antioxidants)  as  well  as  sweeteners   (e.g.  sucrose),   flavors  
(e.g.  mint)   or   colors   (Stijnman  et  al.,   2011).  Excipients   can  have  very   complex   formulations   in  order   to  
enhance   bioavailability   and   therapeutic   profiles,   increasing   patient   convenience,   adherence   and  
compliance  while  at  the  same  time  preventing  unwanting  behavior  like  crumbling,  sticking,  poor  handling  
mechanical  strength  and  product  degradation  due  to  environmental  water  uptake.    
There  are  many  different  definitions  for  orodispersible  films  (ODF)  among  the  literature,  with  broad  terms  
like  thin-­film,  oral  film,  oral  strip,  oral  thin  film,  buccal  film  and  oral  mats,  as  some  of  the  many  examples  
found.   These   are   sometimes   mixed   together   misleading   the   reader   to   think   that   they   have   the   same  
meaning  when  in  reality  they  do  not,  creating  misunderstanding  and  confusion.  There  is  an  urgent  need  to  
have  proper   regulation   for   oral   films  and   their   different   production  methods.  Nevertheless,   in   the   latest  
edition  of  the    European  Pharmacopoeia  (Ph.  Eur.  8th  Edition,  2015)  an  “Orodispersible  films”  subchapter  
was  added,  contained  within  “Oromucosal  preparations”.  The  latter  is  defined  in  Ph.  Eur.  5th  as  “solid,  semi-­
solid  or  liquid  preparations  containing  one  or  more  active  substances  intended  for  administration  to  the  oral  
cavity  to  obtain  a  local  or  systemic  effect  (...)  that  are  to  be  absorbed  primarily  at  one  or  more  sites  on  the  
oral  mucosa.”.(Ph.  Eur.  5th,  2000)  Not  to  be  misinterpreted  with  buccal  films  –  “oromucosal  praparations  
intended  to  be  attached  to  oromucosal  sites”  -­  or  sublingual  tablets  –  “solid  preparations  each  containing  a  
single dose  of  one  or  more  active  substances  (..)  being  usually  obtained  by  compressing  uniform  volumes  
of  particles.”  It   is  also  mentioned  that  “tablets  are  intended  for  oral  administration,  (...)  swallowed  whole,  
(...)  chewed,  (...)  dissolved  or  dispersed  in  water  before  being  administered  and  some  are  retained  in  the  
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mouth  where  the  active  substance  is  liberated.”  (Ph.  Eur.  5th,  2000)   
FDA  defines  a  drug  delivery  system  as  “Modern  technology,  distributed  with  or  as  a  part  of  a  drug  product  
that  allows  for  the  uniform  release  or  targeting  of  drugs  to  the  body”  (U.S.  Food  and  Drug  Administration,  
2009)  and  a  soluble  film  as  “A  thin  layer  or  coating  which  is  susceptible  to  being  dissolved  when  in  contact  
with  a  liquid”.(U.S.  Food  and  Drug  Administration,  2009)  An  orodispersible  film  is  a  soluble  film  with  drug  
delivery  properties.  Plus,  has  the  ability  to  rapidly  disintegrate  or  disperse  in  situ  when  in  contact  with  a  
liquid,  fast  releasing  its  drug  content  into  the  oral  cavity.  (Borges  et  al.,  2015)    
With  these  kind  of  products,  a  higher  bioavailability  maybe  obtained  related  to  the  fast  availability  of  the  
drug,  even  if  some  part  of  the  drug  is  swallowed.  
2.4     Nausea  and  vomiting  
Cancer  therapy  is  one  of  the  fastest  growing  sectors  in  the  pharmaceutical  industry,  expected  to  reach  a  
market  value  of  $225  billion  until  2017  (Global  Industry  Analysts,  2011).  World  Health  Organization  (WHO)  
reports  14.1  million  new  cases  of  cancer  occurred  worldwide  by  2012,  560  thousand  of  which  related  to  
head  and  neck  cancer  in  the  UK  only.  Nausea  and  vomiting  (N&V),  or  emesis,  are  common  side  effects  
that  can  occur  during  or  post  chemo  or  radiotherapy  treatments.  The  global  market  for  antiemetics’  was  
worth  $2.4  billion  in  2009,  being  expected  to  reach  3.6  billion  by  2015.  With  an  expected  increase  of  70%  
in  new  cancer   cases,  and  with  above  100  cancer   types,   the  need   to   find  alternative   solutions   that   can  
enhance  therapeutic  profiling  and  drug  bioavailability  is  of  major  importance.  (Global  Data,  2012).  
Nausea  and  vomiting  (N&V)  can  arise  from  a  number  of  situations  that  can  be  related  to  the  administration  
of  certain  opioids  or  if  constipation  or  infection  is  developed.  Chemotherapy-­induced  nausea  and  vomiting  
(CINV)  can  be  classified  as  acute  (i.e.  first  24  hours),  delayed  (i.e.  more  than  24  hours),  anticipatory  (ANV),  
breakthrough  (i.e.  after  5  days)  and  chronic  (Niederhuber  et  al.,  2013).  
CINV  treatments  mostly  involve  the  ingestion  of  pills,  which  can  be  hard  to  swallow  and  susceptible  to  first-­
pass   effect.  Plus,   the   ingestion   of   tablets   upon  nausea   symptoms   can  many   times   induce   vomiting,   or  
emesis.    
In   order   to   avoid   it,   excipients   that   are   quickly   dissolved   and   absorbed   in   the   oral   mucosa   (e.g.  
orodispersible  films)  are  able  to  bypass  gastroentesinal  drug  absorption,  guaranteeing  faster  drug  releases  
and  drug  bioavailability  in  the  systemic  circulation.    A  number  of  orodispersible  film  that  contain  antiemetic  






  Table  2.2  –  Antiemetic  ODF  available  on  the  market.  (Slavkova  and  Breitkreutz,  2015)  




Setofilm   Norgine  
Ondissolve   Takeda  Pharmaceuticals  
Motilum   Domperidone   Zentiva,  Sanofi  
Vogalib     Metopimazine   Schwarz  Pharma  
Naus-­ease  
Meclizine  hydrocloride  
Sunascen  Therapeutics  LLC  
Zentrip   Sato  Pharmaceutical  Co.,  Ltd  
Rizamelt   Rizatriptan  benzoate   Mylan  
2.4.1   Metoclopramide  hydrochloride  
Metoclopramide  hydrochloride  (Figure  2.3)   is  a  low  molecular  weight,  water  soluble  salt,   that  acts  as  an  
acetylcholine  release  promoter  with  central  anti-­emetic  action,  used  to  stimulate  the  gastrointestinal  motility.  
Metoclopramide  can  be  use   to  relieve   the  symptoms  of  nausea  and  vomiting  during  migraine  or  cancer  
therapy.  (Ph.  Eur.  5th,  2000)  
  
Figure  2.3  –Metoclopramide  hydrochloride  molecule  (adapted  from  Sigma).  
It   can   be   used   to   relive   acute   nausea   and   delayed   nausea;;   for   acute   nausea   it   is   recommended   that  
metoclopramide  is  taken  before  antioneoplastic  agent  administration,  an  agent  used  to  prevent,  inhibit  or  
halt  the  development  of  a  neoplasm  (e.g.  tumor).  (Niederhuber  et  al.,  2013)  
Metoclopramide  hydrochloride   is  marketed  by  Salix  and   IPCA  Labs  Ltd.  as  a   tablet/orally  disintegrating  
tablet  with  brand  name  Metozolv  ODT  (5  to  10  mg)  and/or  Perinorm  (5  to  10  mg).  Ani  Pharmaceuticals  
markets  metoclopramide  hydrochloride  as  an  oral  solution  (5mg)  and  tablet  (5  to  10  mg)  under  the  brand  
name   Reglan.   Hospira   (Pfizer)   also   provides   metoclopramide   hydrochloride   as   an   injectable   under   a  
generic  name  (FDA  Drug  database,  FDA,  accessed  24th  March  2016).  
In  order  to  prevent  emesis,  an  oral  dosage  form  that  allows  for  faster  drug  absorption  and  prevents  emesis  
due   to   drug   administration   is   in   order.   Hence,   the   goal   in   this   chapter   is   to   combine   FucoPols’  
hydrophilic  properties  with  its  possible  fiber  forming  abilities  in  order  to  produce  an  orodispersible  
film,  using  metoclopramide  hydrochloride  as  the  antiemetic  chosen  for  the  relieve  of  nausea  and  
emesis  symptoms.    
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2.5   Experimental  section  
2.5.1   FucoPol  downstream  processing    
FucoPol  purification  steps  were  performed  according  to  (Freitas  et  al.,  2010).  400  mL  samples  of  culture  
broth  were  diluted  using  deionized  water  1:2  (v/v)  for  viscosity  reduction.  Approximately  200  mL  samples  
of  diluted  culture  broth  were  transferred  to  250  mL  centrifugation  bottles  (Nalgene)  where  cell  debris  and  
denatured  proteins  were  removed  by  two  separate  centrifugation  cycles  of  45min  at  8.000  rpm  and  4  ºC  
(Avanti  J-­25,  Beckman),  using  a  JA-­14  rotor  (Beckman).  These  cycles  were   interweaved  with  a   thermal  
treatment  of  1  hour  at  70  ºC  (Conterm  oven,  JP  Selecta),  in  order  to  ensure  bacterial  enzyme  inactivation  
and  preventing  polymer  degradation.  The  broth  was  then  dialyzed  for  48h  with  a  12.000  MWCO  dialysis  
membrane  (NaloMembran  SO  farblos,  Nalo)  against  deionized  water  and  freeze-­dried  for  48  hours  (Lyo  
Quest-­55  8  port  manifold,  Telstar).    
2.5.2   Orodispersible  film  production  by  electrospinning  
In  order  to  produce  orodispersible  films,  three  solutions  were  prepared  (e.g.  S1,  S2  and  S3),  containing  an  
average  of  120  mg  of  FucoPol,  60  mg  of  poly  (ethylene  oxide)  and  10  mg  of  metoclopramide  in  6  mL  of  
deionized  water  (Table  2.3).  The  resulting  orodispersible  film  contained  94.7  wt.%  of  polymers  and  5.26  
wt.%  of  drug  content.  Solutions  S1,  S2  and  S3  were  also  used  in  the  production  of  orodispersible  films  by  
solvent  casting,  for  comparison  purposes.  Solutions  S1,  S2  and  S3  were  transferred  into  a  100  mm  teflon  
disc  (Bola,  Germany)  provided  by  Ana  Rita  Ferreira,  and  dried  overnight  in  a  30ºC  thermostated  room.  
Table   2.3   –   Sample   formulations   used   in   the   production   and   characterization   of   electrospun   and   solvent  
casting   orodispersible   films:   Sample   S1   -­      2   wt.%   of   FucoPol   (FP)   (bacterial   exopolysaccharide   produced   and  
provided  by  Pure  Cultures  Group  from  UCIBIO-­REQUIMTE/FCT/UNL,  Mw  ~106);;  Sample  S2  –  3  wt.  %  of  a  physical  
blend  between  FP  and  poly(ethylene  oxide)  (PEO)  (Sigma-­Aldrich,  Mw  2x106),  using  the  proportion  2:1  (w/w);;  Sample  













   S1   120   -­   -­  
S2   120   60   -­  
S3   120   60   10  
Solvent:  Deionized  water  
All  samples  were  prepared  overnight  and  pumped  the  following  day  through  a  syringe  with  12.04  mm  of  
internal  diameter  (Inject,  Braun)  at  a  rate  of  0.5  mL.h-­1  (KDS100  Syringe  Pump,  kd  Scientific)  using  a  21-­
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gauge  needle  (Sterican  100,  Braun).  Fiber  formation  was  induced  by  a  high  voltage  regulated  power  supply  
(Glassman  High  voltage  regulated  DC  Power  Supplies,  EL  Series)  at  13.5  kV  and  collected  in  computer  
controlled   parchment   paper   plate   (Papstar   baking   paper).   A   rotating   collector   (Figure   2.4)  was   chosen  
instead  of  a  static  one   in  order   to  avoid  a  heterogeneous   fiber  density  distribution  upon  electrospinning  
process.  The  collector  was  placed  approximately  23  cm  from  the  tip  of  the  needle.  
  
Figure  2.4  –  Schematic  representation  of  the  computer  controlled  electrospinning  process  (A),  with  special  
attention  to  fiber  collection.  A  set  of  spatial  coordinates  (defined  by  the  user)  are  introduced  into  a  graphical  interface,  
establishing  a  connection  between  the  user  and  the  Arduino  microcontroller,  used  to  control  the  mechanical  structure  
were   the   collector   is   placed   (Lopes,   2012).   The   spatial   Cartesian   coordinates   (x,y,z)   used   were   (111,182,31);;  
(114,182,61);;  (114,165,61)  and  (114,165,31).  
Electrospinning   was   performed   under   controlled   humidity   (20-­35%,   Tasciugo   Ariadry   Light   DNC   65,  
DeLonghi)  and  temperature,  at  (20-­27ºC,  Haice).  Prior  to  electrospun  orodispersible  film  characterization,  
all  samples  were  dried  overnight  at  ambient  temperature,  and  stored  in  a  vacuum  desiccator.    
2.5.3   Analysis  of  electrospinning  working  parameters    
2.5.3.1   Apparent  viscosity  
The  use  of  highly  viscous  solutions  in  electrospinning  can  clog  the  needle,  or  promote  solution  accumulation  
in   the  tip  of   the  needle   that  can   lead  to   the  formation  of  beads   in   the  electrospun  fibers.  Highly  viscous  
solutions  cannot  be  electrospun  since  the  electrostatic  repulsion  is  unable  to  surpass  the  superficial  tension  
that  allows  the  formation  of  the  Taylor’s  cone  and  the  ejection  of  fibers.  In  order  to  assess  the  viscosity  of  
a  given  polymeric  blend  rheometric  studies  were  performed.    
A   rheometer   is   a   device   that   measures   the   deformation   of   a   solid,   liquid   or   gas   under   rotational   or  
extensional  forces.  When  measuring  the  flow  between  two  parallel  flat  plates  (i.e.,  one  plate  is  mobile,  the  
other   is   stationary)   the   fluid   is   subjected   to   laminar   flow  and   the   resistance  of   fluid   against   irreversible  
positional  changes  in  its  volume  is  called  viscosity,  expressed  by  the  Equation  2.1  as  shear  stress  (𝜏)  (e.g.  
1   2   3   4  
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the  tangencial  force  applied  to  a  specific  area)  multiplied  by  shear  rate  (𝛾)  (e.g.  a  gradient  of  velocity  at  
which  shearing  deformation  occurs).  (Schramm,  1994)    
   𝜼 =
𝜸	   𝒔:𝟏
𝝉	  (𝑷𝒂)   
Equation  2.1  
Rheological  measurements  were  performed  by  Post  Doc  Reseacher  Coro  Zabala  at  CENIMAT,  FCT/UNL.  
The  values  were  the  apparent  viscosity  seems  constant  (i.e.  newtonian  viscosity)  were  obtained  from  flow  
curves  of  all  samples  used  in  electrospinning,  using  a  stress-­controlled  rheometer  Bohlin  Gemini  HR  nano,  
with  cone-­plate  geometries  40mm  and  20mm  diameters.  
2.5.3.2   Differential  Scanning  Calorimetry  (DSC)    
Differential  Scanning  Calorimetry  (DSC)  is  a  thermoanalytical  technique  that  uses  temperature  to  measure  
the   amount   of   heat   required   to   induce   physical   transformations   on   a   given   sample,   by   registering   the  
different  amount  of  heat  absorbed,  melting  at  temperature  Tm  or  crystallizating  at  a  given  temperature.  DSC  
analysis  also  registers  mass   loss  and   is  able   to  measure   the   temperature  at  which  sample  degradation  
occurs.  (Höhne  et  al.,  2013)  
Since  FucoPol  is  known  to  be  amourphous  from  previous  work  (Lourenço,  2015),  the  behaviour  of  FucoPol  
in  the  presence  of  a  physical  crosslinker  and/or  a  drug  was  assessed  by  differential  scanning  calorimetry  
(DSC),  performed  by  Prof.ª  Madalena  Dionísio  at  FCT/UNL.  Calorimetric  experiences  of  samples  S2  and  
S3  were  carried  out  using  DSC  Q2000  from  TA  Instruments  Inc.  (Tzero™  DSC  technology).  Analysis  was  
performed  under  anhydrous  high  purity  nitrogen  at  flow  rate  of  50  mL.min-­1.  Approximately  3  mg  of  both  
samples  were  sealed  in  aluminium  hermetic  pans  (TA  Tzero  Pan  and  lid)  and  submitted  to  temperatures  
ranging  from  -­90  to  +1800C,  at  a  rate  of  50C.min-­1.  The  lid  of  the  pan  was  breached  in  order  to  allow  water  
evaporation.  
2.5.4   Orodispersible  film  morphological  analysis  
2.5.4.1   Scanning  Electron  Microscopy  (SEM)  
Scanning  electron  microscopy  (SEM)  is  a  type  of  electron  microscopy  that  uses  high  voltage  to  produce  a  
beam  of  accelerated  electrons  that  probes  a  given  sample  in  a  square  pattern  (raster  scan).  The  loss  of  
energy  that  arise  from  the   interaction  between  the  sample  and  the  electron  beam  is  converted   into   low-­
energy  secondary  electron  emisson,  detected  by  a  secondary  and  backscattered  electron  detector  and  
converted,  acording  to  a  speficic  position,  to  produce  an  image.  Other  type  of  electron  microscopes  include  
transmition   electron   microscope   (TEM)   and   environmental   scanning   electron   microscope   (ESEM).  
(Goldstein  et  al.,  2012)  
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In  order  to  measure  the  average  fiber  diameter  of  the  electrospun  fibers,  as  well  as  overall  visual  imaging  
of  its  morphological  appearance,  SEM  imaging  was  performed  at  Instituto  Superior  Técnico  (IST)  by  Isabel  
Nogueira.   Film   morphology   was   obtained   by   Hitachi   S-­2400   Scanning   Electron   Microscope   at   an  
accelerating  voltage  of  15kV  and  a  magnification  of  5  and  10K.  Samples  2  and  3  were  frozen  and  fractured  
in  liquid  nitrogen  for  cross-­section  analysis  and  attached  to  an  aluminum  stub  using  carbon  tape.  Previous  
to  SEM  analysis,  samples  S2  and  S3  were  gold  coated  in  order  to  avoid  charge  effects.    
2.5.4.2   Atomic-­Force  Microscopy  (AFM)  
AFM  is  a  type  of  scanning  probe  microscopy  that  uses  a  piezoelectrical  element  to  oscillate  a  cantilever  in  
order  for  it  to  probe  the  surface  of  a  given  sample.  As  the  cantilever  oscillates,  a  detector  records  its  motion  
and  displacement,  converting  the  positional  differential  into  an  electrical  signal  with  proportional  intensity  to  
the  displacement  of  the  cantilever.  
Atomic-­Force  microscopy  was  performed  within  a  collaboration  (Ana  Rego,  IST).  Samples  S2  and  S3  were  
imaged  by  Bruker  Innova  Microscope  using  tapping  mode  and  TESP  cantilevers  (Bruker  AFM  probes),  at  
ambient  temperature  and  pressure.  The  resulting  images  were  software  analyzed  by  NanoScope  Analysis  
1.5.  
2.5.5   Orodispersible  film  chemical  composition  
2.5.5.1   X-­Ray  Photoelectron  Spectroscopy  (XPS)  
How  two  surfaces  interact  depends  on  the  physical  properties  of  the  layers  in  contact,  which  in  turn  are  
defined  by  the  elements  that  are  present  in  the  sample  and  in  which  way  they  are  connected  to  each  other.  
X-­Ray   photoelectron   spectroscopy   (XPS)   is   an   elemental   analysis   that   can   detect  which   elements   are  
present  in  the  sample  in  the  first  10  nm  of  its  outer  surface.    In  order  to  do  that,  an  X-­Ray  beam,  produced  
by  the  incidence  of  an  electron  beam  in  a  aluminum  surface,  is  used  to  promote  electron  ejection  through  
photon-­electron  interaction.  This  interaction  will  annihilate  the  photon  and  release  energy  that  will  induce  
electron  emission  from  the  atom.    The  kinetic  energy  is  a  function  of  electron  binding  energy  (BE)  and  can  
be  quantified  by  an  electron  energy  analyser  (van  der  Heide,  2011).  
X-­ray  photoelectron  spectroscopy  (XPS)  analyses  were  performed  within  a  collaboration  (Ana  Rego,  IST).  
Samples  S2  and  S3  were  analyzed  using  XSAM800  X-­ray  spectrometer  operated  in  transmission  mode  
(FAT)  with  a  pass  energy  of  20  eV,  a  power  of  120  W  and  an  incidence  of  Mg  anode  non-­monochromatic  
radiation  of  hν=1253.6  eV.  Spectral  data  was  obtained  using  Vision  2  with  a  step  of  0.1  eV,  while  charge  
shift  was  corrected  using  C  1s  and  carbon  singly  bound  to  oxygen  binding  energy  as  reference  (285  eV  
and  286.5  eV,  respectively).  0.318  (C  1s),  0.736  (O  1s)  and  0.505  (N  1s)  were  the  sensitivity  factors  used  
during  the  procedure.  
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2.5.5.2   Fourier  Transform  Infrared  Spectroscopy  (FTIR)    
FTIR  is  a  technique  that  uses  the  Michelson  interferometer  to  alter  the  distribution  of  infrared  light  that  is  
absorved  or  emitted  by  a  sample,  in  order  to  record  the  samples’  infrared  spectrum.  The  Fourier  transform  
allows  the  conversion  of  raw  data  into  light  output  as  a  funtion  of  infrared  wavenumber.  FTIR  spectroscopy  
was  performed  since  infrared  spectroscopy  is  often  used  to  identify  specific  groups  of  atoms  or  bonds  that  
have  known  frequency  (i.e.  functional  groups),  allowing  the  confirmation  of  a  given  compound  in  a  complex  
mixture.    (Smith,  2011)  
Post  Doc  Researcher  Rita  Branquinho  at  CENIMAT,  FCT/UNL  analyzed   samples  S2  and  S3  using  an  
Attenuated   Total   Reflectance   (ATR)   sampling   assessory   (Smart   iTR)   equipped   with   a   single   bounce  
diamond  crystal  on  a  Thermo  Nicolet  6700  Spectrometer.  The  spectra  were  acquired  with  a  45°  incident  
angle  in  the  range  of  4000–525  cm−1  and  with  a  4  cm−1  resolution.  
2.5.6   Orodispersible  film  characterization  
2.5.6.1   Weight,  thickness  and  pH  
As  a  way   to  assess  electrospinning   reproducibility  and   to  guarantee   that   the  electrospun  orodispersible  
films  were  within  the  requirements  (Hoffmann  et  al.,  2011)  samples  S2  and  S3  were  measured  and  weighed  
with  digital  display  micrometer  (0-­25  mm,  Mitutoyo)  and  KERN  770  analytical  balance  (Ph.  Eur.  5th,  2000).  
The  number  of  samples,  n,  was  ten  for  either  S2  and  S3  (n=10).  
pH  was  measured  in  order  to  assess  orodispersible  film  neutrality,  since  alkaline  or  acidic  pH  may  cause  
irritation  of  the  oral  mucosa.  The  ODFs  pH  was  measured  by  bringing  the  electrode  in  direct  contact  with  
all  the  samples  involved  in  the  production  of  orodispersible  films  by  electrospinning.  The  final  pH  resulted  
was  the  average  between  4  consecutive  measures  (Shamma  and  Elkasabgy,  2014)  
2.5.6.2   Mechanical  properties  
Film  resistance  to  manual  handling  was  assessed  by  stress-­strain  tests,  performed  in  dry  films  of  2  cm2,  
using  Rheometric  Scientific  (Minimat  Firmware  3.1)  at  room  temperature.  Samples  S2  and  S3,  of  2cm2,  
were  cut  and  stretched  uniaxially  at  a  speed  of  1  mm.min-­1  at  room  temperature,  with  a  maximum  load  of  
20  N  and  a  maximum  displacement  of  90  mm.  Distance  between  clamps  was  set  to  10  mm.  Load  extension  
data  was  obtained  and  converted  to  stress/strain  curves  by  applying  Equation  2.2  and  Equation  2.3:  
   𝜎(𝑀𝑃𝑎) =
𝐹	  (𝑁)




   𝜀 =
∆𝑙	  (𝑚𝑚)
𝐿I	  (𝑚𝑚)
   Equation  2.3  
where  𝜎  is  the  stress,  𝜀  is  the  strain,  F  is  the  applied  force,  A  is  the  cross-­sectional  area  in  contact  with  the  
clamps,  ∆𝑙  is  the  displacement  of  the  sample  under  uniaxial  elongation  and  L0  is  the  distance  between  the  
clamps.  
2.5.6.3   In  vitro  disintegration  time1
Orodispersible  systems  must  disintegrate  under  3  minutes,  ideally  30  seconds  to  1  minute  (Hoffmann  et  
al.,  2011).  Disintegration  time  was  registered  according  to  Vuddanda  et  al.,  2016;;  samples  S2  and  S3  (n=3)  
were  applied  on  the  surface  of  a  sponge  (Scotch-­Brite)    measuring  2  cm  wide,  5.4  cm  long  and  0.6  mm  in  
height.  The  sponge  was  wetted  in  250  mL  of  simulated  saliva  (Marques  et  al.,  2011)  at  pH  6.8.  The  time  
required   for   total   disintegration   was   registered.   The   same   procedure   was   applied   to   solvent   casting  
membranes,  for  comparison  purposes.    
2.5.6.4   Uniformity  and  drug  content1  
In  order  to  assess  the  drug’s  distribution  and  its  amount  in  the  ODF,  peripheral  and  central  segments  of  
samples  S2  and  S3  (n=3)  were  transferred  to  5  mL  glass  flask  containing  2  mL  of  simulated  saliva  (Marques  
et  al.,  2011)  at  pH  6.8  and  left  for  approximately  1  hour  at  37ºC  and  100  rpm  (Orbital  shaker  Rotaterm,  JP  
Selecta).  The  samples  were  diluted  1:15  (v/v)  and  released  metoclopramide  was  quantified  at  272  nm  by  
UV  analysis  using  a  Lambda  25,  Perkin  Elmer  UV/Vis  spectrometer  and  two  1  mL  QS  Quartz  suprasil  high  
precision  cells,  with  10  mm  optical  path  (Hellma  Analytics).    
2.5.6.5   In  vitro  drug  release  kinetic  profile1  
The  amount  of  metoclopramide  released  from  the  ODF,  as  a  function  of  time,  was  possible  to  be  obtained  
by  drug  release  kinetic  profiling.  Samples  S2  and  S3  (n=3)  were  transferred  to  glass  flasks  containing  10  
mL  of  simulated  saliva  (Marques  et  al.,  2011)  at  pH  6.8,    37ºC  and  100  rpm  (Orbital  shaker  Rotaterm,  JP  
Selecta).  Several  aliquots  were  retrieved  after  5,  10  and  30  seconds,  as  well  as  5,  10,  15  and  30  minutes,  
in  the  course  of  4  hours.  Due  to  their  hygroscopic  character,  the  samples  were  placed  inside  a  membrane  
with  a  mesh  of  1  µm  to  avoid  collecting  part  of  the  film  during  the  assay.  Metoclopramide  was  quantified  by  
UV/Visible  spectrophotometry  (PerkinLambda)  using  two  QS  High  Precision  Cells  with  1  cm  optical  path  
                                                                                                              
1  Simulated  saliva  was  prepared  according  to  Marques  et  al.,  2011,  by  weighing  8  g.L-­1  of  sodium  chloride  
(Panreac),   2.38   g.L-­1   of   sodium   phosphate   dibasic   (Sigma-­Aldrich),   0.19   g.L-­1   of   potassium   phosphate  
monobasic  (Sigma-­Aldrich)  and  0.05  mg/L-­1  of  Lysozyme  (Sigma-­Aldrich).  Phosforic  acid  (Sigma-­Aldrich)  
was  used  to  adjust  pH  6.8.  
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(Helma  Analytics),  at  272  nm.  The  total  mass  of  drug  released  is  equal  to  the  sum  of  all  aliquots  retrieved  
throughout  the  4  hours  of  drug  release.  Transport  mechanism  that  induces  drug  release  was  determined  
by   the   Korsmeyer-­Peppas   equation.   Through   Equation   2.4   it   is   possible   to   predict   which   diffusional  
mechanism   are   involved   in   the   drug   release   profile   of   metoclopramide   (e.g.   Fickian   and   non-­Fickian  




= 𝑘𝑡𝑛   Equation  2.4  
Here,  k  is  a  constant  that  reflects  the  macromolecular  network  comprising  the  drug  loaded  system,  n  is  the  
diffusional  exponent,  indicative  of  the  transport  mechanism  and  t  is  the  time.  Fickian  diffusion  is  defined  by  
n=0.5  and  non-­Fickian  diffusion  by  n>0.5,  for  slabs.  The  same  procedure  was  applied  to  solvent  casting  
membranes,  for  comparison  purposes.      
2.5.6.6   Cytotoxicity  
All  the  components  used  to  produce  the  orodispersible  films  were  assessed  in  terms  of  cytotoxicity,  since  
through  their  combination,  a  toxic  product  could  be  obtained.  Due  to  being  an  oral  application,  epithelial  
VERO   cells   from  monkey   kidney   (Cercopithecus   aethiops)   were   grown   in  Dulbecco’s  modified  Eagle’s  
medium  (DMEM  5030,  Sigma)  supplemented  with  1  %  (v/v)  of  GlutaMAX  (Life  Technologies),  1%  (v/v)  of  
sodium   pyruvate   (Life   Technologies),   1   %   (v/v)   penicillin/streptomycin   (penicillin-­streptomycin   10000  
units/mL,  Invitrogen)  and  10  %  (v/v)  fetal  bovine  serum  (FBS)  (Invitrogen).  Cells  were  maintained  in  25  cm2  
culture  flasks  in  a  CO2  incubator  at  37  °C  in  a  99  %  humidified  atmosphere  of  5  %  (v/v)  CO2.    
Cell  culture  medium  was  removed  and  2  mL  trypsin  (TrypLE  Express,  ThermoFisher  Scientific)  was  added  
to  remove  cell  adhesion  from  the  culture  flask;;  incubation  was  set  for  5  minutes  at  37  °C  in  a  99  %  humidified  
atmosphere  of  5  %  (v/v)  CO2.  Loss  of  cell  adhesion  was  confirmed  using  an  inverted  microscope  and  5  mL  
of  DMEM  were  added  to  the  culture  flask  to  neutralize  the  trypsin.  The  solution  was  transfered  to  a  15  mL  
falcon  where  it  remained  until  cell  counting. The  number  of  viable  VERO  epitelial  cells  was  assessed  by  
the  trypan  blue  assay,  a  dye  that  can  trespass  the  plasma  membrane  of  non-­viable  cells  (Strober,  2001).  
10  μL  of  trypan  blue  was  added  to  a  1  mL  cell  suspension  sample  and  a  20  μL  sample  was  retrieved  and  
transferred  on  to  a  hemocytometer  (Figure  2.5),  were  the  number  of  viable  cells  was  determined  using  an  








𝟔	  (𝒏𝒖𝒎𝒃𝒆𝒓	  𝒐𝒇	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  𝒇𝒂𝒄𝒕𝒐𝒓  
      Equation  2.5  
Afterwards,  VERO  cells  were  seeded  with  a  density  of  1.2  x  104
  
cells/well  in  a  96-­well  plate  (Figure  2.6)    
with  200  μl  of  DMEM  media  each,  supplemented  with  1%(v/v)  of  gentamicin  (Life  Technologies)  and  1%  
(v/v)  of  streptomycin  (Gibco).  Cells  were  maintained  at  37  °C  in  a  99  %  humidified  atmosphere  of  5  %  
(v/v)  CO2  for  24  hours  prior  subtracts  incubation.  After  24  hours  of  cell  growth,  where  each  well  presented  
a  cell  monolayer,  medium  was  removed  and  replaced  by  200  μL  of  fresh  media  containing  10  mg  of  each  
substrat.   Cell   viability   assay   was   determined   using   resazurin   (20%   (v/v),   Alfa   Aesar),   an   oxidation-­
reduction  pH  indicator.  
  
Figure  2.6  –  Cytotoxic  assays;;  schematic   representation  of   the   two  96-­well  plates  used   to   test  of   initial  subtracts  
cytotoxicity  used  to  produce  samples  S1,  S2  and  s3:  Plate  (1)  –  1  %  (w/v)  FP  (1  to  5);;  1  %  (w/v)  PEO  (6  to  10);;positive  
control  (C+):  DMEM  media  with  10  μl  of  Dimethylsulfoxide  (DMSO)  (11);;  negative  control  (C-­):  cells  grown  in  DMEM  
media  (12);;  Plate  (2)  –  1.5  %  (w/v)  MET  (1  to  5);;  2.6  %  (w/v)  sample  S3  (6-­10);;  positive  control  (C+):  DMEM  media  
with  10  μl  of  DMSO  (Merck)  (11);;  negative  control  (C-­):  cells  grown  in  DMEM  media  (12).  Successive  dilutions  of  each  
component  were  performed  in  each  plate:  ½,  ¼,  1/8,  1/8,  1/16,  1/32  (w/v)  from  A  to  F,  with  respective  media  control  H  
(1  to  4).  Adapted  from  http://www.cellsignet.com,  assessed  in  1st  March  2016 
1   2  
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2.6   Results  and  discussion  
Part  of  the  goal  of  this  dissertation  was  to  assess  the  never-­before-­tested  fiber  forming  abilities  of  FucoPol,  
in  order  to  produce  an  orodispersible  film  by  electrospinning.  Several  FucoPol  concentrations  were  tested  
using   different   solvents.   Standalone   FucoPol   fibers   were   unable   to   be   obtained,   even   at   high   EPS  
concentrations;;  instead  the  formation  of  droplets  of  different  shapes  and  sizes  was  observed,  in  a  process  
called  electrospray  (Annex  1).  The  use  of  electrospray  as  an  appointed  method  to  produce  FucoPol  nano  
or  micro  spheres/capsules  is  viable,  although  capsule  production  by  electrospray  is  out  of  the  scope  of  this  
dissertation.   In   order   to   produce   an   orodispersible   film   containing   FucoPol,   several   crosslinking,   fiber  
forming,  biocompatible  polymers  were  tested.  Poly(ethylene  oxide)  was  chosen  since  it  was  the  one  that  
could  produce  fibers  at  the  lowest  concentration  (Annex  2).  From  this  moment  on,  the  results  shown  are  
related  to  the  characterization  of  an  orodispersible  film  produced  by  electrospinning,  using  the  formulations  
displayed   in   Table   2.3,   subsection   2.5.2.,   recollecting   that   S1,   S2   and   S3   represent   the   experimental  
formulations   prepared   in   order   to   obtain   electrospun  ODFs,   while   all   the   compounds   present   in   those  
formulations   will   be   mentioned   as      FP   (i.e.   FucoPol),   PEO   (i.e.   poly   (ethylene   oxide)),   MET   (i.e.  
metoclopramide  hydrochloride).  
2.6.1   Analysis  of  electrospinning  working  parameters    
2.6.1.1   Apparent  viscosity  
The  viscosity  of  a  given  solution,   in  electrospinning,   is  a  good  assessment  of   the  polymers  capacity   to  
produce   fibers,   since   viscosity   is   very   commonly   related   to   the   solution’s   concentration.  Highly   viscous  
solutions   usually   have   higher   polymer   content   than   lower   viscosity   ones,   enabling   fiber   production  
(electrospinning),  that  usually  end  up  producing  spheres  (electrospray)  or  extremely  beaded  fibers.    EPS  
have,   in   general,   high  molecular  weights,   but   not   all   have   demonstrated   to   have   fiber   forming   abilities  
(Stijnman  et  al.,  2011).  They  can  act  as  thickeners  due  to  their  high  stability  at  lower  polymer  concentrations.  
Low  molecular  weight  polymers,  like  poly  (ethylene  glycol)  (PEG)  and  polyvinylpyrrolidone  (PVP)  are  many  
times  used  in  orodispersible  film  formulations;;  however,  the  amount  of  low  molecular  weight  PEG  required  
to   produce   fibers   exceeds   the   amount   of   high  molecular  weight   polymer   required   to   obtain   fibers.   The  
minimum  amount  of  poly  (ethylene  oxide)  tested  that  could  induce  fiber  formation  upon  electrospinning  was  
0.5  wt.%   (Annex  2).  The  solution  presented   low  viscosity  at  ambient   temperatures  and   fiber  production  
during  electrospinning  was  sometimes  unstable,  with  occasional  dripping  and  beaded   fibers  production.  
Adding   FP   increased   the   solutions’   viscosity,   helping   to   stabilize   the   Taylor’s   cone   and   overall  
electrospinning  process.  The  study  of  the  effect  of  temperature  on  the  rheological  properties  of  FP  is  already  
known  from  previous  work,  exhibiting  good  thermal  stability  under  a  wide  range  of  temperatures  (Cruz  et  
al.,  2011;;  Torres  et  al.,  2015).  Viscosity  is  closely  related  to  high  polymer  concentrations,  but  in  complex  
mixtures,  the  addition  of  cross-­linkers  and  plasticizers  can  increase  the  viscosity  of  a  given  solution.  
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Apparent  viscosities  of  S1,  S2  and  S3  were  assessed  using  1s-­1  to  700  s-­1  shear  forces,  at  25  ºC  (average  
temperature  encountered  in  performing  electrospinning  assays).  Flow  curves  presented  in  Figure  2.7  :  
  
Figure  2.7  –  Viscosity  (η)  of  different  compounds  used  to  produce  the  electrospun  ODF.  All  the  control  samples  
were  prepared  according  to  the  individual  concentrations  found  in  each  ODF  sample  (Table  2.3).  Flow  curves  were  
obtained  at  25ºC.  
All   individual   chemical   components   were   assessed   in   order   to   analyze   the   influence   that   different  
formulations  would  impose  upon  the  ODFs’  viscosity.  S1  exhibits  similar  behavior  to  FP  0.81%  reported  by  
Cruz  et  al.,  2011,  an  FP  sample  subjected  to  consecutive  temperature  fluctuations  (15  ºC  to  80  ºC).  The  
sample  revealed  enhanced  stability,  maintaining  its  rheological  properties  in  a  wide  range  temperatures,  
validated  by  coincidence  of  flow  curves.  The  polymers’  intrinsic  mechanical  properties  are  easily  overcome  
by   shear   forces   that   disrupt   the   polymers   internal   structure,   since   the   Newtonian   plateau   is   rapidly  
overthrown   by   pseudo-­plastic   behavior   (Cruz   et   al.,   2011).   Nonetheless,   all   tested   solutions   present   a  
Newtonian  plateau  (η0)  at  low  shear  rates,  where  the  viscosity  is  higher.  This  is  known  as  shear-­thinning  
behavior,  present  in  all  formulations  over  100  s-­1.  
  
Apparent   viscosity  was   directly   extrapolated   from   the   diagram  presented   in   Figure   2.7,  where   the   flow  
curves  and  the  y  axis  (η  (Pa.s))  cross.  FP  and  PEO  have  a  stand-­alone  viscosity  of  0.32  and  0.206  Pa.s,  
at  at  25ºC,  respectively.  As  expected,  S2  shows  an  increase  in  viscosity  with  values  around  1.52  Pa.s,  at  
25ºC.   S3  maintained   the   apparent   viscosity   of   S2   since   the   amount   of  metoclopramide   present   in   the  
solution   is   residual   when   in   comparison   to   the   polymeric   components   of   the   film.   For   electrospinning,  
solutions  viscosities   ranging   from  1   to  10  Pas.s  are  still  viable   to  be  electrospun  without  hampering   the  
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2.6.1.2   Differential  Scanning  Calorimetry  (DSC)  
Differential  scanning  calorimetry  was  performed  in  order  to  evaluate  the  ODFs  phase  transformations  as  
melting  (transition  from  crystal  to  liquid)  that  occurs  at  a  definite  temperature,  Tm,  crystallization  (transition  
from  melt  to  a  crystalline  solid)  occurring  at  Tc,  and  the  glass  transition  taking  place  over  a  temperature  
range,  for  which  a  glass  transition  temperature  is  defined  (e.g.  in  the  mean  point  of  the  transition),  Tg.  The  
latter   transformation   is  briefly  explained:  when  a  material  does  not  crystallize   it  enters   in  a  supercooled  
regime.  Upon  further  cooling,  the  viscosity  dramatically  increases  and  the  material  vitrifies  in  a  disordered  
solid  (amorphous  material)  when  crossing  the  temperature  range  of  the  glass  transition.  The  materials  that  
experience  this  phase  transformation  are  designated  glass  formers,  becoming  hard  and  fragile  (e.g.  silicate  
glass).  The  glass  structure  is  still  solid,  but  the  intermolecular  arrangements  are  looser  due  to  an  increase  
in   Gibbs   free   energy.   In   particular,   for   polymers,   as   the   temperature   is   raised   on   crossing   the   glass  
transition,   they   start   to   exhibit   a   rubber-­like   behavior,   and  at   even  higher   temperatures   they  eventually  
become  free-­flowing  materials  allowing  to  be  molded.  Semi-­crystalline  polymers  melt,  upon  further  heating  
at  a  given  temperature,  Tm.  (Shawe  et  al.,  2000)  
  
A   previous   sample   of   FP,   from   the   same   batch,   was   analyzed   by   DSC   in   order   to   assess   the   ideal  
processing   temperature  of  FP,  without  melting   the   samples.  When  analyzing  FP   it  was  not   possible   to  
detect  neither  a  glass  transition  or  a  melting  temperature,  detecting  only  a  degradation  temperature  around  
268   ºC.   This  means   that   although   FP   is   essentially  made   by   an   intricate   heterogeneous   proportion   of  
sugars,  it  lacks  the  internal  three-­dimensional  structural  order  found  in  crystalline  materials.  FP  is  reported  
as  an  amorphous  polymer  due  to  having  a  random  structural  arrangement,  also  found  in  liquids  material  
(Cândido,  2015).  However,   the  chains’  arrangement  seems  to  be   too  rigid   to  allow  a  significant  change  
between  the  heat  capacity  of  the  glass  and  the  one  of  the  rubber-­like  material,  since  no  heat  flux  step  was  
observed  in  the  thermal  response  that  can  be  attributed  to  a  glass  transition.    
  





Figure  2.8  –  Thermal  analysis  (DSC)  of  S3  at  a  temperature  range  of  -­90  ºC  to  180  ºC  at  5  ºC.min-­1.  Sample  S3  
was  inserted  into  an  aluminum  hermetic  pans  in  order  to  allow  water  evaporation.  DSC  analysis  for  over  4  hours,  using  
two   heating   cycles   for   water   evaporation   (blue)   and   sample   melting   (green)   and   two   cooling   cycle   for   sample  
recrystallization  (red).  
  
PEO  and  MET  present  a  stand-­alone  melting  temperature  of  66.23  ºC  and  98ºC,  respectively,  with  PEO  
having   a   glass   transition   temperature   around   52ºC;;   MET   do   not   present   recrystallization   temperature  
(Annex  3).  Water  evaporation  temperature  is  visible  in  the  first  heating  cycle  (blue)  where  the  temperature  
reaches  180  ºC.  Afterwards,  the  system  is  cooled  down  (red)  and  recrystallization  occurs  around  45.69  ºC.  
A  third  heating  cycle  (green)  is  performed  in  order  to  assess  the  melting  temperature  that  is  detected  around  
64.39   ºC.   Since   FP   is   amorphous,   the   Tm   and   Tc   temperatures   displayed   in   Figure   2.8   are   probably  
originated   by   the   presence   of   PEO   in   sample   S3;;   moreover,   the   detected   melting   and   crystallization  
phenomena  occur  close  to  the  temperatures  found  in  pure  PEO  (Tm:  66.23ºC,  Tc:  48.61  ºC),  whereas  MET  
only  melts  at  100  ºC.  (Annex  3).  The  low  amount  of  MET  present   in  sample  S3  could  explain  why  DSC  
analysis  is  not  greatly  influenced  by  it.  
  
The  combination  of  the  melting  temperatures  of  PEO,  MET  and  ODF  is  equal  or  higher  than  60  ºC,  so  it  is  
safe  to  say  that  working  electrospinning  temperatures  (20  to  30  ºC)  will  not  promote  or  induce  cristalization  
or  melting  upon  fiber  production,  phenomenon  many  times  encountered  in  electrospinning  processes,  if  the  
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2.6.2   Orodispersible  film  morphological  analysis  
2.6.2.1   Scanning  Electron  Microscopy  (SEM)    
In  the  beginning  of  section  2.6  we  stated  that  in  the  experimental  conditions  tested  (Annex  1),  FP  seemed  
to  not  possess  the  ability  to  produce  fibers,  only  droplets  or  beads.  Morphological  imaging  of  electrospun  
samples  S2  and  S3  was  assessed  by  SEM;;  results  are  shown  in  Figure  2.9  and  Figure  2.10.  The  fibers  
observed  are  defectless,  without  bead  formation  and  are  likely  derived  from  the  amount  of  PEO  present  in  
the  solution.  Some  fibers  appear  to  be  fused  together,  a  behavior  that  can  be  explained  by  a  possible  fiber  
aggregation   due   to   the   creation   of   interconnected   honeycomb-­like   structures,   characteristic   of   high  
molecular   weight   PEO   (Deitzel   et   al.,   2001).   Average   fiber   diameter,   measured   by   ImageJ,   was  
0.294±0.034  µm  for  sample  S2  (Figure  2.9),  having  a  maximum  and  minimum  diameter  of  0.420  µm  and  
0.253  µm,  respectively.  Plus,  the  fiber  cannot  be  melted  together  since  from  previous  DSC  analysis  it  was  
perceived   that  melting   only   started   to   occur   at   temperatures   close   to   60   ºC   far   from   the   ones   used   in  
electrospinning  (20  to  30  ºC).  
  
Figure  2.9  –  SEM  imaging  of  sample  S2  under  5K  (left)    and  20K  (right)  amplifications.  Electrospinning  conditions  
were   set   to   0,5mL.h-­1,   13.5   kV,   23cm,   20-­30%   and   25-­30ºC.   Average   fiber   diameter   and   standard   deviation   –  
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Figure  2.10  -­  SEM  imaging  of  sample  S3  under  5K  (left)    and  20K  (right)  amplifications.  Electrospinning  conditions  
were   set   to   0,5mL.h-­1,   13.5   kV,   23cm,   20-­30%   and   25-­30ºC.   Average   fiber   diameter   and   standard   deviation   –  
0.163±0.082  µm  –    were  measured  from  n=25  different  fibers,  using  ImageJ  software.  
Metoclopramide   hydrochloride   is   considered   as   ‘’very   soluble’’   drug,   in   water.   However,   its   solubility  
parameters  are  not  clear  throughout  the  literature:  Meurant,  1987  reports  a  water  solubility  of  0.2  mg/mL  
while  Kasim  et  al.,  2004  report  a  water  solubility  of  1g/mL.  Stosik  et  al.,  2008  measured  the  solubility  of  a  
tablet  containing  10  mg  of  metoclopramide  hydrochloride  and  found  that  it  was  only  soluble  in  265  mL  of  
water.  Bhimba,  2013,  also  performed  solubility  measurement  and  found  that  1,415  g  of  the  drug  was  soluble  
in  1mL  of  phosphate  buffer  at  pH  7.4.  From  Figure  2.10  it  is  perceivable  that  the  addition  of  metoclopramide  
affects  the  fiber  morphology,  since  the  drug  was  not  able  to  solubilize  in  the  experimental  conditions  (i.e.,  
10   mg   of   metoclopramide   in   6   mL   of   water).   Average   fiber   diameter   in   sample   S3   decreased,   when  
compared  to  sample  S2,  due  to  fiber  heterogeneity,  reaching  0.163±0.082  µm,  presenting  a  maximum  and  
minimum  diameter  of  0.405  µm  and  0.045  µm,  respectively.  
Generally,  as  fiber  diameter  gets  close  to  the  nanoscale  (i.e.,  1  to  100  nm)  a  greater  amount  of  substance  
comes   in   contact   with   the   surrounding   material.   Although   the   morphology   of   sample   S3   presents  
heterogeneous  fiber  diameters  that  will  probably  hamper  the  mechanical  stability  of  the  film,  increasing  the  
ODFs  superficial  area  of  contact  with  the  oral  mucosa  through  smaller  fiber  diameters  can  result  in  faster  
film   dissolution,   enabling   faster   drug   release   and   absorption.   Furthermore,   since   the   goal   of   the  
orodispersible  film  is  to  disperse  in  the  shortest  amount  of  time  possible,  its  mechanical  strength  is  not  that  
relevant  and  the  occurrence  of  defected  fibers  does  not  have  a  great  impact  in  its  performance.  Analyzing  
SEM  images,  it  is  possible  to  conclude  that  for  our  formulation  and  purpose,  electrospinning  is  able  to  create  
a   thin   fibrous   film   that   displays   high   area   to   volume   ratio   that   cannot   be   found   in   any   other   common  
manufacturing  procedure.  Plus,  film  requirements  are  easy  to  model  since  electrospinning  has  at  least  5  
degrees  of  freedom  that  aid  in  fiber/film  design  and  modulation  (i.e.  rate,  voltage,  needle/collector  distance,  
Sample  S3  
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process   time,   humidity   and   temperature).   In   order   to   obtain   thicker   ODFs   one  must   only   increase   the  
amount   of   time   in  which   a   viscous   solution   is   electrospun   (i.e.   deposition   time),  meaning   that   a   higher  
solution  volume  will  have  to  be  electrospun.  
Nonetheless,   in   order   to   achieve   reproducible   results   and   homogeneous   fibers,   other   drugs   should   be  
tested  and  their  water  solubility  should  be  measured,  avoiding  erroneous  results.  
2.6.2.2   Atomic-­Force  Microscopy  (AFM)  
AFM  analysis   (Figure  2.11)  was  originally   intended   to  act   as  a   substitute   to  SEM  analysis   since   in   the  
beginning,  samples  S2  and  S3  were  melting  upon  SEM  analysis.  We  believed  at  the  time  that  FP  was  not  
withstanding   the  energy  generated  by   the  SEM  electron  beam,  due   to  FP  being  essentially  made  by  a  
mixture   of   sugars.   That   suspicion  was  not   confirmed   since  SEM  was  eventually   performed  without   the  
presence  of  melting.  
  
AFM  is  performed  using  ambient  temperature  and  pressure,  being  a  suitable  alternative  for  an  approximate  
fiber  diameter  measurement,  without  chemical  modification.  AFM  was  also  performed  as  a  complement  to  
X-­Ray  Photoelectron  Spectroscopy  (XPS),  in  order  to  assess  if  the  X-­Ray  radiation  would  influence  fiber  
morphology.   XPS   analysis   of   sample   S2   is   reported   ahead.   AFM   analysis   reported   an   average   fiber  
diameter  equal  to  0.826  µm  and  0.481  µm  previous  to  and  after  XPS  analysis,   in  sample  S2.  Given  the  
absence  of  damage  signs  in  the  fiber,  the  discrepancy  in  fiber  diameter  can  be  explained  by  the  lack  of  
assurance  that  the  same  sample  region  is  being  analyzed  twice.  
  
Before  XPS  Analysis   After  XPS  analysis  
Sample  S2  
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Figure  2.11  –  2D  and  3D  AFM  imaging  of  sample  S2.  AFM  analysis  was  performed  at  environmental  temperatures  
and  pressures.  
In  order  to  evaluate  if  the  amount  of  FP  present  in  sample  S2  was  causing  the  discrepancies  found  in  the  
average  fiber  diameter  when  measured  by  AFM,  or  if   the  melting  behavior  of  samples  S2  and  S3  found  
upon  performing  SEM  was  due  to  FP  surrounding  PEO  fibers,  samples  S2  and  S3  were  analyzed  by  X-­
Ray  Photoelectron  Spectroscopy  (XPS)  in  order  to  have  a  correct  assessment  of  the  superficial  composition  
of  the  electrospun  fibers.  
  
2.6.3   Orodispersible  film  chemical  composition  
2.6.3.1   X-­Ray  Photoelectron  Spectroscopy  (XPS)  
In  order   to  understand   if  FP  had  a  contribution   in   fiber  production,   the  elemental  compositions  of  native  
(i.e.,  FP,  PEO,  MET)  and  hybrid  films  (i.e.  samples  S2  and  S3)  were  determined  by  XPS.  Figure  2.12  shows  
the  survey  spectra  for  all  the  analyzed  samples,  used  as  received:  
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Figure  2.12  -­  Survey  spectra  for  samples  S1,  S2  and  S3.    
  
The  main   spectral   regions  are   identified   in  Figure  2.12  showing   that   carbon   (photoelectrons  C  1s)  and  
oxygen  (photoelectrons  O  1s)  are  present  in  all  the  samples,  as  expected.  However,  in  sample  S1,  and  in  
all  the  samples  containing  FP,  nitrogen  (photoelectron  N  1s)  and  sodium  (photoelectrons  Na  1s)  are  also  
present,  possibly  due  to  poor  purification  steps  or  sample  contamination.  Spectra  for  sample  S2  and  S3  
have  very  similar,  therefore,  from  now  on,  just  the  sample  S3  will  be  mentioned.  Detailed  XPS  regions  C  
1s  and  O  1s  for  the  samples  S1,  S2  and  S3  are  shown  in  Figure  2.13.  The  simulated  spectra  for  sample  
S2  was  assessed  assuming   they  were  homogeneously  physically  blended.  The  difference  between   the  









Figure  2.13  -­  XPS  C  1s  and  O  1s  regions  of  pure  PEO  (green),  sample  S1  (red)  and  S3  (orange).  In  
yellow,   simulated   spectra   with   the   relative   contributions   of   0.5   of   PEO   and   0.5   of   FP   is   included   for  
comparison  effects.  
  
When  observing  the  C  1s  region,  carbon  atoms  singly  bound  to  oxygen  (C-­O)  can  be  found  in  all  the  spectra  
due  to  the  presence  of  binding  energies  (BE)  around  286.5  eV.  In  ODF,    a  peak  at  284.8±0.2  eV  appears,  
possibly   assignable   to   carbonaceous   contamination   (C-­C   and/or   -­H2C-­).   In   sample   S1,   a   peak   was  
observed  at  higher  binding  energy  (288.1±0.2  eV)  assignable  to  a  carbon  double  bonded  to  oxygen  (C=O  
and/or  O-­C-­O).  When  analyzing   the     O  1s   region,   it   is  possible   to  observe   that  PEO  has  a  component  
centered  at  532.8±0.2  eV  assigned  to  the  oxygen  singly  bound  to  carbon  (O-­C);;  a  very  small  component  
centered  at  534.7±0.2  eV  is  due  to  water  absorption.  For  samples  S1  and  S3,  besides  the  peak  assignable  
to  O-­C  at,  respectively  532.5±0.2  eV  and  532.7±0.2  eV,  also  a  component  at  lower  BE  (531.3±0.4  eV)  is  
found,   being   typical   of   oxygen   in   carbonyl   groups   (O=C).   The   “simulated”  O   1s   and  C   1s   peaks  were  
obtained,   without   any   prior   normalization,   assuming   that   sample   S2   is   homogeneously   distributed   and  
blended   in   the  proportion  1:1(wt.).  A  perfect  match   is   obtained   for  O1s   region  but   not   for  C  1s   region,  
suggesting  that  there  can  be  some  carbon  contamination  in  the  sample.    
  
Ideally,  FP  and  PEO  should  contribute  equally  to  the  surface  composition  of  sample  S2,  since  the  simulation  
was  obtained  by  50%  of  FP  and  50%  of  PEO.  However,  simulation  for  the  C  1s  region  was  not  a  perfect  fit  
using  those  compositions  since  FP  and  PEO  were  actually  blended  in  the  proportion  2:1  (wt.).  The  data  
contrarily   suggests   that   a   certain   PEO   is   present   at   the   surface   of   the   fibers.   Table   2.4   shows   the  
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quantitative  results  obtained  by  XPS.  Sample  S3  presents  a  lower  O/C  ratio  than  the  ones  found  in  sample  
S1  and  PEO  which  may  be  attributed  to  the  increase  of  carbon  in  sample  S3  sample  related  to  a  carbon  
contamination.    
  
Nitrogen  was  also  found   in  XPS  N  1s  analysis   in  sample  S1  (400.2  eV),  element  never   found  before   in  
previous  FP  analysis  (Antunes  et  al.,  2015;;  Dhadge  et  al.,  2014;;  Ferreira  et  al.,  2014;;  Freitas  et  al.,  2010)  
As   a   result,   it   was   not   possible   to   pinpoint   the   atomic   percentages   corresponding   to   MET   since   both  
compounds  have  nitrogen  in  their  composition.  To  assess  if  the  nitrogen  in  sample  S1  arrives  from  a  sample  
contamination   or   poor   downstream   processing,   an   elemental   analysis   could   be   performed   in   polymer  
samples  from  the  same  batch,  before  and  after  purification  steps.  
  
Table  2.4  –XPS  atomic  percentages  and  ratios  
   S1   PEO   S3  
C   59.2   61.7   63.2  
O   35.3   38.3   34.6  
N   5.5   -­   1.9  
O/C   0.60   0.62   0.55  
O-­C/C-­O   1.39   0.63   0.84  
N/C   0.09   -­   0.03  
  
2.6.3.2   Fourier  Transform  Infrared  Spectroscopy  (FTIR)    
FTIR  analysis  was  performed   in  order   to  evaluate   if  all  ODF   individual  components  were  present   in   the  
sample,   after   electrospinning   and   solvent   casting   process.   Since   the   FTIR   spectras   from   both  
manufacturing  techniques  were  the  same,  only  electrospinning  FTIR  data  from  samples  S2  and  S3  will  be  




Figure  2.14  –  FTIR  spectra  of  sample  S2  (dark  blue).  FP  (dark  blue)  and  PEO  (green)  FTIR  spectra  were  used  as  
controls.  
  
FP  spectra  is  identical  to  the  one  reported  by  Freitas  et  al.,  2010,  displaying  a  broad  O-­H  band  around  3276  
cm-­1  that  contains  the  C-­H  band  at  2923  cm-­1.  The  characteristic  broadness  of  the  O-­H  band,  present  in  
most  exopolysaccharides  is  due  to  the  great  amount  of  hydroxyl  groups  present  in  this  type  of  polymers  
(Synytsya  et   al.,   2003).     FP  also  presents  a  possible  C-­N  band  between  1000  and  1200  cm-­1  that   can  
possibly  be  derived   from  amount  of   nitrogen   found  upon  XPS  analysis.  FP  FT-­IR  spectra  presented   in  
Figure  2.14  and  FP  FT-­IR  spectra  reported  by  Freitas  et  al.,  2010  come  from  different  batches;;  yet,   the  
experimental  and  the  reported  data  share  a  high  similarity,  proving  that  biosynthesis  of  bacterial  polymers  
has  low  batch-­to-­batch  variability,  being  able  to  obtain  consistent  and  reproducible  polymers  from  batch-­to-­
batch,  if  fermentation  parameters  are  maintained.    
  
The  presence  of  semi-­crystalline  PEO  is  confirmed  by  bands  around  1090  and  1057  cm-­1  (C-­O-­C  stretching)  
and    2875  cm-­1  (C-­H  stretching)  (Gondaliya,  2011).  Sample  S2  FT-­IR  spectra  appears  to  result   from  an  
overlap  of  pure  FP  and  pure  PEO  individual  FT-­IR  spectra,  suggesting  that  the  polymers  may  be  physically  
blended.  Furthermore,  sample  S2  FTIR  spectra  show  the  absence  of  new  peaks,  which  would  not  occur  if  
chemical  bonding  was  present.  As  a  result,  sample  S2  spectra  results  from  a  widening  of  the  2916  cm-­1  
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Figure  2.15  -­  FT-­IR  spectra  of  sample  S3.  The  FTIR  spectra  of  sample  S2  blend  and  MET  were  used  as  controls.    
The  presence  of  MET  in  the  electrospun  fibers  was  also  assessed  by  FT-­IR.  In  Figure  2.15  it  is  not  possible  
to  see  the  presence  of  metoclopramide  since  there  is  only  5.26  wt.%  of  the  drug  in  94  wt.%  polymer  content.  
Plus,  since  by  SEM  MET  seemed  to  be  heterogeneously  disperse  in  sample  S3,  the  portion  of  sample  S3  
chosen  for  FTIR  analysis  could  have  had  a  low  drug  content,  explaining  why  metoclopramide  could  not  be  
detected  by  FTIR.  The  presence  of  metoclopramide  in  the  electrospun  ODF  is  supported  by  SEM  analysis  
due  to  morphological  change  in  the  fibers  produced  by  electrospinning  and  further  in  vitro  pharmacokinetic  
studies  that  will  be  discussed  later  in  2.6.4.4.  
  
Physical  blending  between  the  used  polymers  was  expected  considering  all  components  were  physically  
blended   at   room   temperature   and   pressure,   without   pH   control.   Plus,   FP   backbone   structure   remains  
undisclosed,   making   it   difficult   to   achieve   chemical   manipulation   or   modification   of   certain   intrinsic  
characteristics.   Physical   blending   will   not   affect   the   time   required   for   the   ODF   to   dissolve   since   both  
polymers  are  already  hydrophilic.  It  is  also  proven  that  electrospinning  is  innocuous  to  the  polymeric  solution  
since  chemical  properties  remain  unchanged  before  and  after  fiber  formation,  with  all  the  initial  components  






















2.6.4   Orodispersible  film  characterization  
2.6.4.1   Mechanical  properties  
Orodispersible  films  require  manual  handling  in  order  for  them  to  be  orally  administered.  The  amount  of  
stress/strain  that  sample  S3  is  able  to  sustain  was  measured  by  uniaxial  elongation.  The  results  obtained  
are  displayed  in  Table  2.5.    
Table  2.5  –  Mechanical  properties  of  sample  S3  comprising  the  Young’s  modulus  (E),  stress  (σ)  and  strain  (ε);;  S.D.  








21.05±3.4   2.3±0.9   30.7±10.5  
    
Sample  S3  display  an  elastic  modulus  (E)  within  the  range  of  Isoprene  (IR)  (10  to  40  MPa)  or  low  density  
rigid  polymer  foams  (23  to  80  MPa)  (Gibson  et  al.,  2010).  Ferreira  et  al.,  2014  reported  that  FP  had  a  typical  
behavior  of  a  ductile  film.  Sample  S3  exhibits  a  similar  behavior  with  low  tensile  strength  at  break  (2.3  MPa),  
high  elongation  at  break  (21.05  %)  and  an  elastic  modulus  (30.7  MPa)    within  the  range  of  the  ones  found  
for  electrospinning  films  (Yao  et  al.,  2014).  However,  instead  of  ductile,  sample  3  presents  what  is  thought  
to  be  the  typical  behavior  of  a  brittle   film,  presenting  a  clean  break  upon  film  rupture  (Figure  2.16).  The  
mechanical  properties  of  all  polymeric  matrices  are  strongly  dependent  upon  the  addition  of  any  kind  of  
additive  to  the  native  formulation,  namely  plasticizers  and/or  cross-­linking  agents.  
  
Figure   2.16   –   Schematic   representation   of   the   difference   between   ductile   and   brittle   behavior   (left);;  
Experimental  data  retrieved  from  stress/strain  mechanical  tests  by  sample  S3  uniaxial  elongation  (right).  Three  






















   42  
maximum  load  of  20N  and  a  maximum  displacement  of  90  mm.  Tests  were  performed  at  ambient  temperature  and  
pressure.  
Ferreira   et   al.,   2014   reports   that   citric-­acid   was   used   as   a   cross-­linking   agent   in   the   production   of  
biodegradable  films  with  potential  packaging  applications.  In  our  formulations,  high  molecular  weight  PEO  
was  used  as  a  physical   cross-­linking  agent   since   it   allowed   fiber   formation  upon  small  amount  of  PEO  
addition,  maintaining  FP  as  the  main  component  in  sample  S3.  Water  content  is  also  an  important  factor  
that  needs  to  be  considered  when  analyzing  the  mechanical  properties  of  hygroscopic  polymeric  matrices;;  
if  the  polymer  has  a  high  water  content,  the  physical  structure  of  sample  S3  can  start  to  degrade  before  
mechanical  assessment.  For  this  reason,  it   is  important  that  prior  to  mechanical  or  any  type  of  analysis,  
ODFs  should  be  stored  in  vacuum  or  in  an  air  tight  compartment  that  will  avoid  the  samples’  mechanical  
impairment  by  environmental  conditions,  namely  humidity.  
2.6.4.2   Weight,  thickness  and  surface  pH  
Fiber  deposition  in  electrospinning  tends  to  follow  a  Gaussian  curve,  meaning  that  the  center  of  the  film  will  
have  a  higher  fiber  density  relatively  to  the  outer  edges  of  the  film.  As  was  said  in  subsection  2.5.2,  weight  
and  thickness  values  were  corrected  by  looping  a  static  collector  between  known  coordinates,  allowing  the  
film   to   display   similar   thickness   throughout   its   entire   area.   However,   as   was   previously   mentioned   in  
subsection  2.6.2.1,  the  drug  was  not  homogeneously  distributed  in  sample  S3,  resulting  in  film  areas  that  
exhibits   higher   drug   loadings.   Solid   drug   deposition   can   lead   to   self-­assembly   phenomenon   since   the  
electrical  field  will  be  heightened  in  those  areas  (Reis  et  al.,  2013).  Hence,  fibers  tend  to  deposit  in  areas  
where  the  fiber  density  is  higher,  leading  to  discrepancies  in  weight  and  thickness.  Even  so,  electrospun  
sample  S3  is  according  to  the  requirements  for  orodispersible  platforms  (Bala  et  al.,  2013)  with  average  
thickness  around  104  ±  20  µm  and  an  average  weight  of  32.600±  0.003  mg  for  an  entire  electrospun  film.  
ODF   requirements  state   that  sample  S3  can  have  a   thickness  between  1  and  100  µm,  however,  when  
sample   S3   exhibited   50   µm,   poor   manual   handling,   breaking   or   rupturing   at   the   slightest   touch   was  
observed.  As  a  rule,  every  system  must  be  evaluated  since  each  polymer  or  blend  behaves  differently;;  for  
our  formulation,  the  only  sample  capable  of  sustaining  the  number  of  characterizations  performed  in  this  
dissertation  had  to  have  100  µm  in  thickness  (i.e.  sample  S3).    
Sample  S3  surface  pH  (Figure  2.17)  was  around  6.84±0.01,  a  value  within  the  natural  pH  of  the  oral  mucosa  
(Aframian  et  al.,  2006).  This  indicates  that  the  film  has  a  low  potential  to  irritate  the  sublingual  mucosa,  and  





Figure   2.17   –   Surface   pH   of   samples   S1,   S2   and   S3.  Surface   pH   is   an   average   result   from   four   consecutive  
measurements.  
2.6.4.3   Disintegration  time    
Dispersion   or   disintegration   time   of   orodispersible   films   is   not   under   rigid   protocols   by   the   European  
Pharmacopoeia   (Ph.   Eur.   5th,   2000).   It   can   be   measured   using   automatic   tablet   disintegration   tester  
(DisiTest,  Pharmatron)  or  by  Petri  dish  assay,  where  an  orodispersible  film  establishes  direct  contact  with  
a   solvent   at   specific   pH   and   temperature,   under   possible   agitation.   Both  methods   are   not   suitable   for  
orodispersible  film  formulation  since  they  require  a  large  amount  of  fluid  that  is  not  encountered  within  the  
oral   cavity   in   resting   conditions,   as  mentioned   in   subsection  1.2.   Larger   volumes  of   fluids  will   naturally  
decrease  the  time  required  for  an  orodispersible  film  to  disintegrate  or  dissolve.  Vuddanda  et  al.,  2016  used  
a  wet  sponge  (2  x  6.4  x  0.6  cm)  to  mimic  surface  structure  and  physiology  of  oral  cavity.  In  this  dissertation  
the   same   method   was   used   to   register   the   amount   of   time   required   for   sample   S3   to   disintegrate,   a  
methodology   described   in   subsection   2.5.6.3.   Solvent   casting   produced  ODFs  were   also   assessed   for  
comparison  purposes.    
  
Figure  2.18  –  Wetting  an  disintegration  of  sample  S3  and  solvent  casting  ODFs.  The  samples  were  in  direct  
contact  with  a  sponge  that  was  previously  hydrated  using  250  mL  of  simulated  saliva  at  pH  6.8.  The  time  
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from  a  digital  watch  (Casio).  Figure  2.18  show  how  both  formulations  behave  under  the  same  conditions:  
sample  S3  dissolved   in  6   to  10  seconds,  while   solvent   casting  ODFs   turned   to  gel   and  only   started   to  
disappear  after  3  minutes.  In  in  vivo  oral  conditions,  dissolution  times  are  expected  to  decrease  even  further  
for  both  formulations,  since  the  oral  cavity  is  in  dynamic  motion  due  to  the  movement  of  the  tongue  and  the  
stimulation  of  saliva  production.  Plus,  the  fact  that  electrospun  orodispersible  films  have  higher  interspace  
porosity  and  higher  area  to  volume  ratio,  makes  the  amount  of  connections  between  the  film  and  the  oral  
mucosa  much  higher,  enabling  the  adherence  of  the  ODF  in  a  smaller  time  frame,  which  leads  to  faster  
disintegration  times.  
2.6.4.4   In  vitro  drug  delivery  kinetic  profile  
MET  release  studies  were  performed  using  sample  S3  (ES)  and  solvent  casting  ODFs  (SC)    (Figure  2.19).  
Analyzing  plot  1,  it  is  possible  to  observe  the  release  of  60%  of  MET  into  the  medium;;  the  results  were  fitted  
to  Korsmeyer  and  Peppas  equation  for  slabs  (Ritger  and  Peppas,  1987).  The  standard  deviation  for  both  
assays  had  an  average  value  of  0,012  for  electrospinning,  and  0,13  for  solvent  casting.  Error  bars  were  
omitted  from  the  plots  bellow  since  they  were  unintelligible.  
Figure  2.19  –  Drug  release  kinetic  profile  of  MET  (1).  Drug  release  from  sample  S3  (ES)  and  solvent  casting  ODFs  
(SC)  is  detail  (2).  MET  was  quantified  by  UV/Visible  spectrophotometry  using  a  calibration  curve  available  in  Annex  4.  
Considering  that  the  total  amount  of  MET  in  the  casting  solution  was  5.26%  (subsection  2.5.2),  electrospun  
and   solvent   casting  ODFs  were   able   to   entrap   approximately   3%,  which   accounts   for   60%  of   the   total  
amount  MET  available  (  Figure  2.19,  plot  1).  Although  sample  S3  and  solvent  casting  ODFs  have  similar  
MET   release  profiles,   for   the   same  amount   of   time   (plot   2)   electrospun  ODFs   release  60%  of   its  MET  
content  while  solvent  casting  ODFs  release  only  approximately  35%  of  its  MET  content  (  Figure  2.19,  plot  
2).    
The  results  show  that  electrospun  OFDs  have  a  faster  drug  release  than  solvent  casting  ones,  which  is  a  







































also  noted  that  neither  ODFs  released  the  5.26%  of  MET  initially  incorporated  in  the  casting  solution;;  the  
difference  in  drug  loading  and  entrapment  efficiency  can  be  related  to  the  viscosity  of  the  solution.  That  is,  
when  preparing  a  solution  for  electrospinning  or  solvent  casting,  it  is  common  to  prepare  an  excess  sample  
volume   in  order   to  have  more  or   less  1  mL  that   is   retained   in   the   flask,  due   to   the  high  viscosity  of   the  
sample  (e.g.  preparing  a  solution  containing  4  mL  and  be  able  to  retrieve  3  mL).  The  viscous  nature  of  the  
sample  prevents  the  total  retrieval  of  the  solution  and  as  a  consequence,  part  of  the  drug  is   left  behind.  
Additionally,   considering   that   metoclopramide   is   insoluble   in   the   experimental   conditions   described   in  
subsection  2.5.2,  the  drug  will  not  have  a  homogenous  dispersion  in  the  electrospun  ODF,  possibly  leading  
to  the  analysis  of  samples  with  lower  drug  content.  In  order  to  promote  a  uniform  drug  dispersion,  acidic  
solvents  can  be   tested   in  order   to  see   if  an  acidic  environment   is  able   to  dissolve  MET,  although  some  
cannot  homogeneously  dissolve  FP  (Annex  1).    
Either  way,  the  goal  was  to  assess  the  time  required  for  both  formulations  to  release  the  total  amount  of  
drug  present  in  the  ODF  samples  prepared  by  different  methods.  The  release  kinetics  from  both  ODF  was  
modeled  according   to  Korshmeyer  and  Pappas  equation   that   relates   the   fractional   release  of  drug  at  a  
given  time  (Mt),  to  60%  of  total  drug  release  over  time  (M∞).  
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Figure   2.20   –  Metoclopramide   release   studies  modeled   according   to   Korsmeyer   and   Peppas.  Drug   release  
modeling  of  electrospun  (ES)  and  solvent  casting  (SC)  ODFs  –  plot  1  to  4.  
Looking  at  Figure  2.20,  plot  1  it  is  possible  to  conclude  that  the  release  of  MET  at  pH  6.8  had  an  anomalous  
transport  (non-­Fickian  mechanism)  in  electrospun  ODFs,  since  the  diffusional  exponent,  n>0.5.  This  means  
that  both  mechanisms  –    water  uptake  and  Fick’s  diffusion  –  are  responsible  for  MET  release.  Since  the  
ODF  is  extremely  thin  and  hydrophilic,  water  uptake  is  difficult  to  be  measured,  although  it  can  possibly  be  
the  leading  cause  for  ODF  disintegration.  Also,  since  the  diffusional  exponent,  n,   is  further  from  0.5,  it  is  
thought  that  drug  release  is  more  controlled  by  water  uptake  than  diffusion.  (Cabral,  2013)  
The  release  mechanism  of  MET  for  solvent  casting  ODFs  at  pH  6.8,  (Figure  2.20,  plot  2)  is  still     slightly  
anomalous,  although   the  diffusional  exponent   is  very  close   to  0.5   implying  a  greater  contribution  of   the  
diffusional  mechanism  than  the  swelling.  (Ritger  and  Peppas,  1987)  
2.6.4.5   Cytotoxicity  
As  a  validation  of  the  previous  reported  results,  eletrospun  ODFs  effect  on  cell  viability  was  assessed  by  
resazurin   assay.   Viable   cells   are   able   to   metabolize   non-­fluorescent   resazurin   to   strongly-­fluorescent  
resorufin.  The  amount  of  resazurin  that  is  reduced  by  metabolically  active  cells  is  proportional  to  the  amount  
of  viable  cells  and  can  be  measured  by  UV  analysis  at  570  and  600  nm.      
Primarily,  cell  viability  was  assessed  when  in  contact  with  a  range  of  concentrations  of  FP,  PEO,  MET  and  
ODF,   for   24   hours.   Afterwards,   fresh   medium   was   provided   and   24   hours   later,   resazurin   assay   was  
performed.  The  percentage  of  relative  viable  cells  is  presented  in  Figure  2.21.  
  
Figure  2.21  –  VERO  cell  viability  after  exposure  to  sample  S3  and  its  individual  components.  Cell  viability  was  
assessed  24  hours   later   to   cell   exposure  by  UV/Visible  analysis  of   the  metabolized   resazurin  at  570  and  600  nm.  
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Cytotoxic  assays  revealed   that   the  electrospun  ODF   is  non-­toxic   to  epithelial  VERO  cells  when   its  drug  
content  is  lower  than  5  mg/1.2  million  cells.  The  presence  of  metoclopramide  has  a  cytotoxic  effect  in  all  
formulations  in  values  higher  than  1  mg/well  (i.e.  200  µL)  which  is  when  MET  reaches  its  solubility  threshold.  
Apart  from  MET,  FP  and  PEO  had  no  relevant  effect  in  the  cells  viability.    
2.7   Concluding  remarks  
In  this  chapter  a  bacterial  expolysaccharide  –  FucoPol  (FP)  –  was  used  to  produce  an  orodispersible  film  
(ODF)  by  electrospinning;;  solvent  casting  method  was  used  for  comparison  purposes.  It  was  not  possible  
to  produce  fibers  from  stand-­alone  FucoPol,  and  for  that  reason,  high  molecular  weight  poly(ethyle  oxide)  
(PEO)  was  used  as  a  physical  cross-­linking  agent.  The  electrospun  orodispersible  film  (ODF)  presented  
fiber  diameters  around  0.1  to  0.2  micrometers  and  a  mechanical  brittle  behavior,  with  dissolution  rates  from  
6  to  10  seconds.  ODF  release  100%  of   its  drug  content   in   less  than  5  minutes  by  anomalous  transport,  
which  means  that  both  swelling  and  diffusion  are  responsible  for  drug  release.    Metoclopramide  dosages  
above  1mg/mL  are  toxic  to  the  cells  and  ODFs  surface  pH  is  within  the  oral  cavity  usual  pH,  proving  that  
the  obtained  ODF   formulation   is   innocuous   to   the  oral   flora.  Solvent  casting   films  had   lower  dissolution  
rates  (1  to  3  minutes)  and  slower  release  profiles  (5  to  10  minutes).  
Future  work  could  proceed  in  order  to:  
•   Perform  a  drug  and  solvent  screening  that  dissolve  both  FucoPol  and  the  chosen  drug,  creating  
homogenous  fibers  with  possible  higher  loading;;  
•   Optimize  drug  entrapment  yields  by  mixing  different  amount  of  drug  and  quantifying   it  upon   the  
production  electrospun  films;;  
•   Optimize  drug  release  protocols  in  order  to  have  a  quantitative  and  qualitative  test  that  is  suited  for  
fast  dissolution  matrices;;  
•   Perform  a  screening  of  cross-­linkers  and  plasticizers   in  order   to  use  FucoPol   in  cutaneous  and  
tissue  engeneering  applications;;  
•   Perform  an  elemental  analysis  of  same  batch  EPS  in  order  to  assess  the  presence  of  nitrogen  in  
the  sample;;  
•   Produce  microcarriers  by  electrospray,  since  FucoPol  has  no  fiber  forming  abilities.  
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3  Production  of  FucoPol-­based  3D  




As  mentioned   in  Chapter   1,   subsection   1.2.3,   the   goal   of   this   dissertation   is   to   use   the   bacterial  
exopolysaccharide   FucoPol,   produced   by  Enterobacter   A47   in   a   bioreactor   synthesis,   in   order   to  
produce  3D  constructs  for  oral  drug  delivery.    
  
In   Chapter   2,   the   fiber   forming   abilities   of   FucoPol   were   assessed   in   a   process   known   as  
electrospinning  -­  a  fiber  forming  technique  that  is  able  to  produce  thick  controlled  films  that  display  a  
high  surface  to  volume  ratio.  FucoPol  did  not  show  any  fiber  forming  abilities;;  as  a  result  it  was  cross-­
linked  with  poly  (ethylene  oxide)  in  order  to  produce  an  orodispersible  film  (ODF)  by  electrospinning.  
The  resulting  ODF  showed  faster  polymer  dissolution  rates  and  increased  in  vitro  drug  delivery,  when  
comparing  the  results  to  most  common  ODF  production  methods.  
  
In  Chapter  3,  supercritical  carbon  dioxide  will  be  used  in  order  to  aid  the  production  of  a  FucoPol  dry  
scaffold,  previously  obtained  by  cryogelation.  The  combination  of  different  techniques  will  allow  the  
production  of  a  porous  structure  suitable  for  oral  drug  delivery.  The  procedure  will  be  explained  along  
with   product   characterization   will   be   discussed   through   the   entire   chapter,   finalizing   with   the  
concluding  remarks  and  future  perspectives.  
3  
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3.1   Scaffolds:  3D  porous  constructs  
In   tissue   engineering,   scaffolds   are   defined   as   3D   artificial   structures   capable   of   promoting   cell  
attachment,   migration   and   delivery,   promoting   three-­dimensional   tissue   formation   while   exerting  
mechanical  and  biological  support  in  situ.  (Hollister,  2005)  In  this  dissertation,  scaffolds  will  be  defined  
as   3D   polymeric   porous   structures   eligible   for   drug   delivery.   The   polymers   intrinsic   chemical  
characteristics  as  well  as  pore  size  and  distribution  will  dictate  the  scaffold  final  application.  (Anjum  
et  al.,  2016;;  Knežević  and  Durand,  2015;;  Liu  et  al.,  2014)  
Although   scaffolds   are   not   exclusive   to   polymeric   sources,   most   of   them   are  made   by   synthetic  
polymers   due   to   their   wide   range   of   molecular   weight,   mechanical   properties,   high   purity,  
reproducibility   and   known  molecular   structure   (Rodriguez   et   al.,   2014).   Despite   that   fact,   natural  
polymers   are   gaining   relevance   due   to   their   low   production   costs,   biocompatibility   and  
biodegradability  –  desirable  characteristics  for  physiological  applications.  For  example,  chitosan  –  a  
natural  polymer  which  results  from  the  deacetylation  of  chitin  from  the  exoskeleton  of  crustaceans  
(e.g.  shrimp)  –  has  been  extensively  applied  in  many  sectors  due  to  being  nontoxic,  biocompatible  
and  biodegradable.   It  has  been  used  many   times  as  a  skin  substitute   (Kim,  2015)  or  as  base   for  
monolith  antibody  or  adenovirus  purification  (Barroso  et  al.,  2012)  (Fernandes  et  al.,  2015).  Chitosan  
was   also   blended   with   heparin   in   order   to   obtain   an   artificial   macroporous   scaffold   for   tissue  
engineering  applications  (Yu  et  al.,  2008)  and  blended  with  agarose  –  a  galactose  polysaccharide  
extracted  from  seaweed  –  for  IgG  purification  (Sun  et  al.,  2012).  Cellulose    –  a  glucose  polysaccharide  
is   the  main  structural   component   found   in   the  cell  wall   of  plants  –  has  also  been  used   in  protein  
separation  through  the  use  of  morphology  controlled  membranes  (Barroso  et  al.,  2010)  and  foams  as  
packaging  materials  (Svagan  et  al.,  2011)    
Bacterial  polysaccharides  are  just  now  being  considered  in  the  world  of  clinical  applications,  since  
their   most   promising   features   are   already   being   applied   in   the   food   sector   as   thickening   and/or  
stabilizing  agents.  The  gelling  abilities  of  Kefiran  -­  a  water-­soluble  exopolysaccharide  produced  by  
Lasctobacilus  keriranofaciens  from  water  kefir  grain  –  was  assessed  by  Piermaria  et  al.,  2008  and  
Zavala  et  al.,  2014  in  the  production  of  a  cryogel  when  sucrose  and  fructose  were  present.  Pullulan  
and  dextran  –  glucose  containing  bacterial  polysaccharides  –  hybrid  scaffold  were  also  produced  by  
(Autissier   et   al.,   2010)   using   trisodium   trimetaphosphate   (SMTP)   as   a   cross-­linking   agent   under  
alkaline  conditions  and  in  the  production  of  small  diameter  arterial  grafts  (Chaouat  et  al.,  2006),  with  
pullulan  being  used  as  a  stand-­alone  hydrogel  for  smooth  muscle  cell  culture  (Autissier  et  al.,  2007).  
Sponge-­like  hydrogels  of  gellan-­gum  and  curdlan  microspheres  were  also  reported  by  (da  Silva  et  
al.,  2014)  and  (Mocanu  et  al.,  2009).  
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3.2   Production  methods  for  3D  constructs  
Multiscale  control  of  the  macro  and/or  micro  scale  properties  of  the  3D  constructs  is  possible  through  
the  manipulation  of  the  processing  parameters  involved  in  each  technique,  namely  temperature  and  
pressure,   as   well   as   the   choice   of   solvent   and   polymer.   3D   constructs   can   be  manufactured   by  
numerous   techniques   (Svec,   2010),   (Nichol   and   Khademhosseini,   2010),   (Sears   et   al.,   2016),  
including  the  cast  of  a  solution  onto  a  glass  plate  to  produce  a  3D  scaffold  (i.e.  solvent-­casting);;  salts  
are  added   to   the   solution   in   order   to   produce  a  porous   structure  with   specific   pore  diameter   (i.e.  
particulate   leaching)   (Taherkhani   and   Moztarzadeh,   2016).   Sol-­gel   (Owens   et   al.,   2016),  
electrospinning  (Zhu  et  al.,  2015),  supercritical   fluids  (García-­González  et  al.,  2012),   freeze-­drying  
(Sultana   et   al.,   2015)   and   cryogelation      (Oliveira   et   al.,   2015)   are   other   techniques   used   in   the  
production  of  #D  porous  structures.  
In  this  dissertation  the  focus  will  be  on  cryogelation  technique  associated  with  solvent  extraction  by  
supercritical  carbon  dioxide,  since   the  coupling  of   these   techniques  allows   for   the  production  of  a  
macroporous   interconnected   pore   structure   suitable   for   drug   delivery   (Liang   and   Kiick,   2014),  
separation  and/or  downstream  processing  applications  (Fernandes  et  al.,  2015)  
3.2.1   Cryogelation  
  As  mentioned  in  subsection  1.2.2,     some  polysaccharides  possess  gelling  or  film  forming  abilities  
when   mixed   with   water.   Since   the   grand   majority   is   only   soluble   in   aqueous   solvents,   they   can  
produce  hydrogels,  jellified  structures  with  temperature  as  crosslinker  (e.g.  gelatin).  Some  can  also  
display  foaming  abilities,  producing  supercritical  dried  aerogels,  polymeric  structures  that  result  from  
solvent  extraction  by  supercritical  fluids,  creating  light,  foam-­like  structures  with  controlled  porosity  
upon  system  depressurization.  Cryogels  are  highly  porous  structures  produced  by  freezing  a  solution,  
suspension   or   gel   at   subzero   temperatures.   The   interconnected   porous   structure   is   formed   by  
nucleation  process,  followed  by  ice  crystal  growth  due  to  solvent  crystallization.  Lower  temperatures  
have  faster  freezing  times  (e.g.  -­80  ºC),   inducing  smaller  crystal  formation,  that  in  return  produces  
smaller  pore  sizes.  Higher  subzero  temperatures  (e.g.  -­20  ºC)  promote  slower  freezing  times,  allowing  
ice  crystals  to  grow  heterogeneously,  inducing  the  formation  of  bigger  pores.  By  tuning  the  freezing  
temperature   at   which   a   given   solution   is   frozen,   macro   (>50   nm),   mesoporous   (2   to   50   nm)   or  
nanoporous  (<  2  nm)  structures  are  feasible  to  be  obtained.(Xu,  2013)    
Figure  3.1  shows  a  schematic  representation  of  the  production  of  scaffolds  through  cryogelation.  After  
pore   formation   by   freezing   step,   cryogels   can   have   their   solvent   removed   by   sublimation   (i.e.  
lyophilization),  a  common  method  that  can  hinder   the   internal  cryogel  structure  by  promoting  pore  
collapse,  inducing  polymer  shrinkage  (e.g.  xerogels)  or  cracked  structures,  upon  solvent  evaporation.  
Combining  cryogelation  with  supercritical  fluid  extraction  allows  for  the  internal  structure  of  the  cryogel  
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to  be  maintained,  since  the  scaffold  structure  is  filled  with  liquid-­like  gas  that  will  hold  the  structure  
together,  avoiding  pore  collapse.  
Figure   3.1   –   Schematic   representation   of   cryogelation   process.  A   homogeneous   casting   solution   (1)   is  
frozen  at  subzero  temperatures  where  pore  formation  begins  due  to   ice  crystal  growth  (2);;  solvent  extraction  
process  (3)  is  required  in  order  to  obtain  a  dried  cryogel  with  interconnected  pores  (4).  Adapted  from  LANG  et  
al  
3.3   Supercritical  Fluid  Technology  
  Supercritical  is  what  is  said  of  a  fluid  that  has  surpassed  its  critical  temperature  and  pressure,  i.e.,  a  
fluid   is   supercritical  when   the  difference  between   the   liquid  and  vapor  phases  disappears.   In   this  
region,   the   fluid  exhibits  both   liquid  and  gas  attributes,   displaying  density   that   of   a   liquid  and   the  
diffusivity  of  a  gas  (Table  3.1)  .    




Carbon  dioxide  (CO2)  is  the  most  used  SF,  displaying  a  low  critical  point  (7.37  MPa;;  304.13  K)  (Figure  
3.2)  and  a  GRAS  (Generally  Recognized  as  Safe)  status,  being  easily  separable  from  solvents  and  
polymeric  mixtures  or  residues  due  to   its  gaseous  form  in  standard  conditions  of   temperature  and  
pressure  (Table  3.1).  A  small  change  in  temperature  and/or  pressure  can  increase  de  CO2  solvation  
power  close  to  the  critical  point  since  there  is  an  enhancement  in  the  heat  capacity  of  the  fluid  in  that  
region.  Plus,  CO2  is  nontoxic,  nonflammable  and  cheap,  since  it  can  be  reused.  (Kiran  et  al.,  2012)  
  
Property   Gas   SCF   Liquid  
Density  (g.com-­3)   10-­3   0.3   1  
Viscosity  (Pa.s)   10-­5   10-­4   10-­3  
Diffusivity  (cm2.s)   10-­2   10-­3   10-­6  






Figure  3.2  –  CO2  phase  diagram.  
Supercritical  CO2  has  many  different  applications,  being  used  as  as  a  solvent  in  polymer  synthesis  
(Restani  et  al.,  2012)  or  as  an  anti-­solvent  in  spray  assisted  particle  formation  (PGSS)  (Gonçalves  et  
al.,  2015),  in  extraction  processes  (SFE),  in  membrane  production  by  drying  (RESS)  (Morgado  et  al.,  
2014)  or  as  a  porogenic  agent  (Craveiro  et  al.,  2014).  CO2  can  also  be  used  for  analytical  purposes  
in  supercritical  fluid  chromatography  (SFC)  in  protein  or  virus  purification  (Fernandes  et  al.,  2015).  
Barroso  et  al.,   2012  combined  cryogelation  process  with  a   supercritical   carbon  dioxide  extraction  
process,  in  order  to  obtain  functional  monolithic  platforms  for  antibody  purification.    
3.3.1   Supercritical  carbon  dioxide  (scCO2)-­assisted  drying  
Supercritical  carbon  dioxide  (scCO2)-­assisted  drying  is  a  green  technology  that  can  form  solvent-­free  
ready-­to-­use  3D  constructs  with  high  controlled  morphology,  by  manipulating  process  parameters,  
namely  temperature,  pressure  and  depressurization  rate.  This  procedure  has  cost-­effective  benefits  
since   it   reduces   the   solvent   recovery   process.   Additionally,   CO2   can   be   reused   and   scaffold  
production  is  less  time  consuming  than  other  common  processes,  like  lyophilizaton.    
In   order   to   extract   the   solvent,   it  must   have   affinity   with   CO2.When   drying   polysaccharide-­based  
cryogel  structures,  as  most  polysaccharide  are  water  soluble,  very  often  the  solvent  is  water  since  
water  is  the  greenest  solvent  that  can  be  used  for  pharmaceutical  or  biological  applications.  Aqueous  
solutions  have   low  affinity  with  CO2,   increasing  CO2  consumption  and   the   time   required   to  obtain  
dried  scaffolds.  To  increase  the  affinity  between  water  and  CO2  (i)  a  co-­solvent  is  used  (e.g.  ethanol)  
or  (ii)  water  can  be  entirely  removed  by  a  water-­replacement  step  known  as  phase  inversion.  Phase  
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solvent  which  has  to  precipitate  the  gel  structure,  be  miscible  in  water,  have  high  affinity  for  scCO2,  
be  innocuous  when  present  in  pharmaceutical  formulations.  The  new  solvent  freezing  point  is  also  
relevant,  since  the  solvent  cannot  solidify  in  order  for  phase  inversion  to  occur  (García-­González  et  
al.,  2011,  2012).  
3.4   Xerostomia    
Xerostomia  a  symptom  frequently  associated  with  salivary  gland  hypofunction,  characterized  by  the  
reduction  or  absence  in  saliva  production.  Xerostomia  is  a  side  effect  caused  by  several  factors;;  the  
most  prevalent  is  related  to  polymedication,  affecting  20%  of  elderly  patients,  the  most  polymedicated  
group   of   people   present   in  modern   society.   Head   and   neck   radiation   can   cause   changes   in   the  
secretory   cells   resulting   in   thicker   as   well   as   lower   saliva   flow.   Autoimmune   diseases,   like   the  
Sjögren's  syndrome  affect  many  post-­menopausal  women  due  to  lymphocytic  infliltration  of  salivary  
glands  and  diabetes  mellitus,  among  others.  Patients  who  suffer  from  xerostomia  commonly  describe  
it   as   having   a   ’’dry   mouth’’   sensation,   which   can   lead   to   hoarseness,   difficulty   in   speaking   and  
swallowing.   Plus,   since   the   antimicrobial   activity   of   the   saliva   is   absent,   xerostomia   when   left  
untreated  can  increase  the  occurrence  of  oral  plaque  and  dental  cavities  and  in  worst  cases,  halitosis,  
oral  ulcers,  cracked  tongue  and  oral  candidiasis.    
In  order   to  manage  xerostomia,  saliva  substitutes  and  xerostomia   therapies  are  a  growing  market  
since  2006,  predicted  to  be  worth  $270  million  by  2019  (Global  Data,  2012).  There  are  a  number  of  
over-­the-­counter   products   that   act   a   saliva   substitutes   in   order   to   release   xerostomia   symptoms  
(Table  3.2).  Recent   studies   report   the  use  of   bacterial   exopolysaccharides  as  a   saliva   substitute,  
taking  advantage  of  their  thickening  properties  (e.g.  xantham  gum).  
  
Many   oral   formulations   use   citric   or   ascorbic   acid   to   stimulate   saliva   production,   although   oral  
recurrent  acidic  exposure  will  decrease  the  natural  pH  of  the  oral  cavity,  promoting  enamel  abrasion,  
demineralization  and  leading  to  oral  cavity  increase.  The  use  of  xylitol  as  a  saliva  stimulant  is  a  great  
alternative,  since  oral  bacteria,  including  streptococcus  mutans,  cannot  metabolize  xylitol,.  (Haghgoo  
et  al.,  2015)  
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Ativan   Lorazepam   Benzodiazepine   Tablet   Mylan  
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Mixture  of  calcium,  
sodium,  magnesium  
and  potassium  
   Spray   Pendopharm  
Glandosane®   n.a.      Spray   Fresenius  Kabi  
  
3.4.1   Xylitol  
Xylitol   (Figure  3.3)   is   a   low  calorie   crystalline   carbohydrate  occurring  naturally   in   some   fruits  and  
xylan-­rich  plants.  It  is  many  times  associated  with  oral  dosage  forms  since  a  number  of  clinical  trials  




Figure  3.3  –  Xylitol  molecular  structure.  
  
   56  
Patients   that   suffer   from   hyposalivation   have   a   greater   probability   of   suffering   from   periodontal  
disease  since  they  do  not  possess  the  necessary  saliva  flow  to  have  an  antiseptic  and  healthy  oral  
cavity.   Their   exposure   to   bacterial   oral   disease   increases.   Xylitol   is   frequently   administered   as   a  
sugar-­free  gum  in  order  to  induce  a  stimulus  in  saliva  production  while  fighting  against  cavities.  There  
are  a  number  of  marketed  products  that  already  incorporate  xylitol  in  their  formulations,  namely  sugar-­
free  chewing  gums,  mints  and  candies  (Ly  et  al.,  n.d.).  
Most  xerostomia  relieving  formulations  demonstrate  a  peak  in  saliva  production  over  a  short  period  
of  time,  not  being  able  to  sustain  drug  release.  Plus,  many  symptom  relieving  excipients  come  in  the  
form  of  medicated  chewing  gums  that  can  cause  stress  and  induce  fatigue  in  mouth.  Hydrogels  are  
a  good  alternative  since  as  they  slowly  dissolve  in  the  mouth  they  can  also  capture  some  part  of  the  
produced  saliva,  retaining  it   in  the  oral  cavity  and  increasing  the  time  the  mouth  is  exposed  to  the  
drug.    
Combining  FucoPol  thicknening  abilities  with  xylitol,  a  salivary  stimulant,  xerostomia  symptoms  can  
be   relieved   while   promoting   good   oral   health   in   patients   experiencing   hyposalivation.  
The  objective   is   to  produce  a  FucoPol-­based  cryogel  with   a   specific   xylitol   loading,   using  
supercritical  carbon  dioxide  extraction  process  in  order  to  dry  the  FucoPol  scaffold.  
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3.5     Experimental  Section  
3.5.1   FucoPol  downstream  processing  
FucoPol  used  in  this  chapter  was  extracted  and  purified  following  the  same  procedure  described  in  
2.5.1:  FucoPol  downstream  processing.    
3.5.2   Scaffold  production  
In  order  to  produce  scaffolds,  two  samples  were  prepared,  containing  approximately  1.4  g  and  2.1  g  
of   FucoPol   and   0.7   g   of   xylitol   (Sigma-­Aldrich)   and   added   to   14   and   18  mL   of   deionized  water,  
resulting  in  10%  and  11.67wt.%  of  FucoPol  and  5%  and  3,89wt.%  of  xylitol  in  the  casting  solution.  In  
total,  the  resulting  scaffold  will  contain  66.65%  and  75  wt.  %  of  FucoPol,  and  33.34%  and  25  wt.%  of  
xylitol,  respectively  (Table  3.3).    
Table   3.3   –   Sample   formulations   used   in   the   production   of   scaffolds   by   cryogelation   coupled   with  
supercritical  carbon  dioxide  (scCO2)-­assisted  drying:  Sample  FPX1  -­    10  wt.%  of  FucoPol  (FP)  (bacterial  
exopolysaccharide  produced  and  provided  by  Pure  Cultures  Group   from  UCIBIO-­REQUIMTE/FCT/UNL,  Mw  
~106)  and  5wt.%  of  Xylitol  (Sigma-­Aldrich)  in  14  mL  of  deionized  water;;  Sample  FPX2  –  11.67  wt.  %  of  FucoPol  
and  3.89wt.%  of  xylitol   in  18  mL  of  deionized  water.   *Apparent  viscosity  was  measured  at  25   ºC  and  45   ºC  
(Annex  5).  






FPX1   1.40   0.70  
FPX2*   2.10   0.70  
Solvent:  Deionized  water  
3.5.2.1   Cryogelation  and  water-­replacement  
Cryogel  production  parameters  were  based  on  Barroso  et  al.,  2014.  18  mL  of    samples  FPX1  and  
FPX2  were  transferred  into  2  mL  stainless-­steel  molds.  Cryogelation  process  occurred  for  a  minimum  
of  24  hours  at  -­20  ºC  (VWR Signature Refrigerated/Heating Circulating Bath), subsequently followed 
by water-­replacement.  
A  small  amount  of  FucoPol  and  xylitol  was  immersed  in  a  small  amount  of  water  miscible  solvents  
(Phenomenex,   2011).   The   solvent   where   both   samples   did   not   dissolve   was   chosen   for   water-­
replacement  step.  Cryogels  were  removed  from  the  stainless-­steel  molds  and  submersed  freely  in  an  
given   amount   of   solvent.   Water-­replacement   occurred   for   48   hours,   at   -­20   ºC   (VWR Signature 
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Refrigerated/Heating Circulating Bath). The structures formed after samples FPX1 and FPX2 were 
frozen for 48 hours at -20 ºC  are  designated  as  SCA1  and  SCA2.  
3.5.2.2   Supercritical  carbon  dioxide  (scCO2)-­assisted  drying  
Supercritical   carbon   dioxide   (scCO2)-­assisted   drying   was   used   to   remove   the   solvent   from   the  
polymeric  matrix  using  the  experimental  apparatus  described  below  (Figure  3.4).  
Figure  3.4  –  Schematic  representation  of  the  supercritical  apparatus  used  to  produce  scaffolds;;  (1)  CO2  
tank  (Air  Liquid),  Gilson  HPLC  pump  (2),  Frigomix  S  cryostat,  Braun  (3),  thermostatic  water  bath  (Hart  Scientific,  
Model  2200)  (4),  stainless-­steel  high  pressure  cell  (Temtem  et  al.,  2008)    (5),  Jasco  BP-­2080  Plus  Automatic  
Back  Pressure  Regulator  (6).  Manual  valves  (V1  to  V5);;  CO2  entry  valve  (V4);;  CO2  exit  valve  (V5).  
Water-­free  cryogels  (e.g.  samples  SCA1  and  SCA2)  were  re-­inserted  into  the  stainless-­steel  molds  
and  transferred  inside  a  33  mL  high-­pressure  cell,  that  homogenously  disperses  CO2  inside  the  cell  
(Temtem  et  al.,  2008)  (5).  The  cell  was  closed  with  a  teflon  o-­ring,  8  stainless-­steel  screws  and  a  
sapphire  window,  to  prevent  pressure  oscilations,  and  immersed  in  a  thermostated  water  bath  (Hart  
Scientific,  Model  2200)(4)  at  40±0.01  ºC.  An  inlet  valve  for  CO2  admission  (V4)  is  connected  to  the  
high  pressure  cell  were  CO2  (Air  Liquid),  previously  cooled  at  -­15  ºC  (Frigomix  S,  Braun  cryostat)  (3)  
is  loaded  into  the  stainless-­steel  cell  by  a  HPLC  (Gilson)  pump  (2)  at  a  rate  of  10  mL/minute.  The  
pressure  inside  the  cell  is  monitored  by  a  pressure  transducer  (Setra  Systems  Inc.,  Model  204)  with  
a  precision  of  ±100  Pa  and  a  back  pressure  regulator  (Jasco  BP-­2080  Plus  Automatic  Back  Pressure  
Regulator)  (6)  to  a  maximum  of  150  bar,  for  8h.  In  the  end,  the  system  was  depressurized  along  10  
to  20  minutes.    
3.5.3   Analysis  of  supercritical  process  parameters  
The  behaviour  of  FucoPol,  an  amourphous  polymer  (Lourenço,  2015),  in  the  presence  of  xylitol,  was  
assessed   by   Differential   Scanning   calorimetry   (DSC),   previously   described   in   2.5.3.2   Differential  
Scanning  Calorimetry   (DSC).  Calorimetric  experiences  were   carried  out  by  DSC  Q2000   (Tzero™  
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DSC   technology,   TA   Instruments   Inc.)   under   anhydrous   high   purity   nitrogen   at   a   flow   rate   of   50  
mL.min-­1  and  temperatures  that  ranged  from  -­90  to  +1800C,  at  a  rate  of  50C.min-­1  Sample  SCA2  was  
sealed  in  aluminium  hermetic  pans  (TA  Tzero  Pan  and  lid),  punctured  for  water  evaporation.  
3.5.4   Scaffold  morphological  analysis  
Average  pore  diameter  throughout  sample  SCA2  was  performed  using  Scanning  Electron  Microscopy  
(SEM),   previously   described   in   2.5.4.1   Scanning   Electron   Microscopy   (SEM).   A   Hitachi   S-­2400  
microscope  was  used,  with  an  accelerating  voltage  of  15kV  and  a  magnification  of  5  and  10K.  SCA2  
was  frozen,  fractured  in  liquid  nitrogen  for  cross-­section  analysis,  attached  to  an  aluminum  stub  and  
gold  coated  previously  to  SEM  analysis.  
3.5.5   Scaffold  chemical  composition  
The  presence  of  xylitol  and  FucoPol   in  sample  SCA2  was  attained  by  Fourier  Transform   Infrared  
Spectroscopy   (FT-­IR),   previously   described   in   2.5.5.2   Fourier   Transform   Infrared   Spectroscopy  
(FTIR).  Attenuated  Total  Reflectance  (ATR)  sampling  accessory  (Smart  iTR)  was  used  on  a  Thermo  
Nicolet  6700  Spectrometer.  Spectra  acquisition  was  obtained  with  a  45°  incident  angle  in  4000–525  
cm−1,  with  a  4  cm−1  resolution.  
3.5.6   Scaffold  characterization  
In  order  to  assess  the  process  reproducibility,  5  samples  of  SCA2  (n=5)  were  assessed  in  terms  of  
weight,  thickness  and  surface  pH,  as  previously  described  in  2.5.6.1.    
3.5.6.1   Water  uptake1  
Water   difusion   and   absorption   plays   an   important   role   in   the   performance   and   disintegration   of  
hydrophilic  polymeric  sctructures  like  FucoPol-­based  cryogel.  Swelling  can  be  observed  upon  water  
absorption  by  hydrophilic  structures,  but   that   is  not  always   the  case  (e.g.  kitchen  sponges  absorb  
water  but  do  not  swell;;  their  size  remains  the  same).  Since  the  SCA2  sample  will  be  applied  orally,  
the   amount   of   synthetic   simulated   saliva   that   could   be   absorbed,   previous   to   mass-­loss,   was  
measured  at  1,  3,  5,  7,  10  15,  30,  60,  90  and  120  minutes.  2  samples  of  SCA2  (n=2)  were  transferred  
to  thermostatic  bath  (Concenssus  S.A.R.L.)  containing  two  glass  flasks  filled  with  10  mL  of  simulated  
                                                                                                              
1  Simulated  saliva  was  prepared  according  to  Marques  et  al.,  2011,  by  weighting  8  g/L-­1  of  sodium  
chloride  (Panreac),  2.38  g/L-­1  of  sodium  phosphate  dibasic  (Sigma-­Aldrich),  0.19  g/L-­1  of  potassium  
phosphate  monobasic   (Sigma-­Aldrich)  and  0.05  mg/  L-­1  of  Lysozyme  (Sigma-­Aldrich).  Phosphoric  
acid  (Sigma-­Aldrich)  was  used  to  adjust  pH  6.8.  
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saliva  (Marques  et  al.,  2011)  at  pH  6.8,    37  ºC  under  stirring.  The  samples  were  trapped  in  a  porous  
stainless-­steel  mesh   in   order   to   prevent   excessive  mass   scattering   to   the   aqueous   environment.  
Samples   were   weighted   before   and   after   water   uptake;;   the   difference   in   weight   in   consecutive  
measures,  before  sample  SCA2  starts   to   lose  mass,   translates   into   the  samples’  ability   to  absorb  
water.  
3.5.6.2   In  vitro  disintegration  time1  
The  time  required  for  scaffold  disintegration  was  performed  over  the  course  of  5,  15,  30,  60,  90  and  
120  minutes.  3  samples  of  SCA2  (n=3)  were  transferred  to  glass  flasks  containing  10  mL  of  simulated  
saliva  (Marques  et  al.,  2011)  at  pH  6.8,    37  ºC  and  100  rpm  (Orbital  shaker  Rotaterm,  JP  Selecta),  
Samples  were  trapped  in  a  porous  stainless-­steel  mesh  in  order  to  prevent  excessive  mass  scattering  
to   the   aqueous   environment.   Samples   were   weighted   before   and   after   water   evaporation   by  
lyophilization  (Lyo  Quest-­55,  Telstar).  
3.5.6.3   In  vitro  release  studies1  
Chromatography   is   an   analytical   technique   that   involves   the   separation,   identification   and  
quantification  of  different  components  on  the  basis  of  differences  encountered  between  the  mobile  
and  the  stationary  phase.  There  are  a  number  of  chromatographic  procedures  that  can  be  applied  
according  to  the  properties  of  a  given  sample.  High  performance  liquid  chromatography  (HPLC)  is  a  
liquid  chromatograph  technique  that  is  distinguishable  from  other  liquid  chromatography  techniques  
due  to  the  pressures  provided  to  the  system  in  order  to  separate  a  complex  mixture  (50  to  350  bar).  
The  apparatus  usually  includes  a  sampler,  a  pump  and  a  detector  that  generates  a  signal  proportional  
to  the  amount  of  sample  in  the  complex  mixture.  Although  optical  detectors  account  for  almost  71%  
of   HPLC   detectors,   electrochemical   detectors   (EC)   possess   higher   sensitivities   and   selectivity   of  
detection  without  the  need  for  secondary  reactions.  Plus,  they  are  useful  for  compounds  that  do  not  
possess   chromophore   of   fluorophore   groups   (e.g.   xylitol)   making   them   unsuitable   for   UV   and  
fluorescence  detection.  
  
A  preliminary  study  of  the  qualitative  release  of  xylitol  from  3  SCA2  samples  (n=3)  was  obtained.  The  
samples  were  transferred  to  glass  flasks  containing  10  mL  of  simulated  saliva  (Marques  et  al.,  2011)  
at  pH  6.8,  37  ºC  and  100  rpm  (Orbital  shaker  Rotaterm,  JP  Selecta).  Several  aliquots  were  retrieved  
after  10,  20  and  30  minutes,  over  the  course  of  approximately  4  hours.  Samples  were  trapped  in  a  
porous   stainless-­steel   mesh   in   order   to   prevent   excessive   mass   scattering   to   the   aqueous  
environment.   Xylitol   was   quantified   by   High   Performance   Liquid   Chromatography   (HPLC),   using  
DIONEX,   Model   ICS3000   equipped   with   an   electrochemical   detector.   Sample   separation   was  
conducted  on  an  Aminotrap  and  Carbopac  PA10  4x250mm  column  (Thermo  DIONEX)  at  a  flow  rate  
of  1  mL/minute  of  NaOH  18  mM  mobile  phase;;  column  temperature  was  30  ºC.  Total  run  time  per  
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sample  was  20  minutes,  with  injection  volumes  of  25  µL.  
  
The  total  mass  of  xylitol  released  from  samples  SCA2  is  the  sum  of  all  aliquots  retrieved  throughout  
the  4  hours.  Transport  mechanism  that  induces  drug  release    from  samples  SCA2  was  determined  
by   alternative   solution   for   short-­time   behavior   of   the   Korsmeyer-­Peppas   equation   for   cylinders,  








𝑡r   Equation  3.1  
Here,  k,  a  constant,  is  difined  by  4 𝐷𝜋𝑎2
2
  ,  with  D  being  the  constant  drug  diffusion  coefficient,  a  is  the  
cylinder  radius,  n  is  the  diffusional  exponent,  indicative  of  the  transport  mechanism  and  t  is  the  time.  
Fickian  diffusion  is  defined  by  n=0.45  and  non-­Fickian  diffusion  by  n>045,  for  cylinders.    
3.5.6.4   Cytotoxicity  
Cytotoxic  assays  were  performed  according  to  the  method  described   in  2.5.6.6  Cytotoxicity,  using  
1%  (w/v)  FucoPol,  5  %  (w/v)  of  xylitol  and  1%  (w/v)  of  a  scaffold  sample  was  performed  using  a  96-­
well   plate,   described   in    
Figure  3.5.  
                                   
  
Figure  3.5  -­  Schematic  representation  of  the  two  96-­well  plates  used  to  test  the  substracts’  cytotoxicity  
used  to  produce  sample  SCA2:  Plate  (1)  -­  FucoPol  (1  to  5);;  Xylitol  (6  to  10);;positive  control  (C+):  Dulbecco's  
Modified  Eagle  Medium   (DMEM)  with  10  μl  of  dimethylsulfoxide   (DMSO)   (11);;  negative  control   (C-­):   cells  
grown  in  DMEM  (12);;  Plate  (2)  –  SCA  2  (1  to  5);;  positive  control  (C+):  DMEM  with  10  μl  of  DMSO  (Merk)  (11);;  
negative  control  (C-­):  cells  grown  in  DMEM  media  (12).  Successive  dilutions  of  each  component  were  performed  
in  each  plate:  ½,  ¼,  1/8,  1/8,  1/16,  1/32  (w/v)  from  A  to  F,  with  respective  media  control  H  (1  to  4).  Adapted  from  
http://www.cellsignet.com,  assessed  in  1st  March  2016.  
1   2  
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3.6   Results  and  Discussion  
As  was  mentioned  in  1.3,  FucoPol  was  used  to  create  two  oral  drug  delivery  platforms.  With  that  in  
mind,  in  Chapter  3  the  goal  was  to  assess  the  interaction  between  FucoPol  and  supercritical  carbon  
dioxide  (scCO2).  A  small  amount  of  FucoPol,  in  its  solid  form,  was  inserted  in  a  33  mL  stainless-­steel  
high  pressure  cell  at  200  bar  and  40  ºC.  FucoPol  did  not  “melt”  or  dissolved  in  scCO2,  hence,  FucoPol  
did  not  possess  the  ability  to  form  foams.  (Bhamidipati  et  al.,  2013)  
FucoPol  was  used   in   scaffold   production  using   scCO2-­assisted  drying.   In   order   to   lower   the   time  
required  for  solvent  extraction  and  structure  formation,  and  considering  that  FucoPol  is  water-­soluble,  
scaffold  production  by  cryogelation  was  performed.  However,  water  has  low  affinity  for  CO2.  Hence,  
a  water-­replacement  step  is  required  for  excess  water  removal  from  the  cryogel  structure.  
3.6.1   Scaffold  production  
In  order  to  obtain  a  ready-­to-­use,  dry  scaffold,  the  choice  of  solvent  in  water-­replacement  step  must  
be  carefully  evaluated,  in  the  sense  that  the  solvent  chosen  must  not  dilute  the  sample,  i.e.,  must  not  
dissolve  FucoPol  or  xylitol.  A  number  of  water  miscible  solvents  were  tested  in  order  to  assess  which  
demonstrated  a  better  anti-­solvent  effect  upon  the  individual  components  of  the  cryogel  (Table  3.4).    
  
Table  3.4  –  Water  miscible  solvents   tested  as  anti-­solvents   to  FucoPol  and  xylitol.  The  solvents  were  
classified  as  partially  soluble   (PS),  non  soluble   (NS)  or  soluble   (S)  according   to   their  ability   to  dissolve  each  
component.  Xylitol  solubility  was  assessed  first  and  later,  FucoPol  solubility  was  tested  in  the  solvents  that  did  
not  solubilize  xylitol.  
   Xylitol   FP   Water  
Acetic  acid  (Panreac)   PS   PS   Miscible  
Acetone  (LabChem)   NS   NS   Miscible  
Acetonitrile  (Sigma-­Aldrich)   NS   PS   Miscible  
Dimethylformamide  RS  (Carlo  Erba)   S   -­   Miscible  
Dimethylsulfoxide  RPE  (Carlo  Erba)   S   -­   Miscible  
1,4-­Dioxane  (Scharlau)   PS   -­   Miscible  
Ethanol  96º  (Carlo  Erba)   S   NS   Miscible  
Methanol  RS  (Carlo  Erba)   PS   NS   Miscible  
2-­Propanol  (LabChem)   NS   NS   Miscible  
Tetrahydrofuran  (Sigma-­Aldrich)   NS   PS   Miscible  
  
Acetone  and  2-­propanol  were  the  only  two  solvents  that  did  not  dissolve  both  FucoPol  and  xylitol.  
Since   they   both   have   a   good   affinity   to   CO2   (Table   3.5)   both   solvents   were   used   in   the   water-­
replacement  step.  
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Table  3.5  –  Solubility  and  boiling  temperature  parameters  of  the  solvents  involved  in  water-­replacement  
(Hansen,  2007)  
   δ  (MPa)   Tboiling  (ºC)  
Acetone   19.9   56.1  
2-­propanol   23.6   82.6  
Water   47.8   100  
  
Considering  the  previous  information,  and  the  work  of  Barroso  et  al.,  2014,    a  preliminary  3D  structure  
was  produced  (i.e.  SCA1),  using  sample  FPX1,  in  the  course  of  24  hours  at  -­20  ºC.  Afterwards,  the  
cryogel   was   directly   immersed   in   acetone   in   order   to   avoid   any   possible   diffusivity   barriers   and  
acetone-­water  replacement  occurred  for  48  hours  at  -­20  ºC.  SCA1  was  dried  for  3  hours,  using  scCO2  
at  45  ºC,  150  bar  and  10  mL/minute  of  CO2.  Depressurization  occurred  for  10  minutes.  The  results  









Figure  3.6  –  Scaffolds  prepared  by  cryogelation  at  -­20  ºC  (24h)  using  water-­acetone  replacement  (-­  20  ºC,  
48h  hours)    prior  to  scCO2-­assisted  drying  at  150  bar,  45º  C,  10  mL.min-­1  (3  hours).  
Analyzing  Figure  3.6,  it  is  possible  to  infer  that  water-­acetone  replacement  was  successful  due  to  the  
production  of  rigid,  dry  and  shrunken  scaffold  (i.e.  SCA1)  (García-­González  et  al.,  2012).  However,  
scaffolds  were  extremely  porous,  presenting  heterogeneously  distributed  macroporous  that  disrupted  
the  pore   interconnectivity,   resulting   in   the   formation  of  holes  within   the  polymeric  matrix.  Extreme  
pore   enlargement   associated   with   polymer   shrinkage   may   have   a   higher   manifestation   in   low  
concentrated  polymer  solutions,  due  to  a  higher  water  content  that  will   induce  the  formation  of   ice  
crystals  with  increased  dimensions.  Furthermore,  at  -­20  ºC  the  crystals  experience  slower  freezing  




Since  low  polymer  concentration  could  be  the  contributing  factor  to  pore  collapse  in  SCA1  (Figure  
3.6),  a  second  attempt  to  produce  a  scaffold  was  performed,  using  solution  sample  FPX2  (Table  3.3)  
in   order   to   produce   scaffold  SCA2.   The   solvent   chosen   for   the  water-­replacement   step  was   also  
changed  from  acetone  to  2-­propanol.  From  this  moment  on,   the  results  showed  are  related  to  the  
characterization   of   SCA2,      produced   by   cryogelation   coupled   with   supercritical   carbon   dioxide  
assisted  drying,  using  the  formulations  displayed  in  Table  3.3  of  subsection  3.5.2.  
In  order  to  simplify  data  presentation  and  the  discussion  of  the  obtained  results,  FPX2  will  represent  
the  experimental  formulation  used  to  prepare  scaffold  SCA2,  while  all  the  compounds  present  in  those  
formulations  will  be  mentioned  as    FP  (i.e.  FucoPol)  and  Xylitol,  from  this  moment  on  until  the  end  of  
subsection  3.6.5.4.  
  
3.6.2   Analysis  of  supercritical  process  parameters  
3.6.2.1   Differential  Scanning  Calorimetry  (DSC)  
As  mentioned  in  2.6.1.2,  Differential  scanning  calorimetry  was  performed  in  order  to  evaluate  if  SCA2  
had   any   phase   transformations,   as   melting   (transition   from   crystal   to   liquid)   or   crystallization  
(transition   from  melt   to   a   crystalline   solid),   occurring   at   temperatures   Tm   and   Tc.   Glass   transition  
temperature  is  defined,  Tg.  when  a  material  avoids  crystallization  and  is  supercooled,  increasing  the  
viscosity  and  vitrifying  the  material  in  a  disordered  solid  (amorphous  material).  (Shawe  et  al.,  2000)  
Differential  scanning  calorimetry  was  performed  in  order  to  determine  if   the  scaffolds  can  undergo  
any  kind  of  induced  thermal  degradation  above  40  ºC.  These  were  the  temperatures  used  to  dry  the  
scaffolds   in   supercritical   conditions.   As   reported   in   2.6.1.2,   FP   is   known   to   be   amourphous   form  
previous  work  (Cândido,  2015),  presenting  a  degradation  temperature  around  268  ºC.  SCA2  results  
from  a  blend  of  FP  and  xylitol;;  Figure  3.7  provides  the  DSC  data  from  analyzed  scaffold.  
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Figure  3.7  –  Thermal  analysis  (DSC)  of  scaffolds  produced  by  66.66%  of  FucoPol  and  33%  of  xylitol,  at  a  
temperature  range  of  -­90  ºC  to  180  ºC  at  5  ºC.min-­1.  SCA2  sample  was  inserted  into  an  aluminum  hermetic  
pan  in  order  to  allow  water  evaporation.  DSC  analysis  lasted  over  4  hours,  using  three  heating  cycles  to  induce  
sample   melting   (blue,   green,   brown)   and   two   cooling   cycles   for   sample   recrystallization   (red,   pink).   Water  
evaporation  was  registered  in  the  first  heating  cycle  (blue).  The  last  heating  cycle  (brown  line)  was  performed  at  
30  ºC.min-­1.  
DSC   analysis   show   that   the   scaffold   lacks  melting   or   crystallization   events,   so   SCA2   should   be  
completely  amorphous.  This  is  a  characteristic  behavior  found  in  pure  FucoPol  solutions  (Lourenço  
et  al).  Since  xylitol  acts  as  a  solvent   for  FucoPol,   increasing   the  solubilization  power  of  water,   its  
influence  on  the  thermal  behavior  of  FP  is  apparently  null,  unlike  the  behavior  found  in  2.6.1.2,  where  
FP  was  physically  cross-­linked  with  poly  (ethylene  oxide).    
  
The   combination   of   FP  and   xylitol   does  not   alter   the   amorphous   state   of   FP.  The  blend   remains  
complety  amourphous,  so  it  is  safe  to  say  that  working  supercritical  temperatures  (above  40  ºC)  will  
not  promote  or  induce  melting  of  the  sugar  content  present  in  both  FP  and  xylitol,  since  there  are  no  
registered  phase  transitions.  
3.6.3   Scaffold  morphological  analysis  
Visual  representation  of  the  scaffolds  produced  by  cryogelation,  using  75%  of  FP  and  25%  of  xylitol  
and   2-­propanol   for   the   water-­replacement   step.   Scaffolds   were   dried   using   supercritical   carbon  





Figure   3.8   –  Visual   representation  of   the   scaffolds  obtained  by   cryogelation   at   -­20   ºC   (24h)   using   2-­
propanol-­water   replacement   (-­   20   ºC,   48h   hours)   prior   to   scCO2-­assisted   drying   (150   bar,   40º   C,   10  
mL.min-­1,  8  hours).    
Analyzing  Figure  3.8,  it  is  possible  to  infer  that  2-­propanol-­water  replacement  was  successful,  since  
a   rigid,   dry   scaffold   was   obtained.   The   increase   in   FP   concentration   led   to   a   uniform   scaffold  
morphology,  both  external  and  internal,  not  found  in  the  scaffolds  containing  66.66  wt.%  of  FP  and  
33.33  wt.%  of  xylitol,  produced  using  acetone  for  water-­replacement  step  (Figure  3.6).  When  acetone  
was  replaced  by  2-­propanol,  the  time  required  for  scCO2-­assisted  phase  inversion  increased  from  3  
to  8  hours   since  scaffold  production  below  8  hours  produced  scaffolds  with  a   residual  amount  of  
moisture.  When  comparing  the  two  solvents  (Table  3.5),  2-­propanol  exhibits  a  higher  boiling  point  
that  acetone,  which  can   lead   to   lower  vapor  pressure,   resulting   in  slower  solvent  extraction  upon  
scCO2-­assisted  drying.    
  
Combining  acetone-­water  replacement  with  higher  FP  concentrations  in  sample  FPX2  was  the  next  
step  since  through  this  combination  the  time  required  for  scCO2-­assisted  phase  inversion  is  reduced  
and  the  scaffolds  obtained  will  possibly  have  uniform  morphology;;  however,  given  the  time  and  the  
amount  of  FP  available,  further  process  optimization  was  not  viable.  The  remaining  scaffold  replicates  
were  produced  under  the  same  conditions  as  the  scaffolds  displayed  in  Figure  3.8,  in  order  to  obtain  
comparable  results.    
3.6.3.1   Scanning  Electron  Microscopy  (SEM)  
Morphological   imaging  of  SCA2  polymeric   scaffolds  was  assessed  by  SEM;;   results  are  shown   in  
Figure  3.9.  Through  SCA2  cross-­section  is  possible  to  notice  the  presence  of  asymmetrical  layers  in  
outer   layers  of   the  scaffolds   (red  arrows);;   the  dense  outer   layer  provides   resistance,   integrity  and  
rigidity  to  the  scaffolds’  morphology.  The  production  of  asymmetrical  membranes  upon  sccO2-­drying    
was  also  reported  by  Morgado  et  al.,  2014  in  the  production  of  PVA/chitosan  wound  dressings.    
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Surface   Cross-­section  
     
     
  
Figure  3.9  –  SEM  imaging  of  superficial  and  cross-­section  SCA2  scaffolds  containing  075  wt.%  of  FP  and  
25  wt.%  of  xylitol,  under  30k  (upper  row)  and  100k  (lower  row)  amplifications.  Cryogelation  occurred  for  
24h  at  -­20  ºC  with  subsequent  2-­propanol-­water  replacement  for  48  hours  at  -­20  ºC  and  supercritical  carbon  
dioxide  (scCO2)-­assisted  drying  for  solvent  extraction  for  8  hours  at  40ºC,  150  bar,  10  mL/minute  of  CO2  and  
depressurization  rates  around  10-­20  minutes.  
The   average   pore   diameter   found   in   the   surface   of   the   scaffold,   measured   by   ImageJ   software,  
presented  an  average  size  of  126.26  µm,  indicating  the  presence  of  macroporous  (>50  nm).  However,  
when  observing  the  SCA2  cross-­section  it  is  possible  to  perceive  the  heterogeneous  distribution  of  
the  pores  within   the  polymeric   scaffold,  due   to   the  presence  of  holes  and  pockets.  Average  pore  
diameter  ranged  from  105.4  µm  to  1.94  mm,  values  that  can  be  narrowed  by  decreasing  cryoglation  
temperature.  Lower  subzero   temperatures   (e.g.   -­80   ºC)  promote   faster   freezing   times   that   induce  
smaller  ice  crystal  formation,  which  in  turn  produce  a  higher  number  of  pore  with  smaller  diameters.  
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Additionally,   slower   scCO2-­assisted   dryingdepressurization   rates   can   prevent   further   pore  
enlargement.  
  
By  SEM  imaging,   it   is  possible  to  conclude  that   for  our   formulation  and  purpose,  cryogelation   is  a  
suitable   technique   that   is   able   to   create   a   macroporous   scaffold.   Although   the   SCA2   presents  
heterogeneous  pore  distribution,  xylitol  should  be  released  and  absorbed  by  the  oral  mucosa  since  
xylitol  presents  a  low  molecular  weight,  suitable  to  be  released  from  the  porous  structure.  A  controlled  
release   of   xylitol,   over   time,   can   possibly   require   lower   pore   diameter   and/or   the   presence   of  
dendrimers.   
3.6.4   Scaffold  chemical  composition  
3.6.4.1   Fourier  Transformed  Infrared  Spectroscopy  (FTIR)  
FTIR  analysis  was  performed  in  order  to  evaluate  if  all  the  individual  componentes  of  the  scaffolds  -­  
FucoPol  and  xylitol  -­  were  present  in  the  sample,  after  cryogelation  and  scCO2-­assisted  drying.    FT-­
IR  spectra  of  SCA2  is  presented  in  Figure  3.10.  
  
Figure  3.10  –  FT-­IR  spectra  of  SCA2.  The  individual  FTIR  spectra  of  FP  and  xylitol  were  used  as  controls.  
FP  spectra,  previously   reported   in  2.5.5.2,   remains   identical   to   the  one   reported  by  Freitas  et  al.,  
2010,  displaying  a  broad  O-­H  band  around  3276  cm-­1,  a  C-­H  band  at  2923  and  1400  cm-­1  and  C-­O  or  
possible  C-­N  band  between  1000  and  1200  cm-­1  that  can  possibly  be  derived  from  amount  of  nitrogen  
found  upon  XPS  analysis.   
Xylitol  and  FP  have  somewhat  similar  TIR  spectra,  sharing  bands  around  3296  to  ~3400  cm-­1  (O-­H  
stretching),  2866   to  2994  cm-­1   (C-­H  stretching)  and  1007-­1312  cm-­1  (C-­O  stretching)  Similar   to   the  
ODF  spectra  found  in  2.5.5.2,  SCA2  FT-­IR  spectra  also  appears  to  derive  from  an  overlap  between  
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As  a  result,  ODF  spectra  results  from  a  widening  of  the  3276  cm-­1  band  (O-­H)  due  to  the  contribution  
of   the   3296   cm-­1  band   from   xylitol,   and   a  widening   of   1450   to   1470   cm-­1   bands   (C-­H),   due   to   the  
contribution  of  both  FP  and  xylitol.  SCA2  FTIR  spectra   is  closely  related  to   the  profile  of  FP  FTIR  
spectra,  since  FP  acounts  for  75  wt.  %  of  the  SCA2.    
3.6.5   Scaffold  characterization  
3.6.5.1   Weight,  thickness  and  surface  pH  
In   order   to   assess   the   scaffolds   reproducibility,   weight   and   thickness   measures   were   mesured.  
Scaffolds  that  arise  from  cryogelation  (i.e.  cryotopic  scaffolds)  present  an  average  thickness  around  
700  µm  and  an  average  weight  of  (13.2±6.3)  x  10  mg.  The  surface  pH  (Figure  3.11)  of  SCA2  scaffolds  
was  within  the  normal  pH  range  found  for  the  oral  mucosa  (Aframian  et  al.,  2006).  Pharmaceutical  
excipients  should  have  a  neutral  behavior  in  order  to  be  innocuous  to  the  oral  cavity.  Scaffold  presents  
a  slightly  alkaline  surface  pH  of  7.73,  as  a  result  of  hydroxyl  group  increase  due  to  xylitol  content.  
  
Figure   3.11   –   Surface   pH   of   SCA2   samples.   Surface   pH   is   an   average   result   from   six   consecutive  
measurements  applied  to  FP,  and  SCA2  samples.  
3.6.5.2   Water  uptake  and  in  vitro  disintegration  studies  
Since  SCA2  scaffolds  are  mainly  made  of  FP  –  a  hydrophilic  polymer  –  when  the  cryogels  directly  
contact  the  oral  cavity,  saliva  absorption  will  occur,  simultaneously  to  continuous  disintegration  and  
xylitol  release  from  the  porous  scaffold.  In  order  to  determine  the  amount  of  water  uptake  before  mass  
















     
Figure  3.12  –  Water  uptake  ability   (left)  and   in  vitro  disintegration  time  (right)  of  SCA2  samples  (n=3)  
using  10  mL  of  simulated  saliva  at  pH  6.8,  37  ºC  .  Disintegration  studies  were  also  performed  at  100  rpm.  
SCA2  samples  were  able  to  absorb  30%  of  water  before  experiencing  mass  loss.  When  combining  
the   data   regarding  water   uptake   and   in   vitro   disintegration   studies,   it   is   possible   to   observe   that  
scaffold  degradation  occurs  between  5  to  15  minutes  while  swelling  phenomena  is  observed  up  to  25  
minutes.   One   possible   explanation   could   rely   on   the   vigorous   agitation   encountered   in   in   vitro  
degradation  studies,  that  can  have  increased  scaffold  disintegration,  causing  a  discrepant  behavior  
found  when  combining  both  tests.  Another  assay  should  be  performed  in  order  to  fully  comprehend  
the  scaffold  degradation  coupled  with  its  water  uptake  ability.  The  use  of  same  process  parameters  
is  proposed  in  both  assays:  smaller  degradation  times  and  milder  agitation  speeds  at  37  ºC  and  pH  
6.8.  
3.6.5.3   In  vitro  drug  delivery  kinetic  profile  
Preliminary  qualitative  studies  regarding  the  release  of  xylitol  at  pH  6.8,  from  SCA2  scaffold  samples  
were  performed.  The  results  are  showed  in  Figure  3.13.    
Pharmacokinetic   studies   were   performed   in   the   presence   of   negative   controls   (n=3)   that   did   not  
possess  xylitol  or  the  same  amount  of  FP  present  in  the  scaffold  samples  of  SCA2.  This  was  due  to  
the  fact  that  the  amount  of  FP  available  was  insufficient  to  produce  both  negative  controls  and  drug  
loaded  scaffold.  Plus,  the  time  required  for  FP  production,  purification  and  extraction  combined  with  
cryogel   preparation,   scCO2-­assisted   drying   and   product   characterization,   exceeded   the   time  
available  to  complete  this  dissertation.  Hence,  qualitative  studies  of  the  release  of  FP  were  obttained.  
In  these  studies,  it  is  not  possible  to  have  an  accurate  measure  for  the  amount  of  xylitol  released  or  
entrapped,   since   the   analytical   values   can  be  masked  by   some  part   of   FP   that   is   released  upon  
scaffold  degradation.  Nevertheless,   the  amount  of  FP   that  can  be  considered  as  a  contamination  
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profile   of   xylitol   from   the  SCA2  samples.  With   that   in  mind,   xylitol   release   seems   to   follow  Fick’s  
diffusion   law;;  a  closer   look   to   the  possible  mechanism  of   transport   is  provided  by   the  Korsmeyer-­
Peppas  equation   (Equation  3.1),  applied   for  cylinders.  This  model  only  accounts   for   the   first  20%  
release  of  the  drug.  Since  the  diffusion  exponent,  n,  is  higher  than  0.45,  xylitol  release  can  be  possibly  
associated  with  anomalous  transport,  meaning  that  both  Fickian  and  non-­Fickian  mechanisms  could  
be  involved  in  the  release  of  xylitol  (e.g.  diffusion  and  swelling).    
     
  
Figure   3.13   –   Xylitol   qualitative   release   studies   from   SCA2   samples.   The   presence   of   xylitol   in   SCA2  
samples  was  assessed  by  HPLC  using  an  electrochemical  detector,  a  flow  rate  of  1  mL/minute  of  NaOH  18  mM  
mobile  phase,  a  column  temperature  of  30  ºC  and  an  injection  volume  of  25  µL.    
In  order  to  accurately  perform  pharmacokinetic  studies  that  provide  reliable,  quantitative  analytical  
information   regarding   xylitol   release   from  SCA2  porous   scaffolds,   triplicates   of   a   negative   control  
need  to  be  performed  (75  wt.%  of  FP)  in  the  same  conditions  as  the  SCA2  scaffolds  were  performed  
(3.5.2).  That  way,  the  contribution  of  FP  to  the  acquired  data  can  be  subtracted,  leaving  only  xylitol  
to  be  quantified  over  time.  
3.6.5.4   Cytotoxicity  
In  order  to  confirm  the  scaffolds  lack  of  cytotoxicity,  the  effect  of  SCA2  cryogels,  and  all  its  individual  







































with  cell  media   for  24  hours.  Afterwards,   fresh  DMEM  media  was  provided  and  24  hours   later,  a  
resazurin  test  was  performed.  The  percentage  of  viable  cell  is  displayed  in    Figure  3.14.  
Citotoxic  assays  revealed  that  SCA2  scaffold  samples  did  not  present  any  significant  changes  in  cell  
viability;;   in   fact,   the   presence   of   xylitol   and   FP   presence   seem   to   increase   cell   density,   when  
compared  to  the  positive  control,  a  behavior  that  can  be  related  to  the  sugar  content  present  in  both  
FP  and  xylitol.  
  
Figure  3.14  -­  VERO  cell  viability  after  exposure  to  SCA2  samples  and  its  individual  components,  FP  and  
xylitol.  Cell  viability  was  assessed  24  hours  after  to  cell  exposure  to  the  provided  material.  Cell  viability  was  
determined  by  UV/Visible  analysis  in  order  to  quantify  the  metabolized  resazurin  at  570  and  600  nm.  Negative  
control  (C-­)  contained  10  µL  of  DMSO;;  positive  control  (C+)  consisted  in  DMEM  media.  
3.7   Concluding  remarks  
In   this   chapter   a   bacterial   expolysaccharide   –  FucoPol   (FP)   –  was   used   to   produce   a   cryogel   at  
subzero  temperatures.  Supercritical  fluid-­assisted  drying  was  used  in  order  to  extract  the  solvent  from  
the  polymeric  matrix,  resulting  in  dry,  ready-­to-­use  porous  scaffolds.  Pore  size  and  distribution  upon  
cryogelation  is  intimately  related  with  the  freezing  temperatures  to  which  the  solution  is  exposed  to,  
and  the  time  required  for  cryogelation  to  occur.  As  mentioned  before,  the  work  in  chapter  3  is  based  
on   the   work   of   Barroso   et   al.   2014   who   prepared  macroporous  monolithic   platform   that   allowed  
antibody   purification.   In   this   chapter,   a   FucoPol-­based   macroporous   scaffold   was   produced   by  
cryogelation   at   -­20   ºC,   for   24   hours.   Since   the   scaffold   revealed   a   heterogeneous   pore   size  
distribution,   decreasing   the   cryogelation   temperature   can   possibly   lead   to   smaller   pores   that   are  
homogeneously  distributed  throughout  the  scaffold.  Another  way  that  can  be  used  to  tune  pore  size  
distribution  is  through  the  screening  of  different  organic  solvents  required  for  the  water-­replacement  
step  (Temtem  et  al.,  2006).    
Solvent  screening  can  also  aid  supercritical  carbon  dioxide  (scCO2)-­assisted  drying,  in  the  sense  that  
it  can  decrease  the  time  required  to  produce  a  polymeric  structure.  The  use  of  a  co-­solvent  or  the  
increase  of  pressure  near  the  critical  point  of  carbon  dioxide  can  increase  the  solvation  power  of  CO2,  
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made  from  a  mixture  of  75  wt.%  of  FucoPol  and  25  wt.%  of  xylitol  was  obtained,  revealing  30%  of  
water  uptake,  disintegrating  in  approximately  15  minutes.  The  scaffold  was  validated  by  exposure  to  
epithelial  cells  for  24  h,  revealing  to  be  non-­toxic.  The  pH  at  the  scaffold  surface  is  within  the  oral  
cavity’s  own  pH,  proving  that  the  obtained  formulation  is  innocuous.  
Future  work  should  address  the  following  studies:  
•   Temperature  screening  and  its  effect  on  pore  size  and  distribution  in  cryogelation  and  water-­
replacement  steps;;  
•   Polymer   concentration   screening  in   order   to   assess   the   optimal   polymer   concentration  
required  for  cryogel  production,  while  avoiding  polymer  shrinkage;;  
•   Pressure  optimization:  the  process  should  be  performed  using  high  pressures  in  order  to  try  
to  decrease  the  production  time;;  
•   Temperature  optimization:  tuning  the  temperature  can  increase  the  solvation  behavior  of  CO2  
which  will  decrease  the  time  required  to  produce  the  scaffolds.    
  
  














4  Concluding  remarks  and  future  
work    
  
4.1   Contributions  
In  this  dissertation,  the  main  goal  was  to  use  a  sugar-­rich  bacterial  exopolysaccharide  in  the  production  of  
3D  drug  delivery  platforms  -­  an  orodispersible  film  and  a  scaffold.    
An  orodispersible  film  was  produced  by  electrospinning,  a  fiber  forming  technique  that  allows  the  production  
of   thin  controlled  films  that  possess  unique  properties.   In   this  dissertation,   the  assessment  of  FucoPols’  
fiber  forming  abilities  and  its  ability  to  expand  was  determined  by  electrospinning  and  supercritical  exposure  
of  the  polymer.  The  main  contributions  are  stated  bellow:  
•   FucoPol  did  not  display  the  ability  to  form  fibers  on  its  own  when  exposed  to  electrospinning  
conditions  that  involved  the  use  of  voltages  that  ranged  from  0  to  20  kV,  rates  of  0.1  to  1.5  mL.h-­1,  
relative  humidity  of  20  to  40  %,  temperatures  of  20-­27  ºC,  and  collector/needle  distances  of  10  to  
25  cm.  Polymer  concentration  ranged  from  0.25  wt.%  to  5  wt.%.  FucoPol  did,  however,  display  the  
ability  to  produce  micro  to  nanobeads  by  electrospray,  an  ability  that  was  previously  explored  by  
Lourenço,  2015  using  spray-­drying  technique.  
•   An  orodispersible  film  containing  a  physical  blend  of  66  wt.%  of  FucoPol  with  33  wt.%  of  
poly  (ethylene  oxide)  was  attained  by  electrospinning,  with  experimental  conditions  involving  
13.5  kV  voltage,  0.5  mL.h-­1  rate,  relative  humidity  of  20  to  30  %,  average  temperatures  of  25  ºC  
and  collector/needle  distances  of  23  cm.  




from  0  to  200  bar  at  40  ºC;;  carbon  dioxide  (CO2)  was  the  chosen  supercritical  fluid.  In  order  for  
foaming  to  happen,  a  supersaturation  of  scCO2  state  must  occur,  with  following  phase  separation,  
nucleation  and  porew  growth  either  by  an  increase  of  temperature  or  a  decrease  in  pressure.  Phase  
separation  and  nucleation  did  not  occur.  FucoPol  remain  unaltered,  concluding  that  there  was  a  
potential  application  of  FucoPol  in  the  production  of  porous  polymeric  matrices  that  could  be  dried  
using  continuous  supercritical  conditions  (e.g.  supercritical  carbon  dioxide  drying).  
•   A  3D  macroporous  scaffold  was  attained  by  cryogelation  at  -­20  ºC,  using  a  physical  blend  
between   75   wt.%   of   FucoPol   and   25   wt.%   of   xylitol.  Supercritical   carbon   dioxide   (scCO2)-­
assisted  drying  was  used  to  extract  the  solvent  from  the  cryogel  and  prevent  internal  pore  collapse.  
Solvent  extraction  lasted  for  8  hours,  with  a  carbon  dioxide  (CO2)  rate  of  10  mL/minute  at  40  ºC  
and  150  bar.    
4.2   Future  work  
ODFs   is   still   in   need   of   optimization   regarding   its   initial   formulation;;   its   notorious   hygroscopic   behavior  
needs  to  be  evaluated  and  controlled  since  the  films  were  mechanically  affected  in  the  presence  of  any  
residual  water,  which  can  hamper  manual  handling.  Overall,  our  work  can  be  improved  in  the  future  by:    
•   proper   in   vitro   pharmacokinetic   release   studies   that   are   able   to   decrease   the   inaccuracy  
associated  with  the  measurements,  by  creating  a  more  suited  testing  method;;    
•   the   incorporation   of   hydrophilic   drugs   that   can   be   easily   blended   in   the   casting   solution,  
producing  a  homogenous  dispersion  upon  electrospinning  film  production;;    
•   drug  entrapment  assays  performed  in  order  to  perceive  the  minimal  amount  of  drug  required  to  
achieve  drug  loadings  that  match  the  ones  recommended  by  the  patient  information  leaflets.    
Addittionally,  a  FucoPol-­based  scaffold  was  produced  by  cryotropic  gelation,  a  technique  that  allows  the  
formation   of   porous   structures   by   ice   crystal   growth   control   through   the   manipulation   of   subzero  
temperatures.  Similar  to  electrospinning,  this  process  is  a  low  footprint,  environmentally  friendly  technique  
that   allows   the   formation   of   macroporous   structures.   Supercritical   assisted   solvent   extraction   from   the  
previously   obtained   cryogels  was   performed   in   order   to   prevent   internal   scaffold   collapse,  many   times  
encountered  in  sublimation  methods.  In  this  preliminary  study,  3D  scaffolds  were  obtained,  although  the  
process   requires   some   extensive   degree   of   optimization.   Firstly,   since   FucoPol   naturally   exhibits   poor  
mechanical  strength,  lower  freezing  temperatures  are  better  suited,  in  this  case,  since  smaller  pores  will  
be  obtained  due  to  rapid  freezing  times  that  do  not  allow  ice  crystal  growth.  Second,  solvent  adjustment  
in  water-­replacement  step  needs   to  be  performed  since  acetone  can   lower  supercritical  drying  process  
production  times,  producing  dry  scaffolds  in  3  hours,  instead  of  8  hours.  Even  then,  solvent  exchange  time  
in  water-­replacement  step  must  be  carefully  evaluated  since  it  can  vary  from  polymer  to  polymer,  increasing  
or   decreasing   with   the   complexity   of   the   casting   solution.   Furthermore,   manipulation   of   process  
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parameters  in  supercritical  extraction  is  also  a  feasible  alternative  that  can  lead  to  the  production  of  dry  
scaffolds  in  smaller  time  frames,  since  an  increase  in  pressure  and/or  temperature  improves  the  solvation  
power  of  the  CO2,  which  leads  to  the  removal  of  higher  amounts  of  solvent,  lowering  the  costs  associated  
to  higher  running  times.  
FucoPol   microparticle   production   should   be   explored   by   electrospray   or   supercritical   spray   assisted  
atomization  should  be  a  promising  alternative  since  FucoPol  is  not  soluble  in  CO2,  does  not  have  foaming  
abilities  and  already  displays  the  ability  to  produce  microparticles  by  electrospray.  Furthermore,  hydrogel  
production  by   sol-­gel   approach  should  be  a  practical   alternative   for  FucoPol-­based  scaffolds  due   to   its  
thickening   abilities.   Additionally,   unless   FucoPol   is   cross-­linked   with   polymers   that   display   a   more  
hydrophobic  character,  striving  to  have  pore  controlled  FucoPol-­based  structures  seems  irrelevant,  since  
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6  Supplementary  Information  
  
6.1   Annex  1  
Electrospinning  solutions  for  of  stand-­alone  FucoPol  
•   Solvents  and  polymer  concentration  
  
Table  6.1  –  Solvent  screening  for  FucoPol    electrospun  solutions  (A1  to  A8).  *Acetic  acid  (Sigma  Aldrich).  
**Formic  acid  (Sigma  Aldrich).  
  
  
FucoPol  wt.%    






Water   -­   1%   1.5%   2%   -­   -­   -­   -­  
Acidic  water  1%   0.5%   1%   1.5%   -­   2.5%   3%   3.5%   -­  
Acidic  water  60%   -­   -­   -­   -­   2.5%   -­   -­   -­  
AA*(40%)/FA**(60%)   0.5%   1%   1.5%   2%   -­   3%   -­   5%  
  
Several  solutions  (i.e.  A1  to  A8)  were  prepared  with  FucoPol  concentrations  ranging  from  0.5%  to  
5%  (w/v).  A  number  of  solvents  were  tested  as  showed  in  Table  6.1;;  acetone  and  ethanol  were  not  
accounted  for  since  related  work  shows  that  FucoPol  is  insoluble  in  both  reagents.  
  
•   Electrospinning  process  
Electrospinning  was  performed  in  the  host’s  lab  at  30%  to  40%  of  relative  humidity.  The  polymeric  
solution  was  pumped  through  a  21-­gauge  needle  (12.04  mm  internal  diameter)  by  means  of  a  digital  
pump,  at  a  rate  ranging  from  0.01  to  0.5  mL.h-­1.  The  solution  was  ejected,  with  a  voltage  6.5  to  20  kV  
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6.2   Annex  2  
•   Electrospinning  solutions  for  FucoPol  and  crosslinking  agents  
Table  6.2  –  Cross-­linkers  tested  in  order  to  allow  electrospinning  production  of  an  orodispersible  film  
containing   FucoPol.   1Hydroxilpropil   cellulose;;      2Poly(ethylene   oxide);;   3Poly(vynil   alcohol);;    
4Polyvynilpirrolidone.  
     
   FucoPol  2%  
(w/v)  
Dextran     Glycerol     HPC1   PEO2   PVA3   PVP4   Sorbitol  
  
Electrospinning  
15%   0.2%   5%   0.25%  
-­  
0.5%   0.2%  
   50%   0.37%   7%   0.5%   0.75%   0.5%  
   -­   0.4%   15%   -­   1%   1%  
   -­   1%   -­   -­   -­   1.5%  
   -­   2%   -­   -­   -­   2%  
  
Solvent  casting   -­  
1%  
-­  
0.5%   0.5%   0.25%   2%  
   -­   1%   -­   0.5%   -­  
   -­   -­   -­   -­   -­  
Solvent:  Deionized  water  
  
The  minimal   amount   of   crosslinking   agent   required   for   fiber   production  was   tested.   The   samples  
present  in  Table  6.2  were  additionally  performed  by  solvent  casting  method,  for  comparison  purposes.  
  
•   Electrospinning  process  
Electrospinning  assays  were  performed  at  25%  to  46%  of  relative  humidity.  The  polymeric  solution  
was  pumped  through  a  21-­gauge  needle  (12.04  mm  internal  diameter)  by  means  of  a  digital  pump,  
at  a  rate  ranging  from  0.3  to  0.8  mL.h-­1.  The  solution  was  ejected,  with  a  voltage  12  to  25  kV  and  




6.3   Annex  3  
  
Figure  6.1  –  DSC  data  from  pure  poly  (ethylene  oxide)  showing  Tg  and  Tc  temperatures.  
  
  
Figure  6.2  –  DSC  data  from  pure  metoclopramide  showing  Tg  temperature.  
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6.4   Annex  4  
  
  
Figure  6.3  -­  Metoclopramide  UV  profile  from  200  to  700  nm  (UV/Vis  Perkin  Lambda).  
  
  
Figure  6.4  –  Calibration  curve  used  to  quantify   the  amount  of  metoclopramide  released  upon  in  vitro  
pharmacokinetic  studies.    

























































6.5   Annex  5  
•   Apparent  viscosity  
  
Figure  6.5  –  Apparent  viscosity  of  a  scaffold  sample  at  25  ºC  and  45  ºC  
In  order   for   the   internal  structure  of   the  matrix  not   to  collapse  upon  solvent  exchange  and  scCO2  
drying  step,  an  appropriate  polymer  concentration  must  be  achieved.  Since  the  amount  of  polymer  
content  is  intimately  connected  an  increase  in  the  solutions  viscosity,  rheology  measures  at  25  and  
45  ºC  were  accesses  in  order  to  see  if  the  temperature  had  any  influence  in  the  scaffold.  Scaffold  has  
a   very   similar   behavior   displayed   in   subsection   2.6.1.1   but   at   higher   viscosity   values.   Scaffold  
presents  a  Newtonian  plateau  around  0.011  Pa.s  followed  by  shear-­thinning  behavior    characteristic  
of  disrupting  the  internal  structure.  
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